Drug, bio-affecting and body treating compositions inventions 06/07

20070149439 - Pituitary adenylate cyclase-activating polypeptide (pacap) is an anti-mitogenic signal for selected neuronal precursors in vivo: Pituitary adenylate cyclase-activating polypeptide (PACAP) and its receptor system can be manipulated positively or negatively to regulate mitosis in neuronal precursor cells. The ligand/receptor system involves PACAP, PACAP receptor, PAC1, and related antagonists. The methods of regulation of the present invention may model be used to define cell cycle regulation... Agent: Licata & Tyrrell P.C.

20070149440 - Transferrin and transferrin-based compositions for diabetes treatment: Embodiments of the present invention use transferrin or active derivatives to control or stabilize abnormally elevated levels of blood glucose in mammals, particularly humans. Embodiments of the invention also provide methods for enhancing survival of islet β-cells in vivo and in vitro. In other embodiments, transferrin or active derivatives are... Agent: Faegre & Benson LLP Patent Docketing

20070149441 - Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same: Methods for chemical modification of hyaluronic acid, formation of amine or aldehyde functionalized hyaluronic acid, and the cross-linking thereof to form hydrogels are provided. Functionalized hyaluronic acid hydrogels of this invention can be polymerized in situ, are biodegradable, and can serve as a tissue adhesive, a tissue separator, a drug... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070149443 - Methods of treating obesity using enterostatin: The present invention provides methods of treating or preventing disorders or conditions associated with enterostatin deficiency by administering to a subject in need thereof an effective amount of enterostatin. The present invention also provides methods of selecting a subject for therapy with enterostatin. Exemplary disorders or conditions associated with enterostatin... Agent: Jones Day

20070149442 - Non-hygroscopic compositions of enterostatin: The present invention provides pharmaceutical compositions of enterostatin that can display advantageous hygroscopicity, advantageous stability, or both. The pharmaceutical compositions of enterostatin can be useful for the manufacture of an pharmaceutical product comprising enterostatin.... Agent: Jones Day

20070149444 - Peptides that home to tumor lymphatic vasculature and methods of using same: The present invention provides a conjugate containing a moiety linked to a homing molecule that selectively homes to tumor lymphatic vasculature. The invention also provides a method of directing a moiety to tumor lymphatic vasculature in a subject by administering to the subject a conjugate containing a moiety linked to... Agent: Mcdermott, Will & Emery

20070149445 - Aplidine for multiple myeloma treatment: Aplidine and aplidine analogues are used in the manufacture of a medicament for treating multiple myeloma.... Agent: Fish & Richardson PC

20070149446 - Tamandarin analogs and fragments thereof and methods of making and using: The present invention is directed to a compound of Formula I wherein R1, R2, R3, R4, R5, R6, W, X, Y, and Z are defined herein. The compounds of the present invention are useful as anticancer agents. Specifically, the compounds are useful for treating or preventing cancer and tumor growth.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070149447 - Cyclosporin compositions: A composition comprising a therapeutically effective amount of cyclosporin A, a blend of oils having a specific gravity of from 0.90 to 1.07, and a surfactant is disclosed herein.... Agent: Allergan, Inc.

20070149451 - Combination of a dpp iv inhibitor and an antiobesity or appetite regulating agent: The present invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, comprising of a DPP IV inhibitor or a pharmaceutically acceptable salt thereof and an antiobesity agent, or an appetite regulating agent, or a pharmaceutically acceptable salt thereof. The present invention furthermore relates to the... Agent: Novartis Corporate Intellectual Property

20070149454 - Controlled release delivery system for nasal applications and method of treatment: This invention relates to a gel formulation for nasal administration of a controlled release formulation of hormones to the systemic circulation and/or to the brain. The special lipophilic or partly lipophilic system of the invention leads to higher bioavailability of the active ingredient caused by sustained serum levels in plasma... Agent: Fitch Even Tabin And Flannery

20070149456 - Epithelial sodium channel inhibiting agents and uses therefor: Disclosed herein are peptide cleavage products, generated during natural processing of epithelial sodium channel α- and γ-subunits and their use in inhibiting epithelial sodium channel activity. Also disclosed herein are polypeptide and polypeptide analog derivatives of those agents. These epithelial sodium channel-inhibitory agents may be formulated into a drug product... Agent: Jesse A. Hirshman, Esq.

20070149450 - Method for reducing levels of c-reactive protein: A compound comprising at least a structural entity which binds C-reactive protein (CRP) or parts of it or CRP in its monomeric, pentameric or multimeric form, preferably human CRP and which a) blocks one or more CRP functions on cell surfaces or in a solution, preferably blood or other body... Agent: Jacobson Holman PLLC

20070149452 - Method of treating and/or preventing cancers and aids using sartans and/or statins to modulate vdr, and/or ppar, and/or gcr and/or cb1 receptors; in conjunction with certain bacteriostatic antibiotics: This invention is a method of killing the stealthy intra-cellular bacteria which are key to the pathogenesis of both Acquired Immune Deficiency Syndrome(s) (AIDS) and Cancers. It is currently believed that the disease(s) known as AIDS are caused by a virus, the Human Immunodeficiency Virus (HIV). But much of the... Agent: Trevor Gordon Marshall

20070149455 - Modified and stabilized gdf propeptides and uses thereof: Modified and stabilized propeptides of Growth Differentiation Factor proteins, such as GDF-8 and Bone Morphogenetic Protein-11, are disclosed. Also disclosed are methods for making and using the modified propeptides to prevent or treat human or animal disorders in which an increase in muscle tissue would be therapeutically beneficial. Such disorders... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.

20070149457 - Stable solid forms of enterostatin: The present invention provides co-complexes of enterostatin that can display advantageous hygroscopicity, advantageous stability, or both. The co-complexes of enterostatin can be useful for the manufacture of an pharmaceutical product comprising enterostatin.... Agent: Jones Day

20070149449 - Therapeutic targets in cancer: The present invention relates to novel sequences for use in detection, diagnosis and treatment of cancers, especially lymphomas. The invention provides cancer-associated (CA) polynucleotide sequences whose expression is associated with cancer. The present invention provides CA polypeptides associated with cancer that are present on the cell surface and present novel... Agent: Chiron Corportion

20070149453 - Treating inflammation using a biological agent that causes cells to release cytokine receptors: This disclosure describes inventions related to the use of biological agents that cause cytokine receptors to be released from the surface of cells. One aspect of this invention is based on the unexpected finding that extending the length of an exemplary agent at the N-terminus enhances expression and production of... Agent: Meyer Pharmaceuticals LLC

20070149448 - Use of the cathelicidin ll-37 and dervicaties thereof for would healing: Use of the antimicrobial cathelicidin peptide ll-37, N-terminal fragments of LL-37 or extended sequences of LL-37 having 1-3 amino acids in the C-terminal end, for stimulating proliferation of epithalial and stromal cells and thereby healing of wounds, such as chronic ulcers. The cytotoxic effect of LL-37 may be reduced by... Agent: Birch Stewart Kolasch & Birch

20070149458 - Uses of myostatin antagonists: The present invention provides methods for treating disorders arising from hypogonadism, rheumatoid cachexia, cachexia due to burns, cachexia due to administration of chemical agents, cachexia due to diabetes, diabetic nephropathy, Prader Willi syndrome, excessive TNF-α, and other muscle-related, metabolic and inflammatory disorders by administering myostatin antagonists to subjects suffering from... Agent: Amgen Inc. Law Department

20070149459 - Oxidation process for the preparation of n-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-{n-[(tert-butylamino)carbonyl]-3-methyl-l-valyl}-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide and related compounds: e

20070149460 - Modified lysine-mimetic compounds: Lysine mimetic compounds having useful pharmacological activity such as antiarrhythmic activity and desirable bioavailability properties are disclosed.... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP

20070149461 - Use of canthin-6-one, plant extracts containing same and derivatives thereof in the treatment of trypanosomiases: The invention concerns the use of canthin-6-one from plant extracts containing same, in particular canthin-6-one in the form of a Zanthoxylum chiloperone of the angustifolium variety, and some of its derivatives for making a medicine for the treatment of trypanosomiases, in particularly for treating Chagas disease.... Agent: Lowe Hauptman Berner, LLP

20070149462 - Nucleotide and oligonucleotide prodrugs: which exhibit antiviral properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of anti-HBV treatment. The invention also relates to methods of treating a HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the... Agent: Elmore Patent Law Group, PC

20070149463 - Bifunctional macrolide heterocyclic compounds and methods of making and using the same: The present invention relates generally to the field of anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. More particularly, the invention relates to a family of bifunctional compounds useful as therapeutic agents. These compounds have both a macrolide ring and at least one heterocyclic moiety. The present invention further relates to processes... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070149464 - Combination: Compounds of formula (I) are used in combination with a second antiparasitic agent for the treatment of parasitic infestations in a host animal.... Agent: Warner-lambert Company

20070149465 - Compositions and methods for prevention and treatment of cachexia: Compositions and methods for preventing and treating wasting disorders, such as cachexia and anorexia, are provided. In one aspect, the present invention provides a method for preventing and treating a wasting disorder in a mammal. In one embodiment, the method of the invention comprises administering to such mammal a macrolide... Agent: David P. Lentini

20070149466 - Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders: Provided herein are methods and compositions for treating or preventing metabolic disorders, such as obesity and diabetes. Methods may comprise modulating the activity or level of a sirtuin, such as SIRT1 or Sir2. Exemplary methods comprise contacting a cell with a sirtuin activating compound, such as a flavone, stilbene, flavanone,... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070149472 - Antisense oligonucleotide compositions and methods for the modulation of jnk proteins: Compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of expression of a gene encoding a Jun N-terminal kinase (JNK protein) are provided. Oligonucleotide are herein provided which are specifically hybridizable with nucleic acids encoding JNK1, JNK2 and JNK3, as well as... Agent: Elmore Patent Law Group

20070149475 - Augmentation of wound healing by eif-4e mrna and egf mrna: There is provided a method of augmenting transient protein synthesis in a cell by delivering to the cell mRNA functionally related to protein production. Also provided is a method of augmenting transient protein synthesis in cells by increasing protein synthesis of growth factors from endogenous cellular mRNA and exogenous mRNA... Agent: Kenneth I. Kohn Kohn & Associates

20070149471 - Compositions and methods for sirna inhibition of angiogenesis: RNA interference using small interfering RNAs which are specific for the vascular endothelial growth factor (VEGF) gene and the VEGF receptor genes Flt-1 and Flk-1/KDR inhibit expression of these genes. Diseases which involve angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types... Agent: Pepper Hamilton LLP One Mellon Center

20070149467 - Hypoxia inducible vegf plasmid for ischemic disease: Plasmids useful for treating ischemic disease, such as ischemic heart disease, are described. The plasmids express vascular endothelial growth factor (VEGF) under the control of a promoter (RTP801) that is up-regulated under hypoxic conditions. Pharmaceutical compositions for treating ischemic disease include mixtures of the hypoxia-regulated VEGF plasmids and pharmaceutically acceptable... Agent: Alan J. Howarth

20070149470 - Inhibition of viral gene expression using small interfering rna: The invention provides methods, compositions, and kits comprising small interfering RNA (shRNA or siRNA) that are useful for inhibition of viral-mediated gene expression. Small interfering RNAs as described herein can be used in methods of treatment of HCV infection. ShRNA and siRNA constructs targetING the internal ribosome entry site (IRES)... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070149469 - Medical use of tbk-1 or of inhibitors thereof: The present invention relates to a novel angiogenic factor, TBK-1, we well as to inhibitors thereof and to their use in pharmaceutical or diagnostic compositions.... Agent: Clark & Elbing LLP

20070149468 - Methods and compositions for rna interference: The invention provides methods and compositions for gene silencing by RNA interference. In particular, the invention provides methods for gene silencing or RNA knockdown using small interfering RNAs (siRNAs) having partial sequence homology to its target gene. The invention also provides methods for identifying common and/or differential responses to a... Agent: Jones Day

20070149474 - Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of chlamydia: The instant invention relates to antigens and nucleic acids encoding such antigens obtainable by screening a Chlamydia genome. In more specific aspects, the invention relates to methods of isolating such antigens and nucleic acids and to methods of using such isolated antigens for producing immune responses. The ability of an... Agent: Andrus, Sceales, Starke & Sawall, LLP

20070149473 - Rnai-mediated inhibition of rho kinase for treatment of ocular disorders: RNA interference is provided for inhibition of Rho kinase mRNA expression for treating patients with ocular disorders, particularly for treating intraocular pressure, ocular hypertension and glaucoma. Rho kinase mRNA targets include mRNA for ROCK1 and ROCK2.... Agent: Gloria L. Norberg Winstead Sechrest & Minick P.C.

20070149476 - Combination comprising combretastatin and anticancer agents: An antitumor combination comprising a stilbene derivative and an anticancer compound selected from the group consisting of taxanes, alkylating agents, antimetabolites, vinca alkaloids, platinum compounds, epidophylloptoxins, and antibiotics as the active ingredients is provided. Methods of using these pharmaceutical preparations for the treatment of solid carcinomas and the like are... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070149478 - Compositions of plant carbohydrates as dietary supplements: Compositions of plant carbohydrates for dietary supplements and nutritional support for promotion and maintenance of good health. Defined nutritionally effective amounts of one to eleven essential saccharides, glyconutrients, are used in various inventive compositions as dietary supplements. The dietary composition herein can include phytonutrients, vitamins, minerals, herbal extracts, and other... Agent: Haynes And Boone, LLP

20070149477 - Immunomodulatory methods using oligosaccharides: Methods for modulating immune responses are provided. The methods involve contacting an immune cell with an agent that modulates interaction of a compound comprising a Lewis antigen with the immune cell such that production by the immune cell of at least one cytokine that regulates development of a T helper... Agent: Lahive & Cockfield, LLP

20070149479 - Nanoparticulate inclusion and charge complex for pharmaceutical formulations: A Nanoparticulate inclusion and charge complex that comprises at least two complex partners, whereby a complex partner is an anionic inclusion-forming agent and another complex partner is a cationic active ingredient.... Agent: Millen, White, Zelano & Branigan, P.C.

20070149480 - Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye: The present invention relates to development of efficacious pharmaceutical compositions comprising an anti-angiogenic compound in a therapeutically effective amount complexed with or encapsulated in a cyclodextrin derivative.... Agent: Alcon

20070149481 - N,n-bridged, nitrogen-substituted carbacyclic indolocarbazoles as protein kinase inhibitors: The present invention relates to novel protein kinase inhibitors with advantageous pharmaceutical properties, methods for their preparation, intermediates thereof and pharmaceutical compositions comprising the same, reagents containing the same, and methods of using the same as therapeutics, particularly in CNS diseases.... Agent: Edwards Angell Palmer & Dodge LLP

20070149482 - Phosphonium salts and their method of preparation: A primary phosphine or a secondary phosphine is reacted with an ester compound selected from the group consisting of; a phosphate triester; a phosphonate diester; a sulfate diester; and a sulfonate ester, to form a phosphonium salt of formula (VII) wherein each of RQ, RX, RY, and RZ is independently... Agent: Cytec Industries Inc.

20070149483 - Methods and compounds for modulating triglyceride and vldl secretion: The invention provides uses of autophagocytosis inducing compounds for reducing serum levels of triglycerides and VLDL and the preparation of medicaments. The invention also provides the use of autophagocytosis inducing compounds for treating hypertriglyceridemia, hyperlipidemia, hypercholesterolemia, hyperlipoproteinemia, atherosclerosis, arteriosclerosis, peripheral artery disease, coronary artery disease, congestive heart failure, myocardial ischemia,... Agent: Womble Carlyle Sandridge & Rice, PLLC

20070149484 - Novel pyridopyrazines and their use as modulators of kinases: The invention relates to novel pyrido[2,3-b]pyrazine derivatives of the general formulae (I) and (II), and to their preparation and use as medicaments, especially for the treatment of malignant disorders and other disorders based on pathological cell proliferations.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070149485 - Selected dosage for the treatment of cardiovascular and related pathologies: Method is provided of treating or preventing hypertrophy, hypertension, myocardial ischemia, ischemic heart disease, myocardial infarction, congestive heart failure, organ ischemia, tissue ischemia, acute coronary syndrome, unstable angina, ischemia reperfusion injury, preventing death subsequent to myocardial infarction, cerebral infarction, contractile dysfunction subsequent to myocardial infarction, or arrhythmia in a mammal... Agent: Merchant & Gould PC

20070149486 - Process for manufacture of 4-amino-hydroxybutylidene-1,1-bisphosphonic acid and its salts: The preset invention relates to a cost effective, high yielding, reproducible method for the manufacture of alendronic acid or its salt, such as sodium alendronate, from inexpensive and readily available pyrrolidone using phosphonating agents such as PCl3 in the presence of acids such as sulphonic acids, sulphuric acid or phosphoric... Agent: Blank Rome LLP

20070149487 - Antiviral compositions and methods: Compositions and methods for treating, preventing, or ameliorating one or more symptoms, conditions, or disorders associated with coronavirus infections are provided, in particular small-molecule inhibitors of the chymotrypsin-like cysteine protease of SARS CoV.... Agent: Fish & Richardson P.C.

20070149488 - Tetracycline derivatives and methods of use thereof: A treatment for inhibiting microbial or tumor growth is disclosed, which comprises adding to a subject in need of treatment an effective amount of one or more tetracycline derivatives.... Agent: Diamond Law Office LLC

20070149489 - Preparation of paricalcitol: The present invention is directed to a novel process for preparing Paricalcitol wherein Paricalcitol, dissolved in a solvent, is precipitated from a concentrated or seeded solution.... Agent: Kenyon & Kenyon LLP

20070149490 - process for the extraction of betulinic acid: Disclosed are large-scale industrial processes for obtaining highly pure betulinic acid from ground plane bark. Betulinic acid is 3β-hydroxy-lup-20(29)-ene-28-oic acid of formula... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070149491 - Compounds useful for treating neurodegenerative disorders: As described herein, the present invention provides compounds useful for treating or lessening the severity of a neurodegenerative disorder. The present invention also provides methods of treating or lessening the severity of such disorders wherein said method comprises administering to a patient a compound of the present invention, or composition... Agent: Choate, Hall & Stewart LLP

20070149492 - Method of affecting sleep and sleep-related behaviors: A method of affecting sleep and sleep-related behaviors of a mammal having a diurnal rhythm, by reducing the basal activity of the hypothalamus-pituitary-adrenal axis by administering an effective amount of a sensory regimen is disclosed. Such reduction may be accomplished by reducing at least one of the following: a. the... Agent: Philip S. Johnson Johnson & Johnson

20070149493 - Sustained release hydrocortisone treatment: We describe a treatment regime for the treatment of conditions which result from the abnormal secretion of cortisol.... Agent: Klarquist Sparkman, LLP

20070149494 - Method for producing 5alpha-pregnane derivative:

20070149495 - Histone deacetylase inhibitors: R5 is selected from the group consisting of a carbonyl, a substituted or unsubstituted C1-3 alkyl, a substituted or unsubstituted —C1-3 alkyl-C(O), a substituted or unsubstituted —C(O)—C1-3 alkyl, and a substituted or unsubstituted —C(O)C(O)C1-3 alkyl; M is a substituent capable of complexing with a protein metal ion; and L is... Agent: Takeda San Diego, Inc.

20070149496 - Water-soluble compound: A water-soluble magnetic anti-mitotic compound with a water-solubility of at least 100 micrograms per milliliter, a molecular weight of at least 150 grams per mole, a mitotic index factor of at least 10 percent, a positive magnetic susceptibility of at least 1,000×10−6 cgs, and a magnetic moment of at least... Agent: Michael L. Weiner Technology Innovations

20070149498 - Cancer therapy: The present invention relates, in general, to cancer therapy, and, in particular, to a method of preventing or treating cancer using low molecular weight antioxidants (e.g., mimetics of superoxide dismutase (SOD)) as the active agent or as a chemo- and/or radio-protectant. The invention also relates to compounds and compositions suitable... Agent: Paul, Hastings, Janofsky & Walker LLP

20070149497 - Water soluble tetrapyrollic photosensitizers for photodynamic therapy: or a pharmaceutically acceptable derivative thereof, wherein R1-R8 and R10 are various substituents and R9 is substituted or unsubstituted —CH2CH2CON(CH2CON(CH2COOH)2)2; or —N(CH2COOH)2. The invention also includes a method of treatment by photodynamic therapy by treatment with light after injecting the compound and a method of imaging by fluorescence after injection... Agent: Simpson & Simpson, PLLC

20070149499 - Process for preparing beta-lactamase inhibitors: The present invention relates to processes for preparing β-alkylidene penem derivatives that can be important as broad spectrum β-lactamase inhibitors and anti-bacterial agents.... Agent: Wilmerhale/wyeth

20070149501 - Process for the preparation of diphenyl azetidinone derivatives: The present invention is a process for the preparation of diphenylazetidinone derivatives of the formula (I) or forms thereof comprising the substituents X, R1 and/or R2 as defined herein. More specifically, the invention comprises methods for the preparation of these compounds by cyclization of certain □-amino carboxamides or □-amino carboxylic... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070149503 - Anti-migraine spirocycles: as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as... Agent: Louis J. Wille Bristol-myers Squibb Company

20070149500 - Compounds, compositions, and methods: Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070149502 - Spirocyclic anti-migraine compounds: as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as... Agent: Louis J. Wille Bristol-myers Squibb Company

20070149504 - Use of neurokinin antagonists in the treatment of urinary incontinence: This invention relates to compounds of formula I, wherein the R1, R2, R3, R4, R5, R6 and R7 are as defined in the specification, and, in particular, their use as pharmaceuticals, e.g. use in urinary incontinence.... Agent: Novartis Corporate Intellectual Property

20070149505 - Method of inhibiting adhesion formation: This invention relates to the use of a vitronectin receptor antagonist to inhibit adhesion formation.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070149506 - Azepine inhibitors of janus kinases: The present invention provides compounds that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.... Agent: Fish & Richardson PC

20070149507 - Process for preparing oxcarbazepine: e

20070149508 - Six membered heteroaromatic inhibitors targeting resistant kinase mutations: wherein A is an (un)substituted aryl or (un)substituted heteroaryl moiety, G is N, CH, or CR, R is an unsubstituted or substituted lower alkyl, Y is a hydrophobic linking moiety, and L is a substitutent as defined. The compound (A) can be used for treatment of various angiogenic and hematological-associated... Agent: Dla Piper US LLP

20070149509 - Use of vitamin e: Vitamin E is useful for facilitating the synchronization of circadian rhythm in humans, especially for treatment or prevention of jet lag.... Agent: Nixon & Vanderhye, PC

20070149510 - Quinazolinone and benzoxazinone derivatives and uses thereof: t

20070149512 - N-sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions: The present invention relates to novel N-sulfamoyl-piperidineamides of Formula I and their physiologically acceptable acid addition salts, to pharmaceutical compositions comprising them, processes for their preparation, and their use for the treatment of obesity and its concomitant and/or secondary diseases and related or other conditions.... Agent: Crowell & Moring LLP Intellectual Property Group

20070149511 - Substituted oxazolobenzoisothiazole dioxide derivatives method for production and use thereof: The invention relates to compounds of formula (I), where the groups have the meanings set forth herein and the physiologically-acceptable salts thereof. The compounds are suitable as medicaments for lowering blood sugar levels and for prevention and treatment of diabetes.... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070149513 - Vanilloid receptor ligands and their use in treatments: Substituted pyridines and pyrimidines and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints... Agent: Amgen Inc.

20070149515 - 6-(2,4,6-trifluorophenyl)-triazolopyrimidines, method for the production thereof, use thereof for controlling harmful fungi, and substances containing the same: X is cyano, C1-C4-alkoxy, C3-C4-alkenyloxy, C1-C2-haloalkoxy or C3-C4-halo-alkenyloxy; process for the preparation of these compounds, preparations comprising them and their use in the control of harmful phytopathogenic fungi.... Agent: Birch Stewart Kolasch & Birch

20070149514 - Indole-phenylsulfonamide derivatives used as ppar-delta activating compounds: The invention relates to novel indole-phenylfulfonamide derivatives, to methods for the production thereof, and to their use in medicaments, particularly as potent PPAR-delta activating compounds, for the prevention and/or treatment of cardiovascular diseases, particularly dyslipidemias and coronary heart diseases.... Agent: Jeffrey M. Greenman

20070149517 - 3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (vri) activity: A 3,4-dihydrobenzoxazine compound of the present invention is represented by the following formula [1] (wherein X is a nitrogen atom or CR3; R1 is a hydrogen atom or a halogen atom; R2 is a C1-6 alkoxy group which may be substituted with the same or different 1 to 5 substituents... Agent: Leydig Voit & Mayer, Ltd

20070149516 - Certain chemical entities, compositions, and methods: Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070149518 - Oxazoloisoquinoline derivatives as thrombin receptor antagonists: represents an optional double bond, the dotted line is optionally a bond or no bond, resulting in a double bond or a single bond, as permitted by the valency requirement and wherein An, Mn, Un, Gn, Jn, Kn, R9, R10, R11, R32, R33, B and Het are herein defined and... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070149519 - Benzimidazol substituted thiopene derivatives with activity on ikk3: and compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, compositions and medicaments. Such benzimidazole derivatives are potentially useful in the treatment of diseases associated with inappropriate I-kappa-B kinase-3 (IKK3) (also known as I-kappa-B kinase epsilon (IKKε) or inducible I-kappa B... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070149520 - Hcv inhibitors and methods of using them: The present invention comprises tetrazoloquinoline-compounds that are inhibitors of HCV. Compositions comprising the compounds in combination with a pharmaceutically acceptable carrier are also disclosed, as are methods of using the compounds and compositions to inhibit HCV infection of a cell, particular in the form of treating HCV infection in a... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070149521 - Bicyclic protein kinase inhibitors: and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit protein kinase enzymes and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions... Agent: Osi Pharmaceuticals, Inc.

20070149522 - Method for producing 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide: The invention relates to a method for producing 5-chloro-N-({5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophene carboxamide starting from 5-chlorothiophene-2-carbonyl chloride, (2S)-3-amino-propane-1,2-diol and 4-(4-aminophenyl)-3-morpholinone.... Agent: Jeffrey M. Greenman

20070149523 - Thiazole analogues and uses thereof:  wherein the dotted line represents a single or double bond; * indicates the point of attachment to the thiazole ring; and n is 1, 2, or 3. Also disclosed are pharmaceutical compositions comprising the above compounds and method of treatments for cancer and other diseases.... Agent: Womble Carlyle Sandridge & Rice, PLLC Attn: Patent Docketing 32nd Floor

20070149524 - Substituted diketopiperazines and their use as oxytocin antagonists: x

20070149526 - Diuretic and diuretic-like compound analogs: The present invention provides compounds that are effective in treating central nervous system disorders and maintaining normal brain function. Methods of making and using the compounds are also provided.... Agent: Myers Bigel Sibley & Sajovec

20070149525 - Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors: The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070149527 - New treatments for nervous disorders: This patent application describes the treatment of Addictive disorders, Psychoactive Substance Use disorders, Intoxication disorders, Inhalation disorders, Alcohol addiction, Tobacco addiction and or Nicotine addiction; and Attention Deficit Hyperactivity Disorder (ADHD); comprising administering a therapeutically effective, nontoxic dose of Reboxetine and derivatives and or pharmaceutically acceptable salts thereof to a... Agent: Warner-lambert Company

20070149532 - 3-aminocyclopentanecarboxamides as modulators of chemokine receptors: i

20070149529 - Amino heterocyclic modulators of chemokine receptor activity: Compounds of Formula I and Formula II: (wherein n, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R15, R16, R17, R18, R19, R24, R25, R26, R27, R28, R29, R30, R33, R34, R35, R36, R37, R38, A, j, k, m, n, X, Y and Z are as defined herein)... Agent: Merck And Co., Inc

20070149530 - Antiviral agents: m

20070149531 - Antiviral agents:

20070149533 - Bicyclic compounds with kinase inhibitory activity: The present invention provides novel bicyclic compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.... Agent: Millennium Pharmaceuticals, Inc.

20070149528 - Triazine dimers for the treatment of autoimmune diseases: Compounds containing two mono- or disubstituted triazine rings covalently linked by an organic linker, but not linked directly to each other, may be used to treat autoimmune diseases. Autoimmune diseases which are amenable to treatment with compounds of this invention include rheumatoid arthritis, systemic lupus erythematosus (SLE), idiopathic (immune) thrombocytopenia... Agent: Nixon & Vanderhye, PC

20070149534 - Pyrrolotriazine kinase inhibitors: m

20070149536 - Inhibitors of akt activity: The present invention is directed to compounds comprising a 2,3-diphenylquinoxaline moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.... Agent: Merck And Co., Inc

20070149535 - Protein kinase inhibitors: e

20070149537 - Nk1 and nk2-antagonists and compositions and methods of using the same:

20070149538 - Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors: Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions... Agent: Wilson Sonsini Goodrich & Rosati

20070149539 - Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia: The invention relates to a combination which comprises (a) at least one compound decreasing the c-Src activity and (b) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamdio]-2-methylphenyl }-4-(3-pyridyl)-2-pyrimidine-amine or the monomethanesulfonate salt thereof; to pharmaceutical compositions comprising said combinations; and to a method of treating a warm-blooded animal having leukaemia, especially chronic myelogenous leukaemia, comprising administering to... Agent: Novartis Corporate Intellectual Property

20070149540 - Crystals of quinolinecarboxylic acid derivative solvate: A main object is to provide a crystal of 6-fluoro-1-methyl-7-[4-(5-methyl-2-oxo-1,3-dioxolen-4-yl)-methyl-1-piperazinyl]-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid acetonitrile solvate (Compound B) which is an intermediate for producing preferentially the type III crystal of 6-fluoro-1-methyl-7-[4-(5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl-1-piperazinyl]-4-oxo-4H-[1,3]-thiazeto[3,2-a]quinoline-3-carboxylic acid (Compound A). A crystal of Compound B can be preferentially precipitated by controlling the supersaturation concentration in crystalization using acetonitrile as... Agent: Darby & Darby P.C.

20070149541 - Imidazole compounds: Imidazole compounds, compositions, and methods of using them in leukocyte recruitment inhibition, in modulating H4 receptor expression, and in treating conditions such as inflammation, H4 receptor-mediated conditions, and related conditions.... Agent: Philip S. Johnson Johnson & Johnson

20070149542 - Disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission: i

20070149543 - Agents for treating neurodegenerative diseases: The present invention relates to compounds effective in preventing neuronal cell death, which may be used in the treatment of neurodegenerative diseases. It is based, at least in part, on the discovery that particular compounds were effective in preventing neuronal death in model systems of Huntington's Disease.... Agent: Baker Botts L.L.P.

20070149544 - Biaryl nitrogen-heterocycle inhibitors of lta4h for treating inflammation: e

20070149545 - Substituted indan derivatives: R9 is H, C1-C6 alkyl, C3-C6 cycloalkyl, OCF3, OCHF2, OCH2F, halogen, CN, CF3, OH, C1-C6 alkoxy, C1-C6 alkoxy-C1-C6 alkyl, NR6R7, SO3CH3, SO3CF3, SO2NR6R7, an unsubstituted or substituted heterocyclic or heteroaromatic ring containing one or two heteroatoms selected from N and O, wherein the substituent(s) is(are) C1-C6 alkyl; or COR8; wherein... Agent: White & Case LLP Patent Department

20070149548 - (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines for treating rho kinase-mediated diseases and conditions: Methods for using (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines are disclosed herein to treat rho kinase-mediated diseases or rho kinase-mediated conditions, including controlling intraocular pressure and treating glaucoma, are disclosed. Ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma, and additionally useful for controlling intraocular pressure, the compositions comprising... Agent: Alcon

20070149546 - 4-anilino-quinazoline derivatives as antiproliferative agents: A quinazsoline derivative of the formula (I): wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrxosine kinase in a warm blooded animnal such as man.... Agent: Morgan Lewis & Bockius LLP

20070149547 - Bipyridyl amides as modulators of metabotropic glutamate receptor-5: The present invention is directed to novel amides such as those of Formula (I): (I) which are mGluR5 modulators useful in the treatment or prevention of diseases and conditions in which mGluR5 is involved, including but not limited to psychiatric and mood disorders such as schizophrenia, anxiety, depression, bipolar disorders,... Agent: Merck And Co., Inc

20070149549 - Prenylation inhibitors and methods of their synthesis and use: The present invention is directed to compounds useful in the treatment of diseases associated with prenylation of proteins and pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising same, and to methods for inhibiting protein prenylation in an organism using the same.... Agent: Sheridan Ross PC

20070149551 - 5-phenylpyrimidines, their preparation, compositions comprising them and their use: in which Ra, Rb and Rc are as defined in the description; X is halogen, alkyl, alkoxy or haloalkyl; and m is an integer from 1 to 5; processes for preparing these compounds, compositions comprising them and their use for controlling harmful fungi are described.... Agent: Novak Druce Deluca & Quigg, LLP

20070149550 - Substituted arylpyrazoles: This invention relates to a range of 1-aryl-4-cyclopropylpyrazoles in which the cyclopropyl ring is substituted at the angular position, and pharmaceutically acceptable salts and solvates thereof, to compositions comprising such compounds, processes to their synthesis and their use as parasiticides.... Agent: Warner-lambert Company

20070149552 - Lyophilized compositions of a triazolopyrimidine compound: The present invention relates to lyophilized compositions of a triazolopyrimidine compound, or a hydrate thereof, or a pharmaceutically acceptable salt of Compound I or hydrate thereof; solutions useful in preparing said lyophilized compositions; methods for preparing such compositions; methods of reconstituting the same; kits containing such compositions; and uses of... Agent: Wilmerhale/wyeth

20070149553 - Mitotic kinesin inhibitors: The present invention relates to 2-phenylthienylpyrimidinone compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.... Agent: Merck And Co., Inc

20070149554 - Cancer chemotherapy: each of Ar1, Ar2, and Ar3, independently, is phenyl, thienyl, furyl, pyrrolyl, pyridinyl, or pyrimidinyl; each of R1, R2, R3, R4, R5, and R6, independently, is R, nitro, halogen, C(O)OR, C(O)SR, C(O)NRR′, (CH2)mOR, (CH2)mSR, (CH2)mNRR′, (CH2)mCN, (CH2)mC(O)OR, (CH2)mCHO, (CH2)mCH═NOR, (CH2)mC(O)N(OR)R′, N(OR)R′, or R1 and R2 together, R3 and R4 together,... Agent: Osha Liang L.L.P.

20070149555 - Prophylatic and/or therapeutic agents for chronic musculoskeletal pain: A prophylactic and/or therapeutic agent for diseases accompanied by chronic musculoskeletal pain comprising as an active ingredient a compound having an adenosine A2A receptor antagonistic action, for example, represented by the following formula (I) (wherein R1, R2 and R3 are the same or different, each representing a hydrogen atom, lower... Agent: Fitzpatrick Cella Harper & Scinto

20070149556 - Hydroxypyrimidinone derivatives having inhibitory activity against hiv integrase: (wherein, C ring is nitrogen-containing aromatic heterocyclic ring in which at least one atom in atoms neighboring the atom bound to the pyrimidine ring is unsubstituted nitrogen atom; R10 is hydrogen or lower alkyl; D ring is aryl or heteroaryl) Z1 and Z3 each is independently a single bond, O,... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070149558 - Benzo-fused 5-membered heterocyclic compounds, their production and use: (wherein, R1 and R2 are the same or different and each represents a hydrogen atom, hydrocarbon group or heterocyclic group, or R1 and R2 may form, together with the adjacent carbon atom, a 3-8 membered iso- or heterocyclic group, R3 represents a cyclic group, a hydroxy group, a mercapto group... Agent: Takeda Pharmaceuticals North America, Inc Intellectual Property Department

20070149557 - Cxcr3 antagonists: Compounds, compositions and methods are provided that are useful in the treatment of conditions and diseases mediated by a chemokine receptor. In particular, the compounds of the invention modulate the CXCR3 chemokine receptor. The subject methods are useful for the treatment of inflammatory and immunoregulatory disorders and diseases, such as... Agent: Amgen Inc.

20070149559 - Process for reducing contaminating michael acceptor levels in oxycodone and other compositions: The present invention relates to processes for removal of Michael acceptors from certain compositions wherein the composition is treated with a thiol-containing compound under conditions sufficient to remove Michael acceptors and the resulting thiol-Michael adducts. Certain embodiments of the present invention enable quantification and/or removal of Michael acceptors and/or Michael... Agent: Wolf Greenfield & Sacks, P.C.

20070149560 - Novel fused triazolones and the uses thereof: This invention relates to novel compounds having the structural diagram (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of cancer.... Agent: Astrazeneca R&d Boston

20070149561 - Azaindole inhibitors of aurora kinases: i

20070149562 - Oxopiperidine derivatives, preparation and therapeutic use thereof: The present invention relates to compounds of formula (I) as defined herein that are melanocortin receptor agonists, to the preparation thereof and to the therapeutic use thereof in the treatment or prevention of a condition selected from obesity, diabetes and sexual dysfunctions that can affect both sexes, in the treatment... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070149563 - New compounds: e

20070149564 - Estrogen modulators: The present application is directed to a new class of isoxazoles and their use as estrogen modulators.... Agent: Warner-lambert Company

20070149565 - Nelfinavir conjugates and antibodies useful in immunoassay: Activated haptens useful for generating immunogens to HIV protease inhibitors, immunogens useful for producing antibodies to HIV protease inhibitors, and antibodies and labeled conjugates useful in immunoassays for the HIV protease inhibitor saquinavir. The novel haptens feature an activated functionality at the central, non-terminal hydroxyl group. Also described are monoclonal... Agent: Marilyn L. Amick Roche Diagnostics Corporation

20070149566 - Acidic quinoline derivatives and their use for the prevention and/or treatment of hyperglycaemia-related pathologies: t

20070149567 - Quinoline compounds: Quinoline compounds, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol... Agent: Pfizer Inc.

20070149569 - Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors: The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070149568 - N-substituted nonaryl-heterocyclic nmda/nr2b antagonists: Compounds represented by Formula (I) or pharmaceutically acceptable salts thereof, are effective as NMD NR2B antagonists useful for treating conditions such as, for example, Parkinson's disease, Alzheimer's disease, migraine, epilepsy and pain.... Agent: Merck And Co., Inc

20070149570 - Piperidine derivative and use thereof: or a salt thereof. The compound of the present invention has a superior tachykinin receptor antagonistic action, particularly a substance P receptor antagonistic action, and is useful as a pharmaceutical agent, for example, tachykinin receptor antagonist, an agent for the prophylaxis or treatment of lower urinary tract symptoms, gastrointestinal diseases... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070149571 - Combination therapy for treating or managing acute myelocytic leukemia: The present invention relates to methods and compositions designed for the treatment, management or prevention of cancer. The methods of the invention comprise the administration of an effective amount of one or more inhibitors of JNK in combination with the administration of an effective amount of one or more other... Agent: Jones Day

20070149572 - Method of inhibiting flt3 kinase: e

20070149573 - S-omeprazole magnesium: The present invention discloses a process for preparing a magnesium salt of S-omeprazole. The S-omeprazole salt preferably has a water content below about 4.8% by weight, a magnesium content of about 3.4-4.0% by weight, calculated on the weight of anhydrous, solvent free S-omeprazole magnesium, and has an optical purity of... Agent: Novartis Corporate Intellectual Property

20070149574 - Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein: A novel cyclic compound having a 4-pyridylalkylthio group having an (un)substituted amino group introduced therein or a salt thereof. They are useful as a medicine. The cyclic compound is a compound represented by the following formula (1), which is useful for the treatment of diseases in which angiogenesis participates. In... Agent: Frishauf, Holtz, Goodman & Chick, PC

20070149575 - 5-aminoalkylpyrazole derivatives as pesticidal agents: The invention relates to 5-aminoalkylaminopyrazole derivatives of formula (I) or salts thereof: wherein the various symbols are as defined in the description, to processes for their preparation, to compositions thereof, and to their use for the control of pests (including arthropods and helminths).... Agent: Frommer Lawrence & Haug

20070149576 - Means for protecting against technical materials: e

20070149577 - Compounds with medicinal effects due to interaction with the glucocorticoid receptor: wherein: X is a carbon or nitrogen atom; Ar is phenyl or heteroaromatic ring; R1 is hydrogen, halogen, CN or (1C-4C)alkyl; R2 is hydrogen, halogen or optionally fluorinated (1C-3C)alkoxy; R3 and R5 are independently hydrogen, optionally halogenated (1C-4C)alkyl, optionally halogenated (1C-4C)alkoxy, optionally halogenated aryl(1C-4C)alkoxy, optionally halogenated (1C-4C)alkenyl or hydroxylmethyl; R4... Agent: Akzo Nobel Inc.

20070149578 - Combination therapy: This invention relates to pharmaceutical combinations of amlodipine or a pharmaceutically acceptable acid addition salt thereof and statins or pharmaceutically acceptable salts thereof, kits containing such combinations and methods of using such combinations to treat subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and to treat subjects presenting... Agent: Connolly Bove Lodge & Hutz, LLP

20070149579 - Novel pharmaceutical compounds: i

20070149580 - Use of peroxisome proliferator activated receptor delta agonists for the treatment of ms and other demyelinating diseases: A method for treating demyelinating diseases in a patient in need thereof by treatment with an effective amount of a PPAR delta agonist is disclosed. Demyelinating diseases that may be effectively treated by this method include but are not limited to multiple sclerosis, Charcot-Marie-Tooth disease, Pelizaeus-Merzbacher disease, encephalomyelitis, neuromyelitis optica,... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070149581 - Potent immunosuppressive agents derivatives and use: Provided herein include compositions, all related stereoisomers as well as pharmaceutically acceptable salts provided as simplified analogs of pateamine A, in which the analogs generally are devoid of the C3-amino and C5-methyl groups, also referred to as desmethyl, desamino-pateamine A. Suitable analogs provide anticancer and antiproliferative effects in vivo and... Agent: Gardere Wynne Sewell LLP Intellectual Property Section

20070149582 - 1-(azolin-2-yl)amino-1,2-diphenylethane compounds for combating insects, arachnids and nematodes: The present invention relates to 1-(azolin-2-yl)amino-1,2-diphenylethane compounds of the general formula (I) wherein A is a radical of the formulae A′ or A2: N R A′ A2 and wherein m is 0, 1, 2, 3, 4 or 5, n is 0, 1, 2, 3, 4 or 5, X is sulfur... Agent: Hutchison & Mason

20070149583 - Diazonamide a analog: A specific diazonamide A analog and its salts and conjugates are effective in treating proliferative diseases.... Agent: Morrison & Foerster LLP

20070149584 - Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors: The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070149585 - Compounds useful as serotonin inhibitors and 5-ht1a agonists and antagonists: 3-Amino chroman and 2-amino tetralin derivatives and compositions containing such compounds are disclosed. Such compounds are useful for modulating activity of a 5-HT1A receptor (agonizing or antagonizing) in a patient. These compounds are further useful for inhibiting binding to a serotonin receptor. Methods of using the 3-amino chroman and 2-amino... Agent: Wilmerhale/wyeth

20070149586 - New crystalline and stable form of andolast: Described is a new crystalline Form A of Andolast disodium salt, triclinic, displaying a thermal event at 98-112° C. and melting with decomposition at about 400° C. (DSC). Andolast disodium Form A is a not hygroscopic solid, surprisingly stable to several humidity conditions in a temperature range acceptable for ordinary... Agent: Sughrue Mion, PLLC

20070149587 - Valsartan salts: The invention relates to new salts of valsartan or crystalline, also partly crystalline and amorphous salts of valsartan, the respective production and usage, and pharmaceutical preparations containing such a salt.... Agent: Novartis Corporate Intellectual Property

20070149588 - 6-(2,3,6-trifluorophenyl)triazolopyrimidines, their preparation and their use for controlling harmful fungi, and compositions comprising these compounds: The invention relates to 6-(2,3,6-trifluorophenyl)-triazolopyrimidines of formula (I), in which the substituents are defined as follows: R1 represents alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkenyl, haloalkenyl, cycloalkenyl, halocycloalkenyl, alkynyl, haloalkynyl or phenyl, naphthyl, or a five- or six-membered saturated, partially unsaturated or aromatic heterocycle, containing one to four heteroatoms from the group... Agent: Birch Stewart Kolasch & Birch

20070149589 - Process for the preparation of 4-(benzimidazolylmethylamino)benzamidines: A process for preparing an optionally substituted 4-benzimidazol-2 -ylmethylamino)benzamidine, the process comprising: (a) condensing an optionally suitably substituted diaminobenzene with 2-[4-(1,2,4 -oxadiazol-5-on-3-yl)phenylamino]acetic acid; (b) hydrogenating the product obtained from step (a); and (c) optionally carboxylating the amidino group of the product obtained from step (b).... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070149591 - Compositions of a cyclooxygenase-2 selective inhibitor administered under hypothermic conditions for the treatment of ischemic mediated central nervous system disorders or injury: Methods and compositions for the treatment of reduced blood flow to the central nervous system are provided. The method comprises administering to a subject a composition having a cyclooxygenase-2 selective inhibitor in combination with applying hypothermic conditions to the subject to provide improved neurological function in subjects with ischemic mediated... Agent: Pharmacia Corporation Global Patent Department

20070149590 - Controlled release dosage form of pirazole compounds: The present invention refers to a pharmaceutical composition for oral administration of pirazole compounds.... Agent: Cooper & Dunham, LLP

20070149593 - Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye: The present invention relates to development of efficacious intravitreal pharmaceutical compositions comprising a poorly water soluble agent with anti-angiogenic and/or anti vascular leakage properties in a therapeutically effective amount and a co-solvent in a suitable amount to treat or prevent diseases due to ocular neovascularization and enhanced vascular permeability. Other... Agent: Alcon

20070149592 - Targeting gli proteins in human cancer by small molecules: This invention provides compositions, methods and kits for the diagnosis and treatment of cancers expressing a GLI polypeptide, and in particular a GLI1, GLI2 or GLI3 polypeptide. The invention provides small molecule compounds mimicking the transcriptional activation domain of a GLI polypeptide. The small molecule inhibitors of the invention specifically... Agent: Townsend And Townsend And Crew, LLP

20070149595 - Compounds having lysophosphatidic acid receptor antagonism and uses thereof: (wherein the symbols in formula were described in the description), a salt thereof, a solvate thereof or a prodrug thereof. Since the compound of the present invention binds to and is antagonistic to an LPA receptor (particularly, EDG-2), it is useful for prevention and/or treatment of urinary system disease (prostatic... Agent: Sughrue Mion, PLLC

20070149597 - Medicinal composition as immunosuppressant: wherein R1 and R2 each represents hydrogen; R3 represents lower alkyl or hydroxymethyl; R4 represents hydrogen, alkyl, alkoxy or halogen; R5 represents hydrogen, halogeno, cyclohexyl or phenyl; X represents vinylene (CH═CH), oxygen, sulfur or methylated nitrogen; Y represents a single bond, oxygen, sulfur or carbonyl; Z represents a single bond... Agent: Frishauf, Holtz, Goodman & Chick, PC

20070149594 - Pyrrole derivatives: Compounds of the formula (I), in which X, Y, Z and Ar have the meanings indicated in claim 1, are inhibitors of Raf kinase and can be employed, inter alia, for the treatment of tumours... Agent: Millen, White, Zelano & Branigan, P.C.

20070149596 - Pyrrole derivatives, their preparation and their therapeutic use: m

20070149598 - M3 muscarinic acetylcholine receptor antagonists: Novel thiazole aniline compounds, pharmaceutical compositions, methods of making them and uses thereof in treating M3 muscarinic acetylcholine receptor mediated diseases are disclosed.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070149599 - Polymorphs of bicifadine hydrochloride: A new polymorphic crystalline form of bicifadine hydrochloride, designated form B, which is more thermodynamically stable than the previously known polymorphic form of bicifadine hydrochloride, designated as form A, methods for preparing said crystalline form B and pharmaceutical compositions containing said crystalline form B.... Agent: Jeffrey J. King Black Lowe & Graham PLLC

20070149601 - Bis-indole pyrroles useful as antimicrobials agents: Compounds of Formula I, commonly referred to as bis-indole pyrroles, including isolated naturally-occurring compounds, synthetic and semi-synthetic derivatives thereof having antimicrobial properties and to antimicrobial compositions that include one or more of bis-indole pyrroles and their derivatives or analogs having antimicrobial properties are disclosed. Pharmaceutical compositions comprising such compounds and... Agent: Knobbe Martens Olson & Bear LLP

20070149602 - N-(1h-indolyl)-1h-indole-2-carboxamide derivatives, their preparation and their therapeutic use: m

20070149600 - Substituted octahydroisoindoles:

20070149603 - Ppar active compounds: Compounds are described that are active on PPARs, including pan-active compounds. Also described are methods for developing or identifying compounds having a desired selectivity profile.... Agent: Foley & Lardner LLP

20070149604 - Novel method for preparation of crystalline perindopril erbumine: in a solvent selected from N,N-dimethylformamide, dimethyl acetals of lower aliphatic aldehydes, dimethyl ketals of lower aliphatic ketones and 1,2-dialkoxyethane with tertiary butylamine and crystallization of the erbumine salt thus obtained by heating the reaction mixture to reflux, filtering hot, cooling gradually to 20° C. to 30° C., and further... Agent: Volpe And Koenig, P.C.

20070149605 - Substituted pyrrole derivatives as hmg-coa reductase inhibitors: The present invention relates to substituted pyrrole derivatives of Formula (I), wherein (Y), with the proviso that one of R2, R4 and R5 is a heterocycle and with the further provision that if R2 is not a heterocycle then either R4 or R5 alone is not unsubstituted pyridyl, which can... Agent: Ranbaxy Inc.

20070149606 - Process for producing phenylacetic acid derivative: e

20070149608 - 3-(4-benzyloxyphenyl) propanoic acid derivatives: The present invention provides a novel compound represented by the formula (I) wherein each symbol is as defined in the specification, a salt thereof and a prodrug thereof having a superior GPR40 receptor function modulating action, which can be used as an insulin secretagogue, an agent for the prophylaxis or... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070149607 - Method for producing pyrrolidine derivative: e

20070149609 - Di(amido-substituted)heteroarene compounds as osteoblastogenesis agents: The present invention relates to di(amido-substituted)-heteroarene compounds and their use as osteoblastogenesis agents. The invention provides a method for inducing osteogenesis in a precursor cell capable of undergoing osteogenesis.... Agent: Cooper & Dunham, LLP

20070149610 - Novel compounds from garcinia hanburyi, their use in treating cancer and method of separating epimers thereof: Three pairs of C-2 epimeric xanthones isolated from Garcinia hanburyi and method for efficiently separating the xanthone compounds into individual epimers, each of which possesses varying biological effects. The compounds are useful for their anticancer effects, particularly because they are shown to be non-substrates of the multidrug-resistance transporter. Some of... Agent: Evan Law Group LLC

20070149611 - Cb-delta8-thc composition: An anti-emetic composition comprising Δ8-tetrahydrocannabinol and cannabidiol and the use thereof is described.... Agent: Ade & Company Inc.

20070149612 - Process for preparation of racemic nebivolol:

20070149613 - Fumagillol derivative and the medical use thereof: The disclosure relates to a fumagillol compound which can be usefully used not only as an angiogenesis inhibiting agent showing a superior angiogenesis inhibitory effect with less toxicity, but also as a cancer metastasis inhibitor and a therapeutic agent against cancer and other various inflammatory diseases such as rheumatic disease,... Agent: Bachman & Lapointe, P.C.

20070149614 - Guanidine and amidine acid derivatives and analogs and methods of using the same: The present invention relates to certain novel guanidine or amidine acid derivatives and analogs, to a process for preparing such compounds, having the utility in clinical conditions associated with insulin resistance, to methods for their therapeutic use and to pharmaceutical compositions containing them.... Agent: Pepper Hamilton LLP

20070149615 - Ketone compounds and compositions for cholesterol management and related uses: The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing... Agent: Warner-lambert Company

20070149616 - C3-convertase inhibitors for the prevention and treatment of age-related macular degeneration in patients with at risk variants of complement factor h: The present invention provides methods for identifying a patient at risk for developing AMD by identifying the presence of the Y402H polymorphism or other at risk variants in the complement factor H gene. The present invention further provides methods for treating persons having AMD or at risk for developing AMD... Agent: Alcon

20070149617 - Use of an omega-3 lipid-based emulsion following ischemic injury to provide protection and recovery in human organs: The present invention provides methods of limiting cell death resulting from hypoxic-ischemia comprising, administering an omega-3 lipid-based emulsion after a hypoxic-ischemia insult. The omega-3 lipid-based emulsion preferably comprises at least 20% omega-3 oil, by weight, and wherein the omega-3 oil comprises at least 20% omega-3 triglycerides and/or diglycerides, and wherein... Agent: Kenyon & Kenyon LLP

20070149618 - Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis: The invention describes compositions and methods of use for 2,5-dihydroxybenzene sulfonic acid compounds and pharmaceutically acceptable salts thereof. The invention provides methods for (a) treating skin cancer; (b) treating cancer of the organs; (c) treating leukemia; (d) improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy; (e) treating rosacea;... Agent: Ladas & Parry

20070149619 - Anti-aging agent: Administration of cystine or a salt thereof and theanine or a salt thereof is effective for retarding the progress of aging and reducing the effects of aging.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070149620 - Use of piketprofen for the preparation of a pharmaceutical composition to treat rosacea: The present invention relates to the use of piketoprofen for the preparation of novel pharmaceutical compositions and more particularly dermatological compositions that are useful for treating rosacea.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070149621 - 11beta-benzaldoxime derivatives of d-homooestra-4,9-dien-3-ones: R2 is a hydrogen atom or a C1-C6-alkyl or C1-C6-acyl group. Compounds of formula I bind more strongly to the glucocorticoid receptor than to the progesterone receptor and are effective antiglucocorticoids. According to the invention, they are suitable for the treatment and/or prevention of symptoms and/or diseases that are attributable... Agent: Millen, White, Zelano & Branigan, P.C.

20070149622 - Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity: Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic... Agent: Knobbe Martens Olson & Bear LLP

20070149623 - Therapeutic formulation: A pharmaceutical composition including a salt of rhodizonic acid, an OH anion-generating base, a non-toxic acid, a quinone, a salt-containing sulfite, catechol and, optionally, an acetogenin. The formulation demonstrates positive effects against cancer, autoimmune disease, viruses and provides antioxidant protection against peroxyl, hydroxyl and super oxide radicals.... Agent: Thomas Moga Butzel Long

20070142313 - Microrna1 therapies: Delta protein expression in a cell is reduced by introducing miR-1 into the cell, and detecting a resultant reduction of Delta protein expression in the cell.... Agent: Richard Aron Osman Science And Technology Law Group

20070142266 - Combination comprising a p-gp inhibitor and an anti-epileptic drug: The invention relates to a combination which comprises a P-glycoprotein (P-gp) inhibitor and an antiepileptic drug selected from phenytoin (5,5-diphenyl-2,4-imidazolidinedione), carbamazepine, lamotrigine, gabapentin, oxcarbazepin, valproic acid, and topiramate, and its use for the prevention, delay of progression or treatment of diseases, in particular epilepsy, especially epilepsy which is resistant to... Agent: Novartis Corporate Intellectual Property

20070142267 - Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells: The present invention relates to a composite for the treatment of a variety of medical conditions, the composite comprising an oxidized glutathione-based compound, which has a disulfide bond, and a metal material, in particular where the metal is either platinum or palladium. The oxidized glutathione-based compound and metal material can... Agent: Wolf Greenfield & Sacks, P.C.

20070142268 - Antibacterial compounds having a (pyrrole carboxamide)-(benzamide)-(imidazole carboxamide) motif: e

20070142270 - Aryl sulfonic pyridoxines as antiplatelet agents: Aryl sulfonic pyridoxine compounds with inhibition of serine protease activity and antiplatelet aggregation characteristics for the treatment of cardiovascular and cardiovascular related diseases are described. The methods are directed to administering pharmaceutical compositions comprising aryl sulfonic pyridoxines.... Agent: Merchant & Gould PC

20070142269 - Oligopeptide, derivatives thereof, and pharmaceutical composition comprising the same: y

20070142279 - Agent for promoting induction of vascular differentiation, comprising hepatocyte growth factor: The present invention provides an agent for promoting induction of differentiation of bone marrow cells into endothelial progenitor cells capable of being differentiated into endothelial cells, comprising hepatocyte growth factor as an active ingredient, and such agent is useful in the field of medical therapy or regenerative medicine.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070142283 - Angiogenically effective unit dose of fgf-2 and method of use: The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose composition comprising 0.2 μg/kg to 48 μg/kg of an FGF-2 of SEQ ID NO: 2, or an angiogenically active fragment or mutein thereof in a pharmaceutically acceptable carrier. In another... Agent: Novartis Vaccines And Diagnostics Inc.

20070142277 - Bace455, an alternative splice variant of the human beta-secretase: The present invention relates generally to the fields of genetics, biochemistry, medicinal chemistry and medicine. The present invention more particularly discloses the identification of a human gene variant involved in neuropathological conditions, and methods for the diagnosis, prevention and treatment of such diseases and related disorders, as well as for... Agent: Hunton & Williams LLP Intellectual Property Department

20070142292 - Composition of lactoferrin related peptides and uses thereof: The present invention is directed to a composition consisting of a series of novel biologically active 33-mer peptides.... Agent: Fulbright & Jaworski, LLP

20070142287 - Compositions and methods for treatment of cancer: The present invention provides a pharmaceutical composition that includes a) one or both of i) a peptide ligand that binds a zeta receptor and ii) at least one cancer chemotherapeutic agent; and b) a sustained release formulation. The invention also provides a combination including at least a portion of a... Agent: Proteus Patent Practice LLC

20070142280 - Factor vii or viia-like molecules: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.... Agent: Maxygen, Inc. Intellectual Property Department

20070142274 - Fish protein hydrolyzate: The present invention relates to the use of a enzyme treated fish protein hydrolyzate (FPH). The FPH material lowers the concentration of cholesterol in plasma, and triglycerides in the liver. FPH also induces a favourable change in the fatty acid pattern, and lowers the concentration of homocysteine in plasma. A... Agent: Reed Smith LLP

20070142294 - Identification and cloning of novel human gene, ret16, involved in the intracellular signaling cascade: The present invention describes a newly discovered polynucleotide encoding a protein involved in the cell signaling cascade, called RET16, cloned, isolated and identified from TNF-alpha stimulated human microvascular endothelial cells, as well as mouse and rat RET16 orthologs thereof. Also described are the RET16 polypeptide sequence, expression vectors, host cells,... Agent: Louis J. Wille Bristol-myers Squibb Company

20070142288 - Isolated mcpip and methods of use: A monocyte chemoattractant protein (MCP-1)-inducible protein, MCPIP, its polynucleotide and amino acid sequences from mouse and human, and methods for its use are disclosed.... Agent: Donna J. Russell

20070142273 - Methods and compositions targeting tyrosine kinases for the diagnosis and treatment of osteoarthritis: The invention discloses that members of a subfamily of receptor tyrosine kinases comprising TYRO3, Axl, cMer and ligands thereof, such as GAS6 are suitable targets for the development of new therapeutics to treat, prevent or ameliorate OA. The invention also relates to methods to treat and/or ameliorate OA and pharmaceutical... Agent: Novartis Corporate Intellectual Property

20070142291 - Methods for treating irritable bowel syndrome: Disclosed is a method of manipulating the rate of upper gastrointestinal transit of a substance in a mammal. Also disclosed are methods of manipulating satiety and post-prandial visceral blood flow. A method of treating visceral pain or visceral hypersensitivity in a human subject is also described. A method for prolonging... Agent: Nastech Pharmaceutical Company Inc

20070142293 - Methods of treating diseases with activated protein c: Method of treating a disease or pathological condition with activated protein C or a compound having activated protein C activity by direct regulation of the expression of specific genes associated with the disease or pathological condition.... Agent: Eli Lilly & Company

20070142286 - Methods of treating fibrosing diseases by induction of immune tolerance: The present invention has demonstrated for the first time that orally administered type I collagen (CI) induced tolerance to CI in patients suffering from systemic sclerosis (SSc) and ameliorated clinical manifestations of the disease. Accordingly, the present invention provides methods of treating a fibrosing disease by oral administration of a... Agent: Scully Scott Murphy & Presser, PC

20070142285 - Methods of treatment and uses for camkii and its interaction with hdacs and calpain: The present invention provides for methods of treating and cardiac hypertrophy, heart failure, dilated cardiomyopathy or hypertension comprising the use of CaMKII-HDAC binding domains. The present invention discloses not only the fact that CaMKII binds to HDAC4 at a specific site, but that HDAC4 may dimerize with other HDACs. Both... Agent: Fulbright & Jaworski L.L.P.

20070142282 - Modified vegf-a with improved angiogenic properties: The present invention is directed to methods and compositions for making and using chimeric polypeptides that comprise a VEGFR-2 ligand. The chimeric molecules of the present invention retain VEGFR-2 binding activity and an enhanced angiogenic activity as compared to native VEGF-A.... Agent: Marshall, Gerstein & Borun LLP

20070142271 - Mracs as modifiers of the rac pathway and methods of use: Human MRAC genes are identified as modulators of the RAC pathway, and thus are therapeutic targets for disorders associated with defective RAC function. Methods for identifying modulators of RAC, comprising screening for agents that modulate the activity of MRAC are provided.... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20070142278 - Muteins of fibroblast growth factor 21: The present invention relates to novel muteins of human fibroblast growth factor 21 with improved pharmaceutical properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins.... Agent: Eli Lilly & Company

20070142272 - Neuroprotective activity of activated protein c independent of its anticoagulant activity: Activated protein C (APC), prodrug, and/or a variant thereof may be used as an inhibitor of apoptosis or cell death and/or a cell survival factor, especially for stressed or injured cells or tissues of the nervous system including subjects with neurode-generative disorders. Novel biological functions (e.g., neuroprotection) can be independent... Agent: Nixon & Vanderhye, PC

20070142275 - Peptides with the capacity to bind to transforming growth factor b1 (tgf-b1): The described peptides possess the capacity to bind to Transforming Growth Factor TGF-β1 (TGF-β1), and are potential inhibitors of the biological activity of TGF-β1 through direct binding to this cytokine. These peptides can be used in the treatment of diseases or pathological alterations based on excessive or deregulated TGF-β1 expression.... Agent: Moore & Van Allen PLLC

20070142281 - Preventives/remedies for myeloma tumor and method for diagnosing the same: The present invention provides a preventive or therapeutic drug for a myeloma tumor and osteoclastic bone loss associating therewith, the drug containing as an active ingredient an osteopontin-production regulator or inhibitor; a screening method for a preventive or therapeutic drug for a myeloma tumor, characterized by determining osteopontin production regulatory... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070142276 - Protein involved in carcinoma: The present invention provides a polypeptide, KIAA0659, of use in the treatment and/or prophylaxis of carcinoma. Also provided are agents which interact with or modulate the expression or activity of the polypeptide, methods for the identification of such agents and the use of KIAA0659 in the diagnosis of carcinoma.... Agent: Klauber & Jackson

20070142290 - Surface-modified serum albumin-metal porphyrin composite, and oxygen infusion solution containing the same: A surface-modified serum albumin-metal porphyrin composite that contains serum albumin which clathrates a metal porphyrin and to which a polyoxyethylene group is covalently bonded to the molecular surface of the serum albumin.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070142289 - Use of insulin-like growth factor binding protein 3 (igf-bp3) for inhibition of tumor growth: A method of inhibiting proliferation of cells associated with a tumor in a subject which comprises administering to the subject a tumor cell proliferation amount of IGF-BP3, thereby inhibiting proliferation of the cells. An improved surgical method which comprises surgically resecting a tumor from a subject and administering to the... Agent: Cooper & Dunham, LLP

20070142284 - Vascular endothelial cell growth factor variants and uses thereof: The present invention provides VEGF variants having at least a single amino acid mutation in the native VEGF sequence and selective binding affinity for either the KDR receptor or the FLT-1 receptor. Methods of making the VEGF variants and methods of using the VEGF variants are also provided.... Agent: Merchant & Gould PC

20070142295 - Thrombopoietic compounds: The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal.... Agent: Marshall, Gerstein & Borun LLP

20070142296 - D-amino acid peptides: The present invention provides compounds of the formula X—R1-D-[Dpr, Orn or Lys](A)-R2(Z)-D-[Dpr, Orn or Lys](B)—R3(Y)—NR4R5; or R1(X)-D-[Dpr, Orn or Lys](A)-R2(Z)-D-[Dpr, Orn or Lys](B)—R3(Y)—NR4R5, in which X is a hard acid cation chelator, a soft acid cation chelator or Ac—, R1, R2 and R3 are independently selected from a covalent bond... Agent: Faegre & Benson LLP Patent Docketing

20070142297 - New uses for amino acid anticonvulsants: e

20070142299 - Compositions and methods for regulating apoptosis: Peptides and peptidomimetics capable of modulating apoptosis through their interaction with cellular LAPs (inhibitor of apoptosis proteins) are disclosed. The peptides and mimetics are based on the N-terminal tetrapeptide of LAP-binding proteins, such as Smac/DLABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed... Agent: Pepper Hamilton LLP

20070142303 - Modulation of cell fates and activities by phthalazinediones: Phthalazinediones that function as intracellular redox modulators are useful in treating cells in various disease states where intracellular redox status is impaired. By buffering aberrant redox states, phthalazinediones enable cellular processes essential for survival and augment medical treatments. The phthalazinediones of the invention can modulate functions related to cell growth,... Agent: Bach Pharma, Inc. Att: J. Andrea Park, Esq.

20070142300 - Novel compounds as inhibitors of hepatitis c virus ns3 serine protease: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070142301 - Novel inhibitors of hepatitis c virus ns3 protease: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070142302 - Peptidyl prodrugs that resist p-glycoprotein mediated drug efflux: wherein each X, Y, Z, and Z′ is independently Met, Val, Thr, Tyr, Trp, Ser, Ala, or Gly; R is H or an amino-protecting group; n is 1, and each n′, or n″ is independently 0 or 1; or a pharmaceutically acceptable salt thereof, with the proviso that DRUG is... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20070142298 - Tetrapeptide regulating blood glucose level in diabetes mellitus: The invention refers to the field of medicine and can be applied as a substance capable of regulating glucose level while treating and preventing diabetes mellitus. There is proposed a biologically active new tetrapeptide lysyl-glutamyl-aspartyl-tryp-tophane of general formula Lys-Glu-Asp-Trp-NH2 capable of regulating the glucose level, and pharmacological substance containing an... Agent: Leydig Voit & Mayer, Ltd

20070142304 - Diphenylazetidinone derivatives possessing chloesterol absorption inhibitory activity: Compounds of formula (XV): [Chemical formula should be inserted here. Please see paper copy] (XV) (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their... Agent: Pepper Hamilton LLP

20070142305 - N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders: The invention is directed to N-substituted tricyclic 3-AMINOPYRAZOLE derivatives, which are useful as inhibitors of platelet-derived growth factor receptor (PDGF-R) kinase, and methods for the preparation of said derivatives. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating... Agent: Philip S. Johnson Johnson & Johnson

20070142306 - Strontium-based complexes, pharmaceutical compositions and dietetic products: The invention relates to organic complexes based on sitosterols, acylglycerols and strontium and to the use thereof in the pharmaceutical and dietetic fields. The invention also relates to methods for treating different diseases, particularly bone or blood diseases, by the administration of the aforementioned complexes. The invention further relates to... Agent: Hunton & Williams LLP Intellectual Property Department

20070142307 - Novel estrogenic compounds: wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, R1 is selected from the group consisting of hydrogen, sulfate and glucoronate or other esters, and when the wavy line is a double bond, R1... Agent: Myers Bigel Sibley & Sajovec

20070142308 - Angiogenesis-affecting compounds and methods for use thereof: Angiogenesis may be affected by administering a compound to a group of cells, a tissue or an organism. Such affect may be to inhibit or stimulate angiogenesis. The compounds may be used to treat disease states related to insufficient or unregulated angiogenesis.... Agent: Wiggin And Dana LLP Attention: Patent Docketing

20070142309 - Synthesis of epirubicin from 13-dihydrodaunorubicine: A method of preparing an anthracyclin such as epirubicin from a starting material comprising 13-dihydrodaunorubicine (13-daunorubicinol). The method comprises producing N-Trifluoroacetyl-13-daunorubicinol from 13-daunorubicinol by acylation. The N-Trifluoroacetyl-13-daunorubicinol is reacted with an aprotic solvent and an acylating agent to produce an intermediate sulfoxy salt which is treated with a strong base... Agent: VistaIPLaw Group LLP

20070142310 - 1,3,5-triazines for treatment of viral diseases: The present invention provides compounds and methods for treatment of viral diseases and cancer.... Agent: Townsend And Townsend And Crew, LLP

20070142314 - decoy-containing pharmaceutical compositions and method of using the same: A pharmaceutical composition is provided for treatment and prevention of a disease caused by expression of a gene controlled by NF-κB or ets. The composition comprises at least one decoy and a pharmaceutically acceptable carrier. The decoy is an NF-κB decoy, an ets decoy, or a chimera decoy of NF-κB... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070142312 - Antigen delivery system: A compound for vaccination of an animal comprising (i) a moiety which selectively binds to a dendritic cell in the animal but which does not naturally occur in the animal and (ii) an antigen. Typically, the moiety which selectively binds as said binds to DC-SIGN. The moiety may be HIV-1... Agent: Knobbe Martens Olson & Bear LLP

20070142316 - Antisense iap oligonucleotides and uses thereof: The present invention features antisense IAP oligonucleotides and other negative regulators of the IAP anti-apoptotic pathway, and methods for using them to enhance apoptosis.... Agent: Philip Swain, Phd C/o Gowling Lafleur Henderson

20070142311 - Diagnosis of hyperinsulinemia and type ii diabetes and protection against same: Mouse genes differentially expressed in comparisons of normal vs. hyperinsulinemic, hyperinsulinemic vs. type 2 diabetic, and normal vs. type 2 diabetic liver by gene chip analysis have been identified, as have corresponding human genes and proteins. The human molecules, or antagonists thereof, may be used for protection against hyperinsulinemia or... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070142315 - Immunostimulatory oligoribonucleotides: The invention provides immunostimulatory compositions and use of those compounds in the preparation of medicaments for the treatment of disease as well as in vitro uses. In particular, the compositions of the invention include immunostimulatory oligoribonucleotides that incorporate a sequence-dependent immunostimulatory sequence motif. Specific modifications involving phosphate linkages, nucleotide analogs,... Agent: Wolf Greenfield & Sacks, P.C.

20070142318 - Compositions, methods and kits for repressing virulence in gram positive bacteria: Bacterial virulence is repressed by compositions and methods for activating permanently a repressor of virulence factors. Compositions provided contain at least one non-metabolizable analog of guanine, guanosine, isoleucine and valine.... Agent: Lawson & Weitzen, LLP

20070142317 - Topical composition for treatment of skin disorders: The present invention provides for a topical composition that includes a topical carrier and an adenosine deaminase inhibitor. Suitable specific adenosine deaminase inhibitors include, e.g., deoxycoformycin (dCF), deoxyadenosine (dAdo), cladrabine (CdA), fludarabine (F-Ara-A), cytrabine (Ara-C), and thioguanine. The present invention also provides for a method to treat lymphocyte mediated skin... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20070142319 - Anxiolytic treatment by inhibition of a polysialyltransferase: The invention provides methods and compositions for treating anxiety and fear disorders through inhibition of α-2,8-sialyltransferase activity.... Agent: Townsend And Townsend And Crew, LLP

20070142321 - Method for preventing growth of bacteria on contact lenses with eye drops: The present invention relates to a novel eye-drop solution that has superior microbe and bacteria management properties. Regular use in the eye will prevent bacteria from being attached to the eye. Regular use of the eye-drops will also prevent growth of microbes in the eye. A patient that uses this... Agent: Bausch & Lomb Incorporated

20070142320 - Process for glucan preparation and therapeutic uses of glucan: A process for the production of β-(1,3)(1,6) glucan from a glucan containing cellular source is described, together with compositions and uses/methods of treatment involving glucan. The process of the invention comprises the steps of: (a) extracting glucan containing cells with alkali and heat, in order to remove alkali soluble components;... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070142322 - Method of using chitosan to reduce shedding of e. coli from bovines: A method to reduce fecal shedding of E. coli from bovines is described. The method includes administering an amount of chitosan to a bovine. The amount administered is sufficient to reduce or eliminate fecal shedding of E. coli from the bovine. Also described is a corresponding feed ration for bovines.... Agent: Dewitt Ross & Stevens S.c. Wisconsin Alumni Research Foundation

20070142323 - Oligosaccharides, preparation method and use thereof, and pharmaceutical compositions containing same: The invention relates to oligosaccharides, the preparation method and use thereof, and pharmaceutical compositions containing same. More specifically, the invention relates to oligosaccharides which can be used for the treatment of cancer and, in particular, to prevent and inhibit the formation of metastases. The inventive oligosaccharides can be used, for... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070142324 - Amphiphilic cyclodextrin derivatives, method for preparation thereof and uses thereof: e

20070142325 - Starch: Production of purified, parenterally administrable starch by washing starch containing more than 85% amylopectin in order to remove surface-localized proteins, lipids and endotoxins, subjecting the starch to a molecular weight reduction by acid hydrolysis, and optionally removing residual water-soluble proteins. Purified starch and microparticles based on such starch.... Agent: Mintz Levin Cohn Ferris Glovsky & Popeo

20070142326 - Treatment of a condition in a mammal with administration of aminosugar and uses thereof: The present invention relates to treating joint related conditions in mammals by administering an aminosugar, and wherein said treatment specifically prevents, lessens or reverses pathologies associated with the joint condition, said pathologies being selected from the group consisting of synovitis, subchondral bone edema, and cartilage degradation.... Agent: Catalyst Law Group, Apc

20070142327 - Active compound combinations having insecticidal properties: The invention relates to novel insecticidal active compound combinations comprising, firstly, anthrlamides (group 1) and, secondly, further insecticidal active compounds selected from the group of the (thio)phosphates (group 2) and/or the group of the carbamates (group 3), which combinations are highly suitable for controlling animal pests, such as insects.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070142329 - Benzamide inhibitors of the p2x7 receptor: e

20070142328 - Compounds and uses thereof:

20070142330 - Method and composition for the control of arthropods: The present invention relates to the use of certain siloxanes and mixtures thereof in the control of arthropods such as insects and arachnids, and in particular ectoparasites, such as head lice.... Agent: Elmore Patent Law Group, PC

20070142331 - Lipophilic anticancer drug compounds, compositions and related methods: Lipophilic anticancer drug compounds, compositions that include the compounds, and methods for treating a cell proliferative disease using the compounds.... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20070142332 - Amorphous forms of risedronate monosodium: The monosodium salt of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid in new amorphous forms, methods of preparation and a pharmaceutical formulation.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070142333 - Cycloalkyl inhibitors of potassium channel function: Novel cycloalkyl compounds useful as inhibitors of potassium channel function (especially inhibitors of the Kv1 subfamily of voltage gated K+ channels, especially inhibitors Kv1.5 which has been linked to the ultra-rapidly activating delayed rectifier K+ current IKur), methods of using such compounds in the prevention and treatment of arrhythmia and... Agent: Louis J. Wille Bristol-myers Squibb Company

20070142334 - Inhibitors of p38: The present invention relates to inhibitors of p38, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to inhibitors of ZAP70. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070142335 - Amino alcohol compounds or phosphonic acid derivatives thereof: wherein R1 and R2 are each a hydrogen, R3 is hydrogen; R4 is C1-C2 alkyl; n is 2; X is ═N-D, wherein D is hydrogen C1-C4 alkyl or phenyl; Y is ethylene, ethynylene, —CO—CH2 or phenylene; Z is ethylene or trimethylene; R5 is an unsubstituted C3-C10 cycloalkyl, an unsubstituted C6-C10... Agent: Frishauf, Holtz, Goodman & Chick, PC

20070142336 - Treatment of cancer: The invention relates to the treatment of cancers, in particular, cancers that are resistant to platinum based chemotherapeutic agents. A pharmaceutical composition for the treatment of cancer comprising an effective amount of a compound having two gold(I) atoms each covalently bonded to a carbon atom in a covalent link connecting... Agent: David B Smith Michael Best & Friedrich

20070142338 - Tetracycline derivatives and methods of use thereof: A treatment for inhibiting microbial or tumor growth is disclosed, which comprises adding to a subject in need of treatment an effective amount of one or more tetracycline derivatives.... Agent: Diamond Law Office LLC

20070142337 - Treatment of inflammation and organ dysfunction: Compositions and methods are disclosed for decreasing the amount and activity of matrix-degrading metalloproteinases (MMPs) in and around cells. The compositions and methods are useful for treating and/or preventing symptoms of diseases including but not limited to Hypertension, Type II Diabetes, and Metabolic Syndrome X. Such treatment is effected by... Agent: Moazzam & Associates, LLC

20070142339 - Prevention of arterial restenosis with active vitamin d compounds: The present invention relates to a method for preventing, treating, or ameliorating arterial restenosis after angioplasty in an animal by administering to the animal active vitamin D compounds. The invention further relates to a method for preventing, treating, or ameliorating restenosis after angioplasty in an animal by administering to the... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070142340 - Steroids as agonists for fxr: e

20070142341 - Use of steroid derivatives for the treatment of angiotensin ll related disease e.g. cardiovascular and proliferative disorders: Use of a compound of formula (I) or a 3-enol C1 to 4 alkanoate ester thereof in the manufacture of a medicament for the treatment of an angiotensin II related disease in humans and animals wherein R1, R2, R5, R6 are the same or different and each is hydrogen or... Agent: Jones Day

20070142342 - Pharmaceutical compounds: Steroidal compounds or their salts having general formulas (I) and (II) wherein: s is an integer equal to 1 or 2, preferably s-2: bO 0 or 1; A═R—, wherein R is the steroidal drug radical, C and C1 are two bivalent radicals. The precursors of the radicals B and B1... Agent: Arent Fox PLLC

20070142343 - Compositions and methods for enhancing corticosteroid delivery: The present invention comprises a composition, method of enhancing potency and method of delivering corticosteroids in a vehicle comprising at least two penetration enhancers, and solvents and emulsifiers. The propylene glycol and penetration enhancers are present in ratio to the total of the propylene glycol, penetration enhancers, and solvents and... Agent: Reed Smith LLP

20070142344 - Compositions and methods for enhancing corticosteroid delivery: The present invention comprises a composition, method of enhancing potency and method of delivering corticosteroids in a vehicle comprising at least two penetration enhancers, and solvents and emulsifiers. The propylene glycol and penetration enhancers are present in ratio to the total of the propylene glycol, penetration enhancers, and solvents and... Agent: Reed Smith LLP

20070142345 - Steroids for cancer treatment: The present invention relates to novel compounds which are 7α-substituted 17-alkylene-16α-hydroxy steroidal estrogens. This invention specifically relates to estrogen derivatives which contain 7α-substituents and which exhibit anti-estrogenic properties. The present invention also relates to use of said compounds as a medicament, and for the treatment of estrogen dependent disorders, a... Agent: Fish & Richardson P.C.

20070142347 - Chondropsin-class antitumor v-atpase inhibitor compounds, compositions and methods of use thereof: e

20070142346 - Method of treating breast cancer using 17-aag or 17-ag or a prodrug of either in combination with a her2 inhibitor: A method for treating a breast cancer in a subject by administering 17-allylamino-17-demethoxy-geldanamycin (17-AAG) or 17-amino-17-demethoxygeldanamycin (17-AG), or a prodrug of either 17-AAG or 17-AG, in combination with a HER2 inhibitor.... Agent: Kosan Biosciences, Inc

20070142348 - Microbicidal, prophylactic and therapeutic effect of ctc-96 on papilloma viruses: A method for the therapeutic and prophylactic treatment of subjects infected with the papilloma virus. More specifically, a method of therapeutic treatment of a papilloma virus in a subject by administering an anti-papilloma virus effective amount of CTC-96 to the subject. In addition, a method of prophylactic treatment against a... Agent: Reed Smith, LLP Attn: Patent Records Department

20070142351 - Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands: The invention relates to heterocyclic substituted amide derivatives that display selective binding to dopamine D3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D3 receptor activity in a patient in need of such treatment comprising administering to the... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070142349 - 4-arylmorpholin-3-one derivatives, their preparation and therapeutic use thereof: e

20070142350 - Therapeutic uses of derivatives of piperidinyl- and piperazinyl-alkyl carbamates:

20070142353 - Antibacterial compounds:

20070142352 - Pteridinone derivatives as modulators of chemokine receptor activity: The invention provides certain pteridinone compounds of formula (I), processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.... Agent: Fish & Richardson P.C.

20070142356 - Association of a sinus node if curent inhibitor and a calcium inhibitor, and pharmaceutical compositions containing it: Association comprising a selective and specific sinus node If current inhibitor, more especially ivabradine, and a calcium inhibitor. Medicinal products containing the same which are useful in treating angina.... Agent: The Firm Of Hueschen And Sage

20070142355 - Association of a sinus node if curent inhibitor and an angiotensin converting enzyme inhibitor, and pharmaceutical compositions containing it: Association comprising a selective and specific sinus node If current inhibitor, more especially ivabradine, and an agent that inhibits angiotension-converting enzyme. Medicinal products containing the same which are useful in treating arterial hypertension.... Agent: The Firm Of Hueschen And Sage

20070142354 - Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure: The present invention provides the use in a pharmaceutical composition of a specific cyclic amine derivative, or its pharmaceutically acceptable salts, for the treatment of heart failure of any aetiology.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070142357 - Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases: The present invention relates to certain 1-substituted-2,3,4,5-tetrahydro-3-benzazepine derivatives of Formula (I), that are modulators of the 5HT2C receptor. Accordingly, compounds of the present invention are useful for the prophylaxis or treatment of 5HT2C receptor associated diseases, conditions or disorders, such as, obesity and related disorders.... Agent: Arena Pharmaceuticals, Inc.

20070142358 - Pyrrolo [2,3-b] pyridine derivatives: e

20070142359 - Pyrrolo [2,3-c] pyridine derivatives:

20070142360 - Therapeutic agents useful for treating pain: wherein Ar, Ar1, Ar2, R3-R6, R13, m, and t are disclosed herein, or a pharmaceutically acceptable salt thereof (a “Hydroxyiminopiperazine Compound”); compositions comprising an effective amount of a Hydroxyiminopiperazine Compound; and methods for treating or preventing pain and other conditions in an animal comprising administering to an animal in need... Agent: Jones Day

20070142361 - 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations: The present invention relates to new formulations containing one or more estrogens and 2-Phenyl-1-[4-2-Aminoethoxy)-Benzyl]-Indole compounds which are useful as estrogenic agents, as well as pharmaceutical compositions and methods of treatment utilizing these compounds, which have the general structures below:... Agent: Pepper Hamilton LLP

20070142362 - 4,5-dihydro-(1h)-pyrazole derivatives as cannabinoid cb1 receptor modulators: e

20070142364 - Flumazenil for the treatment of cocaine dependency: The invention relates to the use of flumazenil to produce a medicament for the treatment of cocaine dependency. The flumazenil can be administered sequentially in small quantities at short intervals until a therapeutically effective quantity for the treatment of cocaine dependency has been administered.... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20070142363 - Novel diazabicyclonene derivatives and use thereof: The invention relates to novel derivatives and related compounds and their use as active ingredients in the prepa- ration of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as... Agent: Hoxie & Tso LLP

20070142365 - Naphthyridine integrase inhibitors: The present invention features compounds that are HIV integrase inhibitors and therefore are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070142366 - Jnk inhibitors: The present invention provides novel compounds of formula (I) and their use in the inhibition of c-Jun N-terminal kinases. The present invention further provides the use of these compounds in medicine, in particular in the prevention and/or treatment of neurodegenerative disorders related to apoptosis and/or inflammation.... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070142367 - Method and medicine for treating gastrointestinal disorder including fecal incontinence: A method and a medicine for treating an ambulatory patient having a gastrointestinal disorder that includes fecal incontinence are provided. The method includes administering a dose of the medicine to the patient. The medicine includes a tricyclic antidepressant and a stool softener.... Agent: Thomas W. Adams Renner, Otto, Boisselle & Sklar, LLP

20070142369 - Combination of an h3 antagonist/inverse agonist and an appetite suppressant: The present invention relates to pharmaceutical compositions comprising therapeutic combinations comprising: one or more H3 antagonists/inverse agonists; one or more appetite suppressants selected from the group consisting of CB1 antagonists/inverse agonists, sibutramine, phentermine and topiramate; and optionally one or more HMG-CoA reductase inhibitors. The invention also relates to medicaments and... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070142368 - Substituted pyrazole compounds: Disclosed are protein kinase inhibitors, compositions comprising such inhibitors, and methods of use thereof. More particularly, disclosed are inhibitors of Aurora A (Aurora-2) protein kinase. Also disclosed are methods of treating diseases associated with protein kinases, especially diseases associated with Aurora-2, such as cancer.... Agent: King & Spalding LLP

20070142370 - Azabicyclooctan-3-one derivatives and use thereof: Compounds of Formula (1) process for preparing them, pharmaceutical compositions comprising them. The use of compounds of formula (1) for hyperproliferative diseases, e.g. cancer as well as autoimmune diseases and heart disease.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070142371 - Anti-cytokine heterocyclic compounds: m

20070142372 - Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthritis:

20070142373 - Quinoline derivatives as phosphodiesterase inhibitors:

20070142376 - Control of intraocular pressure using alk5 modulation agents: An ophthalmic pharmaceutical composition useful in the treatment of glaucoma and control of intraocular pressure comprising an effective amount of a selective modulator of ALK5 receptor activity is disclosed. Also disclosed is a method of treating glaucoma and controlling intraocular pressure comprising applying a therapeutically effective amount of a pharmaceutical... Agent: Alcon

20070142374 - Pyrrolidine derivatives as factor xa inhibitors:

20070142375 - Pyrrolidine derivatives as factor xa inhibitors:

20070142377 - Pyridyl alkene and pyridyl alkine-acid amides as cytostatics and immunosuppressives:

20070142378 - Method of treating restless legs syndrome and/or periodic limb movement disorder with (2s,3s) 2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol: Methods for treating Restless Legs Syndrome and/or Periodic Limb Movement Disorder (PLMD) using (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol or a salt or solvate thereof are disclosed.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070142379 - Cyclohexyl derivatives as selective estrogen receptor modulators: The present invention is directed to novel cyclohexyl derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and diseases mediated by an estrogen receptor.... Agent: Philip S. Johnson Johnson & Johnson

20070142380 - Viral polymerase inhibitors: e

20070142381 - Calcium receptor modulating agents: or a pharmaceutically acceptable salt thereof, and compositions containing them, wherein the variables are defined herein, and their use to reduce or inhibit PTH secretion, including methods for reducing or inhibiting PTH secretion and methods for treatment or prophylaxis of diseases associated with bone disorders, such as osteoporosis, or associated... Agent: Amgen Inc.

20070142382 - Compounds and uses thereof:

20070142383 - Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions:

20070142384 - Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders: The present invention provides compounds useful, for example, for modulating insulin levels in a subject and that have the general formula Q-L1-P-L2-M-X-L3-A wherein the definitions of the variables Q, L1, P, L2, M, X, L3 and A are provided herein. The present invention also provides compositions and methods for use... Agent: Amgen Inc.

20070142385 - Treatment of length dependent neuropathy: Compositions, and methods of use thereof, are provided for the treatment of painful neuropathy by local or topical delivery of compounds that interact with α-adrenergic receptors, especially an alpha2 adrenergic agonist such as clonidine, to the entire painful area such that the need for systemic dosing is minimized. The compounds... Agent: Patrea L. Pabst Pabst Patent Group LLP

20070142386 - New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1: There are disclosed novel compounds of formula (I) wherein A, R1, R2, R3 and X are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CX3CR1 receptor antagonists... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20070142387 - Process for producing folic acid derivatives: This invention provides a process for efficient production of folic acid derivatives suitable for forming conjugates of anticancer drug with folic acid. It discloses a process comprising a step of reacting 2-amino-protected pteroylimidazole with γ-lower alkyl glutamate; and a step of reacting the resulting product with an amino compound having... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070142389 - Piperidine derivatives: i

20070142390 - 2-aminoaryloxazole compounds as tyrosine kinase inhibitors: The present invention relates to novel compounds selected from 2-aminoaryloxazoles of formula I that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these... Agent: Foley And Lardner LLP Suite 500

20070142388 - Inhibitors of akt activity: The present invention is directed to compounds comprising a 2,3-diphenylpyrazine moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.... Agent: Merck And Co., Inc

20070142391 - Piperazine-2-carboxamide derivatives: The present invention is related to piperazine-2-carboxamide derivatives of formula (I) for the treatment and/or prophylaxis of preterm labor, premature birth, dysmenorrhea and for stopping labor prior to cesarean delivery. Wherein A, X, Y, R1 and R2 are as defined in the description.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070142392 - Uses of rifamycins: The invention features methods, compositions, and kits for treating prosthetic joint infections, foreign body infections, infectious arthritis, and osteomyelitis... Agent: Clark & Elbing LLP

20070142393 - Sulfonyl-derivatives as novel inhibitors of histone deacetylase: e

20070142394 - Substituted aniline derivatives useful as histamine h3 antagonists: R2 is optionally substituted alkyl, alkenyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl or heterocycloalkyl; and the remaining variables are as defined in the specification; and compositions and methods of treating obesity, metabolic syndrome and a cognition deficit disorder, alone or in combination with other agents.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070142396 - Treatment of pain with 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-methoxy-3,4-dihydro-2(1h)-quinolone or salt thereof: Therapeutic methods are provided for treating pain and fibromyalgia by administration of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-methoxy-3,4-dihydro-2(1H)-quinolone or a prodrug or salt thereof.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20070142395 - Treatment of sexual dysfunction with 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-methoxy-3,4-dihydro-2(1h)-quinolone or salt thereof: Therapeutic methods are provided for treating sexual dysfunction by administration of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-methoxy-3,4-dihydro-2(1H)-quinolone, or a prodrug or salt thereof.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20070142397 - Phenypiperazine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition: e

20070142398 - Tetracyclic 3-substituted indoles having serotonin receptor affinity: Tetracyclic 3-substituted indoles having serotonin receptor affinity and pharmaceutically acceptable salts thereof.... Agent: Cooper & Dunham, LLP

20070142399 - Dual function drugs and uses thereof: Dual action compounds are provided that are inhibitors of catechol-omethyltransferase (COMT) enzyme and are also partial agonists or antagonists of the D2 receptor, or agonists of the D1 receptor, or interact in these ways with both D1 and D2 receptors. Use of the compounds for treating neuropsychiatric disorders, particularly schizophrenia... Agent: Darby & Darby P.C.

20070142400 - Enantjomers of 1-[(4-chlorophenyl)phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine: The invention provides a method for the treatment of allergic conditions by administering to a patient an effective amount of dextrorotatory dihydrochloride of 2-[2-[4-[(4-chloro-phenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic acid. The treatment is conducted in the absence of levorotatory dihydrochloride of 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic acid.... Agent: Wenderoth, Lind & Ponack Suite 800

20070142401 - Indolyl-pyrroledione derivatives for the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation: The invention relates to the use of an inhibitor of formula (I), or a pharmaceutically acceptable salt thereof having an activity on protein kinases PKC alpha, PKC beta, PKC gamma, PKC epsilon, PKC theta, CDK-1, KDR, PKA, Flt-1, Flt-2, Flt-3 or Flt-4, or on a combination of the above enzymes,... Agent: Novartis Corporate Intellectual Property

20070142402 - Kinase inhibitors and their uses: The present disclosure provides compounds that inhibit protein kinases, such as JAK, Axl, or Syk kinases, compositions comprising the compounds and methods of using the compounds to inhibit protein kinase and treat and/or prevent diseases associated with inappropriate kinase activity.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070142403 - Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein: A pharmaceutical composition which comprises a pharmaceutically acceptable carrier or diluent and: (a) an inhibitor of the RSV fusion protein; and (b) a benzodiazepine derivative capable of inhibiting RSV replication is found to be highly active against RSV.... Agent: Lahive & Cockfield, LLP

20070142404 - 6-(2,6-dichlorophenyl)-triazolopyrimidines, methods for the production thereof, use thereof for controlling pathogenic fungi, and agents containing the same: R1 and R2 together with the nitrogen atom to which they are attached may also form a five- or six-membered heterocyclyl or heteroaryl which is attached via N and may contain one to three further heteroatoms from the group consisting of O, N and S as ring member and which... Agent: Birch Stewart Kolasch & Birch

20070142405 - Bicyclic heterocyclic p-38 kinase inhibitors: Provided are bicyclic heterocycle-based p38 kinase, including p38α and p38β kinase, inhibitors. Pharmaceutical compositions containing the compounds are also provided. Methods of use of the compounds and compositions are also provided, including methods of treatment, prevention, or amelioration of one or more symptoms of p38 kinase mediated diseases and disorders,... Agent: Novartis Corporate Intellectual Property

20070142406 - Method of cancer screening; method of cancer treatment; and method of diabetes treatment: A method of cancer screening comprising the steps of administering the Blood CA 27,29 testing procedure; if the result is positive administering a mammogram; if the result is positive administering an needle biopsy; if the result is positive administering a PET scan; if the result is positive administering a blood... Agent: Michael A. O'neil Michael A. O'neil, P.C.

20070142407 - Benzo (1,2,5) thiadiazole als crf-antagonisten: The present invention relates to a novel benzothiadiazole of formula (A) in free base or acid addition salt form, its preparation, its use as pharmaceutical and pharmaceutical compositions containing the compound.... Agent: Novartis Corporate Intellectual Property

20070142408 - Compositions and methods for inhibiting tgf-beta: e

20070142409 - 3-substituted-4-pyrimidone derivatives: A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof useful as a tau protein kinase 1 inhibitor:wherein X represents CH or nitrogen atom; R1 represents a C?1#191-C?12#191 alkyl group which may be substituted; R2 represents a C?1#191-C?8#191 alkyl group which... Agent: Greenblum & Bernstein, P.L.C

20070142410 - Synergistic antifungal ddac compositions: The present invention relates to synergistic antifungal compositions comprising didecyl ammonium chloride (DDAC) and a post-harvest antifungal agent selected from the group consisting of imazalil, boscalid, fenhexamid, pyrimethanil, thiophanate-methyl, triflumizole, azoxystrobin, dimoxystrobin, picoxystrobin, and pyraclostrobin for protecting plants, fruit or seeds against phytopathogenic fungi.... Agent: Philip S. Johnson Johnson & Johnson

20070142411 - Use of cyclooxygenase-2 selective inhibitors for the treatment of schizophrenic disorders: which are COX-2 (cyclooxygenase-2) inhibitors, and pharmaceutically acceptable salts and solates thereof, for the treatment of schizophrenic disorders. Schizophrenic disorders of the invention are to be intended schizophrenia, delusional disorders, affective disorders, autism or tic disorders, schizophreniform disorders, in particular chronic schizophrenic psychoses and schizoaffective psychoses, temporary acute psychotic disorders.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070142412 - Crystalline form of 2-{4-['3-(4-chloro-2-fluorophenyl)-4-pyrimidin-4-yl-1h-pyrazol-5-yl]piperidin-1-yl}-2-oxoethanol: Crystalline form of the p38 kinase inhibitor 2-{4-[3-(4-chloro-2-fluorophenyl)-4-pyrimidin-4-yl-1H-pyra-zol-5-yl]piperidin-1-yl}-2-oxoethanol can be used, is provided. The crystalline form is a hydrated crystalline form. Also provided are combinations and pharmaceutical compositions comprising the crystalline form, process for preparing the crystalline form and for preparing compositions comprising the crystalline form, in methods for the... Agent: Pharmacia & Upjohn

20070142415 - Heteroarylpyrrolopyridinones active as kinase inhibitors: y

20070142414 - N-substituted pyrrolopyridinones active as kinase inhibitors:

20070142418 - Process for the preparation of rosuvastatin: The present invention provides a process for the preparation of the rosuvastatin intermediate FPP-CHO and its conversion to rosuvastatin and pharmaceutically acceptable salts thereof.... Agent: Kenyon & Kenyon LLP

20070142413 - Pyrazole derivatives as inhibitors of receptor tyrosone kinases: Compounds of formula (I): and their use in the inhibition of Trk activity are described.... Agent: Astrazeneca R&d Boston

20070142416 - Pyrimidinyl amide compounds with inhibit leukocyte adhesion mediated by vla-4: Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a human or animal subject such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease,... Agent: Foley & Lardner LLP

20070142417 - Substantially pure 2-{[2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carbonyl]-amino}-3-phenylpyridin-2-yl-amino)-propionic acid as an ikb kinase inhibitor: or pharmaceutically acceptable salt, or solvate of said compound; to a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of formula (A), and a pharmaceutically acceptable carrier; and the use of a compound of formula (A) having activity as an inhibitor, preferably a selective inhibitor, of IκB (IKK),... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070142420 - 4-heteroaryl-tetrahydroquinolines and their use as inhibitors of the cholesterin-ester transfer protein: Hetero-tetrahydroquinolines can be prepared either by condensing correspondingly substituted hetero-tetrahydroquinoline aldehydes with the desired substituent or by reducing the corresponding keto-substituted hetero-tetrahydroquinolines, followed by introduction of the desired substituent by customary methods. The hetero-tetrahydroquinolines are suitable for use as active compounds in medicaments, in particular in medicaments for treating artheriosclerosis... Agent: Norris, Mclaughlin & Marcus, Pa

20070142419 - Thienyl compounds: t

20070142421 - Pharmaceutical composition: A pharmaceutical composition comprising an analgesic or analgesic combination and a stool softener is disclosed. The analgesic is selected from morphine, meperidine, fentanyl, hydromorphone, oxymorphone, oxycodone, hydrocodone, methadone, propoxyphene, pentazocine, levorphanol, codeine, acetaminophen and combinations of these analgesics. The composition is formulated for oral administration as a liquid or solid... Agent: Sheridan Ross PC

20070142422 - Control of cci-779 dosage form stability through control of drug substance impurities: A method of preparing a rapamycin composition having increased potency is provided. The method involves selecting a rapamycin compound having less than 1.5% oxidative and hydrolytic rapamycin impurities and formulating the selected rapamycin with an antioxidant and optional excipients.... Agent: Howson And Howson Cathy A. Kodroff

20070142424 - Process for producing tacrolimus (fk-506) using vegetable oil as sole source of carbon: A novel fermentation fed batch process for producing the immunosuppressant Tacrolimus (FK-506), using the mutant microorganism Streptomyces sp. utilizing vegetative oil as sole source of carbon in production medium.... Agent: Blank Rome LLP

20070142423 - Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders: n

20070142425 - Use of cci-779 as an antineoplastic agent: This invention provides the use of CCI-779 in the treatment of neoplasms.... Agent: Howson And Howson Cathy A. Kodroff

20070142426 - Method of cancer screening; method of cancer treatment; and method of diabetes treatment: A method of cancer screening comprising the steps of administering the Blood CA 27,29 testing procedure; if the result is positive administering a mammogram; if the result is positive administering an needle biopsy; if the result is positive administering a PET scan; if the result is positive administering a blood... Agent: Michael A. O'neil, P.C.

20070142427 - Noncyclic 1,3-dicarbonyl compounds as dual ppar agonists with potent antihyperglycemic and antihyperlipidemic activity: Disclosed are the preparation and pharmaceutical use of novel noncyclic 1,3-dicarbonyl compounds of formula I, wherein ring A, ring B, R1, R2, R3, R4, R5, X, Y, Z, Q, Ar and n are as defined in the specification. These compounds, as peroxisome proliferator-activated receptor (PPAR) dual agonists for both RXR/PPARgamma... Agent: Buchanan, Ingersoll & Rooney PC

20070142428 - Isoquinoline-3-carboxylic acid amides and pharmaceutical uses thereof: The present invention relates to novel isoquinoline-3-carboxylic acid amides having α7 nicotinic acetylcholine receptor agonistic activity, their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them.... Agent: Novartis Corporate Intellectual Property

20070142429 - Isoquinoline compounds: Isoquinoline compounds with G are provided that influence, inhibit or reduce the action of a G-protein receptor kinase. Pharmaceutical compositions including therapeutically effective amounts of the isoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as... Agent: Michael Best & Friedrich, LLP

20070142430 - Substituted tetrahydro-2h-isoquinolin-1-one derivatives, and methods for the production and use thereof: o

20070142431 - Quinoline 4-carboxamide derivatives and their use as neurokinin 3 (nk-3) receptor antagonists: The invention relates to novel quinoline derivatives, processes for their preparation, pharmaceutical compositions containing them and their use as medicaments particularly in treating disorders of the central nervous system (CNS).... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070142432 - Biaryl substituted nitrogen containing heterocycle inhibitors of lta4h for treating inflammation: e

20070142433 - Angiogenesis-affecting compounds and methods of use thereof: Angiogenesis may be affected by administering a compound to a group of cells, a tissue or an organism. Such affect may be to inhibit or stimulate angiogenesis. The compounds may be used to treat disease states related to insufficient or unregulated angiogenesis.... Agent: Wiggin And Dana LLP Attention: Patent Docketing

20070142434 - N-linked aryl heteroaryl inhibitors of lta4h for treating inflammation: g

20070142435 - [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone hydrochloride as an inhibitor of mast cell tryptase: Furthermore, the present invention is directed to the use of a compound of formula I as an inhibitor of tryptase, comprising introducing the compound into a composition comprising tryptase. In addition, the present invention is directed to the use of a compound of formula I for treating a patient suffering... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070142436 - New salt and polymorph of a dpp-iv inhibitor: The invention is concerned with (2S)-1-{[1,1 -Dimethyl-3-(4-pyridin-3-yl-imidazol-1-yl)-propylamino]-acetyl}-pyrrolidine-2-carbonitrile fumarate and crystalline polymorphs of this compound. This compound and its polymorphic forms exhibits superior properties compared to the previously known compounds and can be used as medicament for the treatment of disorders which are associated with DPP-IV.... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070142437 - Chemical compounds: Oxazole derivatives, which are useful as VEGFR2, CDK2, and CDK4 inhibitors are described herein. The described invention also includes methods of making such oxazole derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070142438 - Azabicyclo (3.1.0.) hexane derivatives useful as modulators of dopamine d3 receptors: and when R1 is chlorine and p is 1, such R1 is not present in the ortho position with respect to the linking bond to the rest of the molecule; and when R1 corresponds to R5, p is 1; or a salt thereof which are useful as modulators of dopamine... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070142439 - Pesticidal composition: or a substituted or unsubstituted heterocyclic group, (wherein X is an oxygen atom or a sulfur atom, R1 and R2 are respectively independently a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted cycloalkyl group,... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070142440 - Pyridinamide derivatives as kinase inhibitors: The invention relates to substituted arylamide derivatives of the formula I, the preparation and use thereof for the preparation of a medicament for the treatment of diseases, in particular tumours and/or diseases that are caused, mediated and/or propagated by angiogenesis. Compounds of the formula I are effective inhibitors of tyrosine... Agent: Millen, White, Zelano & Branigan, P.C.

20070142441 - Ampa receptor potentiators: e

20070142442 - Stabilized pharmaceutical compositions containing a calcium channel blocker: [wherein R1 represents an optionally substituted C1-C4 alkyl group, an amino group or a cyano group; R2 represents an optionally substituted C1-C4 alkyl group, a substituted C3-C4 alkenyl group, or a substituted 4- to 6-membered cyclic amino group; R3 represents a substituted phenyl group; R4 represents an optionally substituted C1-C4... Agent: Frishauf, Holtz, Goodman & Chick, PC

20070142445 - 4-(3,3-dihalo-allyloxy) phenoxy alkyl derivatives: R7 is H, C1-C6alkyl, C1-C6alkoxyalkyl or C1-C6alkylcarbonyl; k, when D is nitrogen, is 1, 2 or 3; or, when D is CH, is 1, 2, 3 or 4; and m is 1 or 2; and, where applicable, their possible E/Z isomers, E/Z isomeric mixtures and/or tautomers, in each case in... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20070142443 - Asymmetric reductive amination of keto acid derivatives for producing amino acid derivatives:

20070142444 - Fungicidal composition comprising a pyridylethylbenzamide derivative and a compound capable of inhibiting the spores germination or mycelium growth by acting on different metabolic routes: A composition comprising at least a pyridylethylbenzamide derivative of general formula (I)(a) and a compound capable of inhibiting the spores germination or mycelium growth by acting on different metabolic routes (b) in a (a)/(b) weight ratio of from 0.01 to 20. A composition further comprising an additional fungicidal compound. A... Agent: Ostrolenk Faber Gerb & Soffen

20070142446 - (indol-3-yl) heterocycle derivatives as a agonists of the cannabinoid cb1 receptor: c

20070142447 - Veterinary composition comprising an arylpyrazole and a nitroenamine with enhanced antiparasitic activity: The invention relates to antiparasitic combinations of arylpyrazoles and nitroenamines, and their use for controlling insect and acarid infestations on animals.... Agent: Intervet Inc. Patent Department

20070142448 - Chromane substituted benzimidazole derivatives: A, B, X, R1, R2, R3, R4, R5, R6, R7 and R8 are each as described herein or a pharmaceutically acceptable salt, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by acid pump antagonistic activity such as, but not limited... Agent: Pfizer Inc.

20070142449 - Angiogenesis inhibitors: Each of Ar1, Ar2, and Ar3, independently, is phenyl, thienyl, furyl, pyrrolyl, pyridinyl, or pyrimidinyl; each of R1, R2, R3, R4, R5, and R6, independently, is R, nitro, halogen, C(O)OR, C(O)SR, C(O)NRR′, (CH2)mOR, (CH2)mSR, (CH2)mNRR′, (CH2)mCN, (CH2)mC)O)OR, (CH2)mCHO, (CH2)mCH═NOR, or R1 and R2 together, R3 and R4 together, or R5... Agent: Osha Liang L.L.P.

20070142450 - Novel urea derivatives and their medical use: This invention relates to novel urea derivatives, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central... Agent: Birch Stewart Kolasch & Birch

20070142451 - Carvedilol hydrobromide: The present invention relates to a salt of carvedilol, corresponding compositions containing such a carvedilol salt or corresponding solvates thereof, and/or methods of using the aforementioned compound(s) in the treatment of certain disease states in mammals, in particular man. The present invention further relates to a novel crystalline form of... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070142452 - Fused pyrrole derivatives: e

20070142453 - 1-alkyl-3-thio-substituted indole-2-alkynoic acids useful for the treatment of alzheimer's disease and related conditions:

20070142454 - 3-arylthioindole-2-carboxamide derivatives and analogs thereof as inhibitors of casein kinase i:

20070142455 - N-acyl-n'-benzyl-alkylendiamino derivatives: This invention is related to compounds and use of N-Acyl-N′-benzyl-alkylendiamino derivatives of the following general formula (I), wherein A is a straight or branched C2-C8 alkyl chain; X is a methylene, oxygen, sulphur or a NR7 group; R1 is a straight or branched C1-C8 alkyl or C3-C8 alkenylene or C3-C8... Agent: Young & Thompson

20070142456 - Method for inhibiting cancer development by fatty acid synthase inhibitors: A method for inhibiting or preventing cancer development by the administration of fatty acid synthase (FAS) inhibitors. In particular, the present invention prohibits or delays the development of invasive cancer from pre-malignant (non-invasive) lesions that express FAS. Compositions containing FAS inhibitors also are provided, as well as methods for administering... Agent: Covington & Burling, LLP Attn: Patent Docketing

20070142457 - Crystalline forms of docetaxel and processes for their preparation: Novel forms of crystalline docetaxel are provided, as well as pharmaceutical compositions, and methods of treatment. Novel processes for making crystalline docetaxel are also provided.... Agent: Kenyon & Kenyon LLP

20070142458 - Olopatadine formulations for topical nasal administration: Topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the nose are disclosed. The aqueous formulations contain approximately 0.6% (w/v) of olopatadine.... Agent: Alcon

20070142460 - Compounds, compositions and methods: Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070142459 - Use of artemisinin for treating tumors induced by oncogenic viruses and for treating viral infections: In certain aspects, the invention relates to methods of treating proliferative cervical disorders (such as cervical cancer and cervical dysplasia) and treating virus infections by administering artemisinin-related compounds. In certain aspects, the invention relates to methods of treating a tumor induced by an oncogenic virus, methods of killing or inhibiting... Agent: Wolf Greenfield & Sacks, P.C.

20070142461 - Cyclic alkyl substituted glycolides and polylactides therefrom: Cyclic alkyl, particularly cyclohexyl, substituted glycolides and polylactides are described. The polylactides have a high glass transition temperature and improved clarity.... Agent: Ian C. Mcleod, P.c Ian C. Mcleod

20070142462 - Method of treating cancer: Methods for treating cancer are provided including administering a patient needing treatment a therapeutically effective amount of one or more antioxidants selected from the group of catalase, N-acetylcysteine, glutathione peroxidase, salen-transition metal complexes, dicumarol, and derivatives thereof.... Agent: Alston & Bird LLP

20070142463 - Active agents combination exhibiting insecticidal and acaricide properties: The present invention relates to novel active compound combinations of cyclic ketoenols of the formula (I) and active compounds of the formula (II) detailed in the disclosure having very good insecticidal and acaricidal properties.... Agent: Bayer Cropscience Lp Patent Department

20070142464 - Nonsteroidal progesterone receptor modulators: a process for their production, the use of progesterone receptor modulators for the production of pharmaceutical agents as well as pharmaceutical compositions that contain these compounds. The compounds according to the invention are suitable for therapy and prophylaxis of gynecological diseases, such as endometriosis, leiomyomas of the uterus, dysfunctional bleeding... Agent: Millen, White, Zelano & Branigan, P.C.

20070142465 - Macrophage activation inhibitor: wherein R3 represents a C1 to C4 alkyl group can inhibit macrophage activation. Accordingly, a macrophage activation inhibitor containing a compound represented by the general formula (1) or its pharmacologically acceptable salt as an active ingredient is useful as an agent for preventing, improving, or treating a disease resulting from... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070142466 - Photoreactive compounds and compositions: The present invention provides a compound of formula (I): PtIV(N3)2X1X2Y1Y2, wherein X1 and X2 are the same or different and each one is a group NR1R2R3 wherein R1, R2 and R3 are the same or different and each can be any one of H and optionally substituted alkyl, aryl, aralkyl,... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20070142467 - 3-alkylaryl aspartate compounds and their use for selective enhancement of synaptic transmission: wherein Ar represents an aromatic group; L represents a linking moiety; R represents hydrogen, alkyl, aryl, or heteroaryl; and indicates that the stereochemistry at the 3-position can be R or S. The compounds of the invention are useful for selectively inhibiting EAAT3 and for enhancing synaptic transmission. Additionally, the... Agent: Leydig Voit & Mayer, Ltd

20070142468 - Compositions containing prodrugs of florfenicol and methods of use: The present invention provides compositions and methods for administering florfenicol to mammals. The compositions contain a prodrug of florfenicol in a pharmaceutically acceptable carrier. In one embodiment the prodrug is an esterized form of florfenicol. Examples of suitable prodrugs include one or a combination of one or a combination of... Agent: Kenyon & Kenyon LLP

20070142469 - Method of using beta-hydroxy-beta-methylbutyrate: Disdosed are methods of treating an individual having a condition characterized by an imbalance in type 1 and type 2 cytokine production, wherein the method comprises administering to the individual an amount of β-hydroxy-β-methylbutyrate (HMB) effective to modulate or otherwise cause an increase in the ratio of type 1 to... Agent: Ross Products Division Of Abbott Laboratories Department 108140-ds/1

20070142470 - Compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them: s

20070142471 - Sulfonamides: The present invention provides R, R1, R2, R3, X, c, d, e, f, g, x, y, a, b, z and n are defined in the specification. These compounds are useful in lowering IOP and/or treating glaucoma or providing neuroprotection to the eye of a human patient.... Agent: Robert J. Baran (t2-7h) Allergan, Inc.

20070142472 - Process for producing optically active 3-(4-hydroxyphenyl)proprionic acids: The present invention relates to a process for producing an optically active 3-(4-hydroxyphenyl)propionic acid useful as intermediates for medicines, through short steps in good yield and with high optical purity. More specifically, the present invention relates to a process for producing an optically active 3-(4-hydroxyphenyl)propionic acid of the formula (6):... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070142473 - Dosage forms and methods using ethacrynic acid: The invention is directed to a method of treating systemic arterial hypertension which preferably uses enter administration of a once-daily dose of ethacrynic acid of less than 50 mg/day to a patient afflicted with arterial hypertension. Doses of less than 25 mg/day ethacrynic acid are also indicated for treating hypertension.... Agent: Accu-break Technologies, Inc.

20070142474 - Jasmonate derivative compounds, pharmaceuticals compounds and methods of use thereof: The present invention provides novel jasmonate derivative compounds, methods for their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for treatment of cancers, especially mammalian cancers.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070142476 - Biphenyl-derivatives as p38 kinase inhibitors: e

20070142475 - Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides and use as renin inhibitors:

20070142477 - Analgesia: The present invention concerns compounds derived from the anaesthetic propofol that are useful as analgesics and methods of using the same. The compounds act as co-activators of strychnine-sensitive glycine receptors and may have greater activity at those glycine receptors than at GABAA.... Agent: Davis Wright Tremaine LLP

20070142478 - Combination antimicrobial composition and method of use: Provided herein is a pharmaceutically acceptable composition comprising a biguanide containing antimicrobial agent and an additional antimicrobial agent. The invention further comprises topically administering the pharmaceutically acceptable composition to a patient in need of treatment.... Agent: Bausch & Lomb Incorporated

20070142479 - Tolterodine, compositions and uses thereof, and preparation of the same: Racemic tolterodine free base in crystalline form, tolterodine with improved purity, compositions and uses thereof, and processes of preparing the same.... Agent: Conley Rose, P.C.

20070142480 - Alleviation of pain in osteoarthritis by means of intra-articular implantation of perfluorodecalin.: Methods of alleviating pain by the intra-articular application of perfluorodecalin are disclosed.... Agent: Trainer 1 Limited

20070135333 - Antisense antibacterial method and compound: An antibacterial antisense conjugate and method of using the same for treating a bacterial infection in a mammalian host are disclosed. The conjugate includes an antisense oligonucleotide conjugated to a carrier peptide that significantly enhances the antibacterial activity of the oligonucleotide. The antisense oligonucleotide contains 10-20 nucleotide bases and has... Agent: Perkins Coie LLP

20070135334 - Peptides and methods using same for diagnosing and treating amyloid-associated diseases: A peptide comprising at least 5 amino acid residues.and less than 15 amino acid residues, the peptide including an amino acid sequence as set forth in SEQ ID NO: 7 as well as pharmaceutical compositions, kits and methods for diagnosing and treating amyloid associated diseases.... Agent: Martin D. Moynihan Prtsi, Inc.

20070135341 - Antifungal peptides and methods of use thereof: A method of treating fungal infections by treatment with CAP37 peptides and derivatives thereof, including peptide analogs having serine or threonine substitutions at least one of the two cysteine residues therein. Other substitutions of the amino acid residues of the peptide are also contemplated.... Agent: Dunlap, Codding & Rogers P.C.

20070135339 - Bacteriocin inducer peptides: Novel peptides produced by bacteriocin-producing bacteria stimulate the production of bacteriocins in vitro. The producer bacteria are cultured in the presence of a novel inducer bacteria and a peptide having a carboxy terminal sequence of VKGLT in order to achieve an increase in bacteriocin production.... Agent: Usda, Ars, Ott

20070135336 - Follistatin isoforms and uses thereof: The present invention relates generally to regulating biological developmental process such as the biological functions involved in such developmental processes including growth and survival of an animal and particularly to methods of modifying the developmental processes and biological functions in cells. The invention also relates to methods of preventing and... Agent: Scully, Scott, Murphy & Presser, P.C.

20070135347 - Human cytokine receptor: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16.”... Agent: Zymogenetics, Inc. Intellectual Property Department

20070135338 - Human glp-1 mimetibodies, compositions, methods and uses: The present invention relates to at least one novel human GLP-1 mimetibody or specified portion or variant, including isolated nucleic acids that encode at least one GLP-1 mimetibody or specified portion or variant, GLP-1 mimetibody or specified portion or variants, vectors, host cells, transgenic animals or plants, and methods of... Agent: Philip S. Johnson Johnson & Johnson

20070135340 - Igf-1 novel peptides: The present invention relates to novel polypeptide constructs based on peptides derived from Insulin-like Growth Factor I (IGF-I). The invention also relates to novel uses for IGF-1-derived peptides, particularly for the prevention and treatment of diseases involving regulation of cellular growth or differentiation, regeneration and tissue repair.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070135349 - Method for increasing the serum half-life of a biologically active molecule: A method is provided for preparing a biologically active molecule having an increased serum half-life. The method involves conjugating a polymer such as polyethylene glycol to the biologically active molecule. Also provided are polypeptide drugs having an increased serum half-life, e.g., human urokinase plasminogen activator (human “uPA” or “hUPA”) or... Agent: Mintz, Levin, Cohn, Ferris Glovsky And Popeo, P.C.

20070135348 - Methods and compositions for the treatment of peripheral artery disease: Compositions and methods for treating peripheral artery disease in a patient are provided. Compositions comprise recombinant fibroblast growth factor-2. Fibroblast growth factor, such as FGF-2, is administered in therapeutically effective amounts to treat or prevent peripheral artery disease including claudication and critical limb ischemia. Pharmaceutical compositions comprising a therapeutically effective... Agent: Novartis Vaccines And Diagnostics Inc.

20070135342 - Modified factor viii: Modified porcine factor VIII is disclosed in which most of the B domain has been removed through genetic engineering. This modified factor VIII is particularly useful for treatment of hemophiliacs, especially those undergoing bleeding episodes.... Agent: Greenlee Winner And Sullivan P C

20070135344 - Novel growth factor and a genetic sequence encoding same: The present invention relates to an isolated molecule having vascular endothelial growth factor-like properties and to a genetic sequence encoding the molecule.... Agent: Crowell & Moring LLP Intellectual Property Group

20070135346 - Prodrugs of cc-1065 analogs: Prodrugs of analogs of the anti-tumor antibiotic CC-1065 having a cleavable protective group such as a piperazino carbamate, a 4-piperidino-piperidino carbamate or a phosphate, in which the protecting group confers enhanced water solubility and stability upon the prodrug, and in which the prodrug also has a moiety, such as a... Agent: Sughrue Mion, PLLC

20070135343 - Sodium chloride solution for drug reconstitution or dilution: The invention provides methods for preparing pharmaceutical formulations for injection such that upon injection the formulation does not cause erythrocyte agglutination, hemolysis, and/or cell shrinkage. To prevent agglutination, a pharmaceutical formulation ready for injection needs to have a sufficient ionic strength. To prevent hemolysis or cell shrinkage, a pharmaceutical formulation... Agent: Wilmerhale/wyeth

20070135335 - Therapeutic molecules: The present invention relates generally to a ligand for a protein associated with modulating obesity, diabetes and metabolic energy levels in animals including humans. More particularly, the present invention provides a ligand of the protein, Beacon, and its homologs. The identification of a Beacon ligand permits the identification of agents... Agent: Scully, Scott, Murphy & Presser, P.C.

20070135345 - Use of glp-2 for the treatment or prevention, of bone-related disorders: The present invention relates to methods for prevention and treatment of bone-related or nutrition-related disorders using a GLP-2 molecule or GLP-2 activator either alone or in combination with another therapeutic. The invention also encompasses methods of monitoring the effectiveness of treatment of the invention.... Agent: Edwards Angell Palmer & Dodge LLP

20070135337 - Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases: The present invention relates to a stereochemically based “non-self” antigen vaccine for the prevention and/or treatment of Alzheimer's and other amyloid related diseases. The present invention provides a vaccine for the prevention and treatment of Alzheimer's and other amyloid related diseases, which overcomes the drawbacks associated with using naturally occurring... Agent: Clark & Elbing LLP

20070135350 - Methods of identifying compounds that modulate il-4 receptor-mediated ige synthesis utilizing a b-cell associated protein: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a BAP-37 as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex... Agent: Dechert LLP

20070135351 - Neuropeptide-2 receptor (y-2r) agonists and uses thereof: e

20070135352 - Use of lh for generating libido and reaching orgasm in female subjects: The use is described of LH (Luteinizing Hormone) to cure a lack of or low libido and/or a difficulty in reaching orgasm in female subjects.... Agent: Young & Thompson

20070135356 - Amino acid conjugates providing for sustained systemic concentrations of gaba analogues: This invention is directed to compounds that provide for sustained systemic concentrations of GABA analogs following administration to animals. This invention is also directed to pharmaceutical compositions including and methods using such compounds.... Agent: Buchanan, Ingersoll & Rooney PC

20070135353 - Crystalline n-formyl hydroxylamine compounds: Certain N-formyl hydroxylamine compounds, such as N-[1-oxo-2-alkyl-3-(N-hydroxyformamido)-propyl]-(carbonylamino-aryl or -heteroaryl)-azacyclo4-7alkanes or thiazacyclo4-7alkanes or imidazacyclo4-7alkanes are useful in the treatment of bacterial infections. Disclosed are crystalline salts of such compounds of formula (I), wherein M is a mono- or di-valent metal; a is ½ or 1.... Agent: Novartis Corporate Intellectual Property

20070135355 - Functionalized diphenolics and absorbable polymers therefrom: r

20070135354 - Hematopoietic stimulation: Methods and products for stimulating hematopoietic, preventing low levels of hematopoietic cells and producing increased numbers of hematopoietic and, mature blood cells are provided. The methods and products can be used both in vivo and in vitro.... Agent: Wolf Greenfield & Sacks, P.C.

20070135357 - Anti-hypercholesterolemic compounds: The instant invention provides novel cholesterol absorption inhibitors of Formula I and the pharmaceutically acceptable salts and esters thereof. The compounds are useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating and preventing atherosclerosis and atherosclerotic disease events.... Agent: Merck And Co., Inc

20070135358 - Steroid modified solatrioses: The invention pertains to steroid modified solatrioses and the synthesis thereof as well as to intermediate compounds useful for the synthesis of the steroid modified solatrioses.... Agent: Kagan Binder, PLLC

20070135359 - Identification of free-b-ring flavonoids as potent cox-2 inhibitors: The present invention provides a novel method for inhibiting the cyclooxygenase enzyme COX-2. The method is comprised of administering a composition containing a Free-B-Ring flavonoid or a composition containing a mixture of Free-B-Ring flavonoids to a host in need thereof. The present also includes novel methods for the prevention and... Agent: Swanson & Bratschun L.L.C.

20070135360 - Method for diagnosis of alzheimer's disease: The invention relates to a method of treating Alzheimer's disease in a mammal comprising administering to the mammal an anti-microbial agent having anti-Chlamydia pneumoniae activity. The invention also relates to a method of diagnosing Alzheimer's disease in a mammal comprising measuring the serum anti-Chlamydia pneumoniae antibody titer in a patient... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20070135361 - Method of diagnosing alzheimer's disease by detection of chlamydia pneumoniae: The invention relates to a method of treating Alzheimer's disease in a mammal comprising administering to the mammal an anti-microbial agent having anti-Chlamydia pneumoniae activity. The invention also relates to a method of diagnosing Alzheimer's disease in a mammal comprising measuring the serum anti-Chlamydia pneumoniae antibody titer in a patient... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20070135362 - Method for demethylating the 3'-dimethylamino group of erythromycin compounds: A method for demethylating the 3′-dimethylamino group of erythromycin compounds.... Agent: Kosan Biosciences, Inc

20070135363 - Novel tricyclic nucleosides or nucleotides as therapeutic agents: Nucleosides and nucleotides containing a tricyclic base portion thereof are useful for treating infectious diseases and proliferative disorders, such as viral infections or cancer respectively.... Agent: Seed Intellectual Property Law Group PLLC

20070135371 - Antisense iap nucleobase oligomers and uses thereof: The present invention features nucleobase oligomers that hybridize to IAP polynucleotides, and methods for using them to enhance apoptosis.... Agent: Philip Swain, Phd C/o Gowling Lafleur Henderson

20070135368 - Cell-to-cell transmission of sirna induced gene silencing in mammalian cells: A method for reducing expression of a target gene in a mammalian cell is provided. The method comprises (a) introducing siRNA into a first mammalian cell such that expression of the target gene is reduced in the first mammalian cell, and (b) exposing a second mammalian cell which does not... Agent: Buchanan, Ingersoll & Rooney PC

20070135364 - Compositions and methods for the modulation of the expression of b7 protein: Anti sense oligonucleotide compositions which specifically hybridize with nucleic acids encoding B7 proteins, and use of these compositions for inhibiting expression of B7 mRNA.... Agent: Knobbe, Martens, Olson & Bear, LLP

20070135366 - Method for assessing cancerous state: The present invention relates to a method for assessing a cancerous state of a mammal-derived specimen, which comprises: (1) a first step of measuring a methylation frequency of FiLbrillin2 gene contained in a mammal-derived specimen or an index value having the correlation therewith, and (2) a second step of determining... Agent: Sughrue Mion, PLLC

20070135367 - Method for controlling sr protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control sr protein activity: The present invention provides: (1) antiviral agents that act by reducing or inhibiting the activity of SR proteins, more specifically, (i) antiviral agents that act by enhancing dephosphorylation of SR proteins, and (ii) antiviral agents that act by inhibiting proteins that phosphorylate SR proteins; (2) antiviral agents that act by... Agent: Klarquist Sparkman, LLP

20070135373 - Method for selective expression of therapeutic genes by hyperthermia: A method for controlling in vivo heat-inducible gene expression for provision of therapeutic polypeptide. The method includes the steps of: (a) providing a construct comprising a polynucleotide encoding a therapeutic polypeptide, wherein the polynucleotide is operatively linked to a heat-inducible promoter; (b) administering the construct to a warm-blooded vertebrate at... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20070135369 - Methods of modulating angiogenesis and screening compounds for activity in modulating angiogenesis: The present invention provides methods of modulating angiogenesis in an individual, as well as methods of identifying a candidate agent that modulates angiogenesis, where such methods involve modulating and identifying agents that modulate expression of gene products of a subset of genes concordantly-regulated by agonists of nicotinic acetylcholine receptor (nAChR),... Agent: Bozicevic, Field & Francis LLP

20070135372 - Modified sirna molecules and uses thereof: The present invention provides chemically modified siRNA molecules and methods of using such siRNA molecules to silence target gene expression. Advantageously, the modified siRNA of the present invention is less immunostimulatory than its corresponding unmodified siRNA sequence and retains RNAi activity against the target sequence. The present invention also provides... Agent: Townsend And Townsend And Crew, LLP

20070135365 - Pharmaceutical composition for preventing or remedying cardiac hypertrophy and cardiovascular disease caused thereby: Compositions and methods for preventing or treating cardiac hypertrophy which inhibit the cardiac hypertrophy signal pathway mediated through G protein coupled receptors (GPCR) or epidermal growth factor (EGF) receptors. The present invention also relates to methods for screening active ingredients, and to animal models of cardiac hypertrophy.... Agent: Knobbe Martens Olson & Bear LLP

20070135370 - Sirna silencing of filovirus gene expression: The present invention provides siRNA molecules that target Filovirus gene expression and methods of using such siRNA molecules to silence Filovirus gene expression. The present invention also provides nucleic acid-lipid particles that target Filovirus gene expression comprising an siRNA that silences Filovirus gene expression, a cationic lipid, and a non-cationic... Agent: Townsend And Townsend And Crew, LLP

20070135374 - Composition for promoting collagen production: The invention provides a composition for promoting collagen production, and more specifically, provides a composition capable of promoting collagen production in human dermis. Further, the invention provides a method for promoting collagen production. The invention provides a composition for promoting collagen production containing a purine nucleic acid-related substance as an... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070135375 - Sulfamoyl sulfonate prodrugs: e

20070135376 - Method to reduce oxidative damage and improve mitochondrial efficiency: Methods for the reduction of mitochondrial oxidative damage and improved mitochondrial efficiency in an animal by administration of medium chain triglycerides or prodrug of medium chain triglycerides to the animal are provided.... Agent: Swanson & Bratschun L.L.C.

20070135377 - Thixotropic anti-viral formulation: A thixotropic anti-viral formulation includes a high molecular weight, thixotropic, gel-forming, naturally occurring polysaccharide extracted from algae and comprised of repeating sulfated and non-sulfated galactose and 3,6 anhydrogalactose (3,6-AG) units, and includes water.... Agent: Tod R Nissle

20070135378 - Method for the direct synthesis of oligorhamnosides, composition comprising oligorhamnosides and use thereof as a medicament: The invention relates to a method of preparing oligorhamnosides, comprising a one-pot reaction in acetonitrile without any rhamnose protection or deprotection reaction. The invention also relates to a composition a mixture of oligorhamnosides, which can be obtained using said method and which has between 2 and 12 rhamnose units. The... Agent: Birch Stewart Kolasch & Birch

20070135379 - Anhydrous pharmaceutical composition associating a siliconated agent and solubilised active principle: The invention relates to an anhydrous pharmaceutical composition associating at least one type of active principle and one type of siliconated agent which comprises at least one type of organopolysiloxane elastomer, wherein said active principle is embodied in the solubilised form thereof in said composition.... Agent: Oliff & Berridge, PLC

20070135380 - O-nitro compounds, pharmaceutical compositions thereof and uses thereof: The present invention provides O-nitro compound, pharmaceutical compositions of O-nitro compounds and methods of using O-nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.... Agent: Morgan, Lewis & Bockius, LLP

20070135381 - Derivatives of branch-chain lipophilic molecular and uses thereof: Novel phospho-derivatives of branched-chain lipophilic molecules useful for permeabilizing biological barriers and for inhibiting tumor growth are disclosed. Pharmaceutical compositions comprising said molecules and their uses are also disclosed.... Agent: Davidson, Davidson & Kappel, LLC

20070135383 - Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors: The present invention provides methods and compositions for the treatment of phospholipase-related conditions. In particular, the invention provides a method of treating insulin-related, weight-related conditions and/or cholesterol-related conditions in an animal subject. The method generally involves the administration of a non-absorbed and/or effluxed phospholipase A2 inhibitor that is localized in... Agent: Ilypsa-mcandrews C/o Mcandrews, Held & Madison Street

20070135382 - Use of peroxisome proliferator-activated receptor gamma (ppary) and/or retinoic acid receptor (rxr) agonists to inhibit platelet functions: Methods of inhibiting mammalian platelet release of CD40 ligand, thromboxanes, or prostaglandin E2, or surface expression of CD40 ligand that involve contacting mammalian platelets with an effective amount of a PPARγ agonist, an RXR agonist, or a combination thereof. As a consequence of inhibiting CD40 ligand and thromboxane release, the... Agent: Nixon Peabody LLP - Patent Group

20070135384 - Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.... Agent: Morgan, Lewis & Bockius, LLP

20070135387 - Inhibitors of protein kinases: Compounds that inhibit protein kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.... Agent: Robert Deberardine Abbott Laboratories

20070135385 - Multivalent indole compounds and use thereof as phospholipase-a2 inhibitors: Indole and indole-related compounds, compositions and methods are disclosed. The compounds of the invention are useful as phospholipase inhibitors. The compounds and compositions of the invention are useful for treatment of phospholipase-related conditions, such as insulin-related, weight-related and/or cholesterol-related conditions in an animal subject.... Agent: Ilypsa-mcandrews C/o Mcandrews, Held & Madison Street

20070135386 - Novel compounds and compositions as cathepsin inhibitors: The present invention relates to novel cathepsin S inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.... Agent: Synnestvedt & Lechner LLP

20070135388 - Novel bicyclic cannabinoids: Bicyclic-cannabinoids and methods of preparation and use are presented. These compounds, when administered in a therapeutically effective amount to an individual or animal, results in a sufficiently high level of that compound in the individual or animal to cause a physiological response. The physiological response may be useful to treat... Agent: Alix Yale & Ristas LLP

20070135389 - Tumor eradication by inositol-tripyrophosphate: The present invention relates to various salts of inositol tripyrophosphate including the calcium, lithium, beryllium, magnesium, potassium, strontium, barium, rubidium and cesium salts of inositol tripyrophosphate, compositions comprising these salts, methods of making the various salts, and methods of use of the above salts. Methods of use include administering the... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20070135390 - Phosphate derivatives: According to the invention, there is provided a phosphate derivative of a phenolic hydroxy compound comprising the reaction product of the following steps: (d) reacting the phenolic hydroxy compound with an alkyl α:ω dialdehyde or a sugar-like polyhydroxy dialdehyde to form a hemiacetal; (e) reducing the terminal aldehyde group on... Agent: Reed Smith LLP

20070135391 - Microbicidal compositions and their use: A composition comprising a copper salt of N′-hydroxy-N-cyclohexyldiazenium oxide (CuHDO) and a diluent is useful for combating and/or killing bacteria, mould, yeast and algae in industrial materials and or industrial processes. In a preferred embodiment CuHDO is generated in-situ within the application or medium. The composition may additionally include at... Agent: Connolly Bove Lodge & Hutz, LLP

20070135392 - Apoptosis promoters: Compounds which inhibit the activity of anti-apoptotic Mcl-1 protein, compositions containing the compounds and methods of treating diseases during which are expressed the Mcl-1 protein are disclosed.... Agent: Robert Deberardine Abbott Laboratories

20070135393 - Prevention of deficits in neurogenesis with anti-inflammatory agents: Methods are provided for protecting an individual from adverse long-term effects of neuroinflammation. Inflammatory blockade maintains neurogenesis capability after cranial irradiation by reducing the negative effects of activated microglia on neural precursor cells. These findings have broad implications for a variety of diseases of cognition, involving neuroinflammation and precursor cell... Agent: Bozicevic, Field & Francis LLP

20070135395 - Novel method for the preparation of intermediates useful for the synthesis fo vitamin d analogues: The present invention relates to novel methods for the preparation of intermediates which are useful in the synthesis of cacipotriol. The present invention relates further to the use of intermediates produced with said methods for making calcipotriol or calcipotriol monohydrate.... Agent: Birch Stewart Kolasch & Birch

20070135394 - Process for the synthesis of vitamin d compounds and intermediates for the synthesis of the compounds: An object of the present invention is to provide a process for synthesizing a vitamin D compound by simple procedures at lower costs. The present invention provides a process for preparing a vitamin D compound and an intermediate thereof, comprising the step of: (a) mixing a ketone or aldehyde, a... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070135396 - 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations: The present invention relates to new formulations containing one or more estrogens and 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole compounds which are useful as estrogenic agents, as well as pharmaceutical compositions and methods of treatment utilizing these compounds, which have the general structures below:... Agent: Pepper Hamilton LLP

20070135397 - 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations: The present invention relates to new formulations containing one or more estrogens and 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole compounds which are useful as estrogenic agents, as well as pharmaceutical compositions and methods of treatment utilizing these compounds, which have the general structures below:... Agent: Pepper Hamilton LLP

20070135398 - Process for the preparation of ciclesonide: Provided is a process for increasing the 22R/22S epidemic ratio of ciclesonide.... Agent: Kenyon & Kenyon LLP

20070135399 - Heteroaromatic sulphonamide prodrugs: o

20070135400 - Estradiol derivatives:

20070135401 - Lestaurtinib crystalline form 1, crystalline lestaurimib anhydrate and amorphous lestaurimib: Lestaurtinib Crystalline Form 1, isolated crystalline lestaurtinib anhydrate and amorphous lestaurtinib, processes to reproducibly make them and methods of treating patients using them.... Agent: Robert Deberardine Abbott Laboratories

20070135402 - Azetidine ring compounds and drugs comprising the same: wherein each symbol is as defined in the description; salts thereof, N-oxides thereof, solvates thereof or prodrugs thereof are useful as preventive and/or therapeutic agent for EDG-5 mediated diseases, for example, diseases caused by blood vessel contraction (e.g. cerebrovascular spasms disease, cardiovascular spasms diseases, coronary artery spasms disease, hypertension, pulmonary... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070135403 - Substituted 2,5-diaminomethyl-1h-pyrrole compounds: Substituted 2,5-diaminomethyl-1H-pyrroles, a process for the production thereof, pharmaceutical compositions containing them, and the use of these compounds for regulating 5-hydroxytryptamine uptake, noradrenalin uptake and/or opioid receptor activity, or for treating or inhibiting disorders or diseases at least partially mediated by a receptor selected from the group consisting of 5-hydroxytryptamine... Agent: Crowell & Moring LLP Intellectual Property Group

20070135404 - Respiratory syncytial virus replication inhibitors: b

20070135406 - Diazabicyclononene and tetrahydropyridine derivatives with a new side-chain: The invention relates to novel bicyclic derivatives, and related compounds and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as... Agent: Hoxie & Tso LLP

20070135405 - Novel diazabicyclononene and tetrahydropyridine derivatives with a new polar side-chain: The invention relates to novel bicyclic derivatives and related compounds and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as... Agent: Hoxie & Tso LLP

20070135407 - Serm reduction of lipid profiles: This invention is directed, inter alia to: 1)improving a lipid profile; 2) methods of reducing circulating lipid levels; 3) methods of increasing high density lipoprotein (HDL) levels; 4) methods of altering ratios of low density lipoprotein to high desnsity lipoprotein levels in a subject; 5) methods of treating atherosclerosis and... Agent: Pearl Cohen Zedek Latzer, LLP

20070135409 - Nonpeptide substituted spirobenzoazepines as vasopressin antagonists: wherein A, X, n, R1, R2, R3, R4, R5, a and b are as described in the specification, which are useful as vasopressin receptor antagonists for treating conditions associated with vasopressin receptor activity such as those involving increased vascular resistance and cardiac insufficiency. Pharmaceutical compositions comprising a compound of Formula... Agent: Philip S. Johnson Johnson & Johnson

20070135408 - Spiropiperidine derivatives for controlling pests: The use of a compound of Formula (I), Y is a single bond, C═O, C═S or S(O)m where m is 0, 1 or 2; the ring represented by T is a 5 or 6 membered heteroaromatic and R1, R2, R3, R8 and Ra are specified organic groups and p is... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20070135410 - 3-aminopyrrolidone derivatives: 3-aminopyrrolidone compounds and pharmaceutically acceptable salts thereof that are active as sodium and/or calcium channel modulators and therefore useful in preventing, alleviating and curing a wide range of pathologies, including, but not limited to cardiovascular, inflammatory, ophthalmic, urologic, metabolic and gastrointestinal diseases.... Agent: Young & Thompson

20070135411 - Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid: a

20070135412 - Compounds for the treatment of ocular dryness caused by photorefractive surgery: The blocking agents of the electrical activity of the damaged nerve endings of the neuroma can be used for the treatment of dryness of the ocular surface caused by photorefractive surgery, such as excimer laser photorefractive keratectomy or laser-assisted in situ keratomileusis. The administration of said blocking agents, which include... Agent: Ladas & Parry

20070135413 - Treatment of glial tumors with glutamate antagonists: The present invention relates to a method of treating glial tumors in a subject, which includes providing a glutamate antagonist or a NMDA receptor antagonist and administering the glutamate antagonist or NMDA receptor antagonist to a subject with a glial tumor of the brain or spinal cord under conditions effective... Agent: Nixon Peabody LLP - Patent Group

20070135414 - Tachykinin antagonists: e

20070135416 - Tricyclic amide derivatives:

20070135415 - Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy: pharmaceutical compositions containing effective amounts of said compounds or their salts are useful as a single agent or in combination with an anti-neoplastic agent or therapeutic radiation having an anti-neoplastic effect for treating diseases or conditions such as cancers. The current invention relates to the making and using of such... Agent: Pfizer Inc

20070135417 - 1h-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles,and chromones and preparation and uses thereof: The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (indazoles and benzothiazoles), which act as ligands... Agent: Millen, White, Zelano & Branigan, PC

20070135418 - Compositions and methods relating to novel compounds and targets thereof: The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides benzodiazepine derivatives and methods of using benzodiazepine derivatives as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell... Agent: Medlen & Carroll, LLP

20070135419 - Short-acting benzodiazepines: e

20070135420 - Short-acting benzodiazepines: It has now been found that compounds of the present invention as described in Benzodiazepine derivatives of Formula (I) containing a carboxylic ester moiety and thereby capable of being inactivated by nonspecific tissue esterases in an organ-independent elimination mechanism and thereby providing a more predictable and reproducible pharmacodynamic profile. The... Agent: Edwards Angell Palmer & Dodge LLP

20070135421 - Short-acting benzodiazepines:

20070135422 - Nitrogen-containing bicycle heterocycles for use as antibacterials: Cyclohexane and cyclohexene derivatives and pharmaceutically acceptable derivatives thereof useful in methods of treatment of bacterial infections in mammals, particularly man.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070135423 - E-fluoro-4-(pyridin-2-yl)-piperidine-1-carboxamide derivatives and related compounds which modulate the function of the vanilloid-1 receptor (vr1) for the treatment of pain: Compounds of formula (I): wherein: A1 is phenyl, a six-membered aromatic heterocycle containing one, two or three nitrogen atoms, or a five-membered aromatic heterocycle containing up to four heteroatoms chosen from O, N and S, at most one heteroatom being O or S; A2 is phenyl, a six-membered aromatic heterocycle... Agent: Merck And Co., Inc

20070135424 - Substituted propenyl piperazine derivatives as novel inhibitors of histone deacetylase: This invention comprises the novel compounds of formula (I) wherein R1, R2, R3, R4 and X have defined meanings, having histone deacetylase inhibiting enzymatic activity; their preparation, compositions containing them and their use as a medicine.... Agent: Philip S. Johnson Johnson & Johnson

20070135425 - Fused heterocyclic compounds: Compounds, compositions and methods are provided that are useful in the treatment and/or prevention of a condition or disorder mediated by a G-protein coupled receptor. In particular, the compounds of the invention are useful in the treatment and/or prevention of eating disorders, obesity, anxiety disorders and mood disorders.... Agent: Jones Day

20070135427 - Glucocorticoid receptor modulators as antiinflammatory agents: m

20070135428 - Lactam containing cyclic diamines and derivatives as factor xa inhibitors:

20070135426 - Lactam-containing compounds and derivatives thereof as factor xa inhibitors:

20070135429 - Dibenzonaphthyridine derivatives and methods of use thereof: The present invention relates to Dibenzonaphthyridine Derivatives, compositions comprising an effective amount of a Dibenzonaphthyridine Derivative and methods for treating or preventing a proliferative disorder, comprising administering to a subject in need thereof an effective amount of a Dibenzonaphthyridine Derivative.... Agent: Wilmerhale/wyeth

20070135431 - Inhibitors of histone deacetylase for the treatment of disease: or a salt, ester, or prodrug thereof, Methods and compositions are disclosed for treating disease states including, but not limited to cancers, autoimmune diseases, tissue damage, central nervous system disorders, neurodegenerative disorders, fibrosis, bone disorders, polyglutamine-repeat disorders, anemias, thalassemias, inflammatory conditions, cardiovascular conditions, and disorders in which angiogenesis play a... Agent: International Patent Group Attn: Ms Lavern Hall

20070135430 - Substituted furo[2,3-g]indazoles for the treatment of glaucoma: Substituted furo[2,3-g]indazoles for lowering intraocular pressure and treating glaucoma are disclosed.... Agent: Alcon

20070135432 - Compounds, methods and compositions: Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070135433 - Imidazole derivatives as raf kinase inhibitors: Novel compounds and their use as pharmaceuticals particularly as Raf kinase inhibitors for the treatment of neurotraumatic diseases, cancer, chronic neurodegeneration, pain, migraine and cardiac hypertrophy.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070135434 - Sulfonyloxy derivatives: v

20070135435 - Certain chemical entities, compositions, and methods: Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070135436 - Chemical compounds: This invention relates to certain unsaturated fatty acid derivatives of therapeutically active 1,3-dioxolane nucleoside analogues and to pharmaceutical formulations containing them. The said derivatives are referred to as “Compounds of formula I” herein. Compounds of formula I can be used in the treatment of a cancerous disease. Treatment of both... Agent: Fitzpatrick Cella Harper & Scinto

20070135437 - Modulation of neurodegenerative diseases: Methods and compositions are disclosed for selectively decreasing protein levels in a central nervous system, meningial, immune system, blood, or muscle cell by administrating a pharmacological agent. In particular, methods and compositions that interfere with SOD-1 protein synthesis or stability, and decrease cellular levels of the protein are disclosed.... Agent: Nutter Mcclennen & Fish LLP

20070135438 - Inhibitors of histone deacetylase for the treatment of disease: or a pharmaceutically acceptable salt, ester, or prodrug thereof, Methods and compositions are disclosed for treating disease states including, but not limited to cancers, autoimmune diseases, tissue damage, central nervous system disorders, neurodegenerative disorders, fibrosis, bone disorders, polyglutamine-repeat disorders, anemias, thalassemias, inflammatory conditions, cardiovascular conditions, and disorders in which angiogenesis... Agent: International Patent Group Attn: Ms Lavern Hall

20070135439 - Novel inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications: The present invention concerns new compounds of formula (I), their process of preparation and their therapeutic use.... Agent: Stites & Harbison PLLC

20070135440 - Amide derivatives bearing a cyclopropylaminoacarbonyl substituent useful as cytokine inhibitors: The invention concerns a compound of the Formula (I), wherein Qa is heteroaryl and is substituted with halogeno; R1 and R2 are each hydrogen; and Qb is phenyl or heteroaryl, and Qb may optionally bear 1 or 2 substituents selected from hydroxy, halogeno and (1-6C)alkyl, or a pharmaceutically-acceptable salt thereof;... Agent: Morgan Lewis & Bockius LLP

20070135441 - New derivatives of 6-{4-[4-(1h-indole-2-sulphonyl)-piperazin-1-carbonyl-phenyl]}pyradizin-3-one: The invention relates to heterocyclic derivatives of formula (I), wherein R2 is amino, a group OR4 or a group —Y—R5 where R4 is hydrogen or C1-4alkyl, Y is C1-4alkylene, R5 is hydrogen, halo, hydroxy, C1-2alkoxy, C1-2alkoxyC1-2alkoxyC1-4, or a group NR7R8 where R7 and R8 are independently selected from hydrogen, C1-2alkyl,... Agent: Morgan Lewis & Bockius LLP

20070135442 - Chroman compounds: e

20070135443 - Novel tyrosine kinase inhibitors:

20070135444 - Treatment of neuroblastoma: 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide or a pharmaceutical acceptable salt thereof can be used in the treatment of neuroblastoma. The invention also relates to a combination of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide or a pharmaceutical acceptable salt thereof with one or more antineoplastic agents.... Agent: Novartis Corporate Intellectual Property

20070135445 - Bicyclic indolyl derivatives and methods for their use as serotonergic agents: Bicyclic indolyl derivatives and compositions containing such compounds are disclosed. Methods of using the bicyclic indolyl derivatives and compositions containing such composition as serotonergic agents, such as in the treatment of depression and anxiety, are also disclosed. In addition, processes for the preparation of bicyclic indolyl derivatives are disclosed.... Agent: Woodcock Washburn LLP

20070135446 - Benzoylguanidlne salt and hydrates thereof: 4-[4-(2-pyrrolylcarbonyl)-1-piperazinyl]-3-trifluoromethylbenzoylguanidine hydrochloride and its hydrates, processes for preparing this benzoylguanidine salt and its hydrates, pharmaceutical compositions containing this benzoylguanidine salt and its hydrates, and its use in treating diseases, particularly those in which inhibition of the cellular Na+/H+exchange is of therapeutic benefit.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070135447 - Broadspectrum 2-(substituted-amino)-benzoxazole sulfonamide hiv protease inhibitors: N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters and metabolites thereof, wherein R1 and R8 each are H, optionally substituted C1-6alkyl, C2-6alkenyl, C3-7cycloalkyl, aryl, Het1, Het2; R1 may also be a radical of formula (R11aR11b)NC(R10aR10b)CR9—; t is 0, 1 or 2; R2 is H or C1-6alkyl; L is —C(═O)—, —O—C(═O)—,... Agent: Philip S. Johnson Johnson & Johnson

20070135449 - Process for selective synthesis of enantiomers of substituted 1-(2-amino-1-phenyl-ethyl)-cyclohexanols: A process for the enantioselective synthesis of an (S)— or (R)-1-[2-dimethylamino)-1-(methoxyphenyl)ethyl]cyclohexanol and analogues or salt thereof are described. The method involves the steps of (a) reacting an (S) or (R) 4-benzyloxazolidinone with a mixed anhydride of a methyoxyphenylacetic acid under conditions which form a oxazolidinone, (4S)— or (4R)-4-benzyl-3-[methyoxyphenyl]acetyl]-oxazolidin-2-one, (b) treating... Agent: Howson And Howson Cathy A. Kodroff

20070135448 - Use of cathepsin k inhibitors for treating of severe bone loss diseases: This invention relates generally to cathepsin K inhibitors and their use in bone growth. Specifically, the invention relates to the use of cathepsin K inhibitors to stimulate new bone formation in patients in need thereof.... Agent: Novartis Corporate Intellectual Property

20070135450 - Compounds and methods of treating insulin resistance and cardiomyopathy: Novel compounds, compositions comprising compounds, and methods for methods for preparing and using compounds are described herein. Methods of treating or ameliorating various conditions, including insulin resistance, pancreatic beta cell apoptosis, obesity, pro-thrombotic conditions, myocardial infarction, hypertension, dyslipidemia, manifestations of Syndrome X, congestive heart failure, inflammatory disease of the cardiovascular... Agent: Forbes Medi-tech Inc. Attention: Ms. Susan M. Ben-oliel

20070135451 - Imidazo[1,2-a]pyridine derivatives for treatment of herpes viral infections: v

20070135452 - Nitrogen-containing fused heterocyclic compounds: wherein X is a nitrogen and R6 is an optionally substituted hydrocarbyl, R1 is an amino substituted by two optionally substituted hydrocarbyl groups, R2 is an phenyl, Y1 is CR3a or a nitrogen, y2 is CR3b or a nitrogen and Y3 is CR3c or a nitrogen, provided that one or... Agent: Mark Chao Takeda Pharmaceuticals North America Inc

20070135453 - 6-(2,4,6-trihalophenyl)triazolopyrimidines, their preparation and their use for controlling harmful fungi, and compositions comprising these compounds: L1, L2, L3 are chlorine or fluorine, where at least one group is chlorine; X is cyano, alkyl, alkoxy, alkenyloxy, haloalkoxy or haloalkenyloxy; processes for preparing these compounds, compositions comprising them and their use for controlling phytopathogenic harmful fungi.... Agent: Birch Stewart Kolasch & Birch

20070135454 - Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1): Compounds of formula (I); which are useful as therapeutic compounds, particularly in the treatment of pain and other conditions ameliorated by the modulation of the function of the vanilloid-1 receptor (VR1).... Agent: Merck And Co., Inc

20070135455 - Substituted thieno- and thiazolo- [2,3-d]pyrimidines and [2,3-c]pyridines as inhibitors of tie2: A compound of the formula(I); wherein the substituents are as defined in the text for use in the production of an anti-angiogenic effect in a warm blooded animal such as man. The compounds are inhibitors Tie2 receptor tyrosine kinase (TEK).... Agent: Astrazeneca R&d Boston

20070135456 - Medicaments with hm74a receptor activity: The present invention provides therapeutically active compounds which are xanthine derivatives, processes for the manufacture of said derivatives, pharmaceutical formulations containing the active compounds and the use of the compounds in therapy, particularly in the treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070135458 - 6-substituted pyrido-pyrimidines: e

20070135457 - Pyrido[2,3-d]pyrimidine-2,4-diamines as pde2 inhibitors:

20070135459 - Substituted 7-aza-quinazoline compounds useful as p38 kinase inhibitors:

20070135460 - 7h-pyrrolopyrimidine derivatives: The invention relates to 7H-pyrrolo[2,3-d]pyrimidine derivatives of formula (I), wherein the symbols and substituents are as defined in the description, to processes for the preparation thereof, to pharmaceutical compositions comprising such derivatives and to the use of such derivatives—alone or in combination with one or more other pharmaceutically active compounds—for... Agent: Novartis Corporate Intellectual Property

20070135461 - Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors: The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.... Agent: Fish & Richardson PC

20070135463 - Bicyclic heterocycles, drugs containing said compounds, the use thereof and method for preparing same: their tautomers, their stereoisomers, their mixtures and their salts, in particular their physiologically acceptable salts with inorganic or organic acids, which have valuable pharmacological properties, in particular an inhibitory action on the signal transduction mediated by tyrosine kinases, their use for the treatment of illnesses, in particular of tumoral diseases... Agent: Bromberg & Sunstein LLP Nortel Networks Limited

20070135462 - Combination therapy: The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour,... Agent: Morgan Lewis & Bockius LLP

20070135464 - Antiinflammation agents: Compounds, compositions and methods that are useful in the treatment of inflammatory, immunoregulatory, metabolic and cell proliferative conditions or diseases are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, metabolism and cell proliferation. The subject compounds contain fused carbocyclic... Agent: Jones Day

20070135465 - Fab i inhibitor and process for preparing same: A compound which is effective for inhibiting Fab I, and a method for treating a bacterial infection.... Agent: Morgan & Finnegan, L.L.P.

20070135467 - Heterocyclic cetp inhibitors: c

20070135468 - Pyridyloxyalkanoic acid amide derivatives useful as fungicides:

20070135466 - Pyrrolopyridines useful as inhibitors of protein kinase: The present invention relates to compounds useful as inhibitors of protein kinases, particularly of JAK family and ROCK family kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.... Agent: Vertex Pharmaceuticals Inc.

20070135469 - Vinylsulfonate and vinylsulfonamide compounds: wherein Ar1 is aryl or heteroaryl, each of R1, R2, and R3, independently, is hydrogen, alkyl, aryl, cyclyl, heteroaryl, or heterocyclyl, X is O or NR, R being hydrogen, alkyl, aryl, cyclyl, heteroaryl, or heterocyclyl, and n is 0, 1, 2, 3, or 4. This invention also covers a method... Agent: Fish & Richardson PC

20070135471 - Methods for preparing irinotecan: Methods for manufacturing 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxy-camptothecin are described comprising I. reacting a mixture of 1-chlorocarbonyl-4-piperidinopiperidine hydrochloride and 7-ethyl-10-hydroxycamptothecin in a polar aprotic solvent with a base in the presence of catalytic amounts of a N-containing cyclic organic compound having 3 to 20 carbon atoms and optionally in the presence of a water... Agent: Norris, Mclaughlin & Marcus, Pa

20070135470 - Utilization of vinpocetine to avoid complications in particular those associated to hearing which occur with epilepsy, and treatment thereof: The present invention is related with the use of vinpocetine and the derivates developed from its formula that maintains the same effects for the treatment of epilepsy and its complications. Our results show that vinpocetine prevents all the abnormalities of the ABR waves that accompany the epileptic cortical activity observed... Agent: Leydig Voit & Mayer, Ltd

20070135472 - Novel crystalline forms of desloratadine and processes for their preparation: Novel polymorph Forms III and V of desloratadine are provided. Pharmaceutical compositions containing such polymorphs are also provided.... Agent: M. Carmen & Associates, PLLC

20070135473 - Method of treating tumors with azaxanthones: The use of azaxanthones for treating diseases associated with tumor cells which express one or more protein of S100 family, and in treating patients that have malignancies consisting of tumors of an epithelial or mesenchymel nature, where these compounds are effective in retarding the progression and/or metastasis of these tumors.... Agent: Gibbons P.C.

20070135474 - Ccr-2 antagonist salt: The present invention provides an efficient synthesis for the preparation of ((1R,3S)-3-isopropyl-3-{[3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl}cyclopentyl)[(3S,4S)-3-methoxytetrahydro-2H-pyran-4-yl]amine and its succinate salt. The present invention additionally provides an efficient syntheses for the preparation of intermediates (3R)-3-methoxytetrahydro-4H-pyran-4-one; (1<i>S</i>,4<i>S</i>)-4-(2,5-dimethyl-1<i>H</i>-pyrrol-1-yl)-1-isopropylcyclopent-2-ene-1-carboxylic acid; and 3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,6-naphthyridine; and for the preparation of the precursor (3S,4S)-N-((1S,4S)-4-isopropyl-4-{[3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl}cyclopent-2-en-1-yl)-3-methoxytetrahydro-2H-pyran-4-amine. The invention additionally resides in the superior properties... Agent: Merck And Co., Inc

20070135475 - Process for the preparation of ccr-2 antagonists: The present invention provides an efficient synthesis for the preparation of ((1R,3S)-3-isopropyl-3-{[3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl}cyclopentyl)[(3S,4S)-3-m ethoxytetrahydro-2H-pyran-4-yl]amine and its succinate salt. The present invention additionally provides an efficient syntheses for the preparation of intermediates (3R)-3-methoxytetrahydro-4H-pyran-4-one; (1S,4S)-4-(2,5-dimethyl-1H-pyrrol-1-yl)-1-isopropylcyclopent-2-ene-1-carboxylic acid; and 3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,6-naphthyridine; and for the preparation of the precursor (3S,4S)-N-((1S,4S)-4-isopropyl-4-{[3-(tri-fluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl}cyclopent-2-en-1-yl)-3-methoxytetrahydro-2H-pyran-4-amine. The invention additionally resides in the superior... Agent: Merck And Co., Inc

20070135476 - Process for producing thiazole derivative: The present invention provides processes for producing a compound (5) based on the following reaction scheme.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070135477 - Benzimidazole derivatives and their use as protein kinases inhibitors: e

20070135478 - Muscarnic acetylchorine receptor antagonists: Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070135479 - Isoquinoline derivatives: wherein X is O, S or NH; Y is OH or NH2; m is 0, 1 or 2; n is 1 or 2; R1 is H, when Y is NH2; or R. is H, (C1-4)alkyl or halogen, when Y is OH; R2 and R3 are independently H, (C1-4)alkyl or halogen;... Agent: Akzo Nobel Inc.

20070135480 - Process for making montelukast and intermediates therefor: e

20070135481 - Compositions and methods of treating retinal disease: Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070135482 - Substituted pyrrolidine and related compounds: wherein R1-R5 and a-e are as defined in the specification; or pharmaceutically-acceptable salt or solvate or stereoisomer thereof. The invention also directed to pharmaceutical compositions containing such compounds; processes and intermediates useful for preparing such compounds; and methods for treating disease conditions mediated by muscarinic receptors using such compounds.... Agent: Theravance, Inc.

20070135483 - Antibacterial mutilins: A compound of formula (I) wherein R and R2 together with the nitrogen atom to which they are attached form pyrrolidinyl or piperidinyl, R1 is a group of formula (II) R3 and R′3 are hydrogen, deuterium or halogen, R4, R5 and R10 are independently of each other hydrogen or alkyl,... Agent: D. Peter Hochberg Co. L.p.a.

20070135484 - Benzenesulfonic acid indol-5-yl esters as antagonists of the 5-ht6 receptor: The present invention relates to compounds of formula I: which are antagonists of 5-HT6 receptor.... Agent: Eli Lilly & Company

20070135485 - Novel mch receptor antagonists: The present invention relates to a melanin concentrating hormone antagonist compound of formula I: or a pharmaceutically acceptable salt thereof, useful for the treamtment useful fog treating Type H diabetes and/or obesity.... Agent: Eli Lilly & Company

20070135486 - Cyclic onium compounds and glucosidase inhibitors: e

20070135487 - Use of a deoxynojirimycin derivative or a pharmaceutically salt thereof: The invention relates to the use of a deoxynojirimycin derivative, or pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of insulin resistance, hyperpigmentation and/or inflammatory processes in the skin, a fungal disease, overweight and obesity, or a microbacterial infection.... Agent: Sughrue Mion, PLLC

20070135488 - Amlodipine nicotinate and process for the preparation thereof: The present invention provides a novel salt of amlodipine, i.e., a nicotinic acid salt of amlodipine, a process for preparing the same, and a pharmaceutical composition comprising the same as an active ingredient.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070135489 - Vegfr-2 and vegfr-3 inhibitory anthranilamide pyridones: Novel VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones and their use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis are selected.... Agent: Millen, White, Zelano & Branigan, P.C.

20070135490 - Phenetanolamine derivatives: v

20070135491 - Flea control agent containing n-substitute indole derivative: Conventional control agents against fleas parasitic on animals do not have sufficient selective toxicity and are hence not safe for the animals to which the control agents are applied. The control agents are not always satisfactory also in control effect and quick-acting properties. Intensive studies were made on the insecticidal... Agent: Nields & Lemack

20070135492 - Imidazoline derivatives having cb1-antagonistic activity: n

20070135493 - Inhibitors of ion channels: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-gated sodium channels. More particularly, the invention provides substituted aryl sulfonamides, compositions comprising these compounds, as well as methods of using these compounds or compositions in the treatment... Agent: Morgan, Lewis & Bockius LLP (sf)

20070135494 - Substituted 5-aminomethyl-1h-pyrrole-2-carboxylic acid amides: Substituted 5-aminomethyl-1H-pyrrole-2-carboxylic acid amides, a process for the production thereof, pharmaceutical preparations containing these compounds and the use of these compounds in pharmaceutical preparations for treatment or inhibition of withdrawal symptoms, memory disorders, neurodegenerative diseases, epilepsy, cardiovascular disorders, water retention, intestinal motility disorders, urinary incontinence, anorexia, tinnitus, pruritus, depression, sexual... Agent: Crowell & Moring LLP Intellectual Property Group

20070135495 - Amlodipine gentisate and a method of its preparation: The present invention relates to an acid salt of amlodipine gentisate and a method of its preparation. More particularly, the present invention relates to a crystalline acid salt of amlodipine gentisate of the following formula 1 prepared by reacting amlodipine and gentisic acid, which is useful for the treatment of... Agent: Ronald R. Santucci, Esq. C/o Frommer Lawrence & Haug LLP

20070135497 - Biphenyl derivative or its salt, and pesticide containing it as an active ingredient: A pesticide having stabilized high pesticidal effects for crop plants infected with plant diseases, is presented. The pesticide contains a biphenyl derivative represented by the formula (I) or its salt, as an active ingredient: wherein X, Y and Z are each independently a halogen atom, a hydroxyl group, a formyl... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070135499 - Hydrazide compounds: Hydrazide compounds with GPCR desensitization inhibitory activity are provided that may be used to influence, inhibit or reduce the action of a G-protein receptor kinase. Pharmaceutical compositions including therapeutically effective amounts of the hydrazide compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to... Agent: Michael Best & Friedrich, LLP

20070135498 - Organic compounds: and the salts thereof, having renin-inhibiting properties. Also disclosed are pharmaceutical compositions comprising these compounds and methods of administering them for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting... Agent: Novartis Corporate Intellectual Property

20070135496 - Substituted benzylaminoalkylene heterocycles: This invention is related to compounds of general formula (I) wherein X is oxygen or sulphur or a NR7 group; R1 is C3-C8 alkyl, or C1-C8 alkyl substituted by phenoxy or phenyl, both phenoxy or phenyl being optionally substituted by one or more fluoro, chloro, trifluoromethyl, C1-C6 alkyl, hydroxyl, C1-C6... Agent: Young & Thompson

20070135500 - Propionamide compounds as antiinflammatory agents: i

20070135501 - Amino acid derivatives: The present invention relates to new amino acid derivatives, process for the production, their use, in particular in transplantation, and pharmaceutical compositions containing them.... Agent: Novartis Corporate Intellectual Property

20070135502 - Heterocyclic compounds and methods of use: provide pharmacological agents which are potent agonists of Peroxisome Proliferator-Activated Receptors (PPARs). Accordingly, the compounds of the instant invention are useful for the treatment of conditions mediated by the PPAR receptor activity in mammals. Such conditions include dyslipidemia, hyperlipidemia, hypercholesteremia, atherosclerosis, hypertriglyceridemia, heart failure, myocardial infarction, vascular diseases, cardiovascular diseases,... Agent: Novartis Corporate Intellectual Property

20070135503 - Furan derivatives as ep4 receptor antagonists: o

20070135504 - Method of treating and/or preventing inflammatory diseases, including many autoimmune and neurological diseases, using drugs to modulate the vdr, and/or ppar, and/or gcr and/or cb1 nuclear and gpcr receptors; in conjunction with antibiotics which target p: This invention discloses a method of killing the stealthy intra-cellular bacteria which are key to the pathogenesis of Th1 immune conditions including Diabetes Type 1, Diabetes Type 2, Rheumatic Arthritis, Reactive Arthritis, Osteo Arthritis, Psoriasis, Scleroderma, Osteoporosis, Atherosclerosis, Myocarditis, Endocarditis, Pericarditis, Stroke, Embolism, Alzheimer's, Cystic Fibrosis, Hashimoto's Thyroiditis, Graves Disease,... Agent: Trevor Gordon Marshall

20070135505 - Aralkyl ester soft drugs: The present invention describes a method for programming a specific course and rate of metabolism for a parent drug compound that leads to an inactive or very weakly active and nontoxic metabolite when the modified drug compound is administered. The parent drug compound is modified by forming one or more... Agent: Macmillan Sobanski & Todd, LLC

20070135506 - Pesticidal compositions: A method of controlling or preventing pathogenic damage or pest damage in a plant propagation material, a plant, parts of a plant and/or plant organs that grow at a later point in time, which comprises applying on the plant, part of the plant, or surroundings thereof, a pesticidal combination comprising,... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20070135507 - Prolinyl derivatives for the treatment of thrombosis: Novel compounds of the formula (I), in which R, R1, R2, R3 and R4 have the meaning indicated in Patent Claim 1, are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumours.... Agent: Millen, White, Zelano & Branigan, P.C.

20070135508 - 3,6-disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists: The present invention relates to a radio telephony network (1) supporting at least one link of a radio channel (6) for a packet data transmission service. The radio telephony network (1) comprises a plurality of network controllers (RNC). Each network controller (RNC) is connected, via an interface Iub, to at... Agent: Ranbaxy Inc.

20070135509 - Indolone compounds useful to treat cognitive impairment: This invention provides a method of treating a subject suffering from a cognitive impairment or a cognitive disorder which comprises administering to the subject an amount of an indolone compound effective to treat the subject's cognitive impairment or disorder.... Agent: Heller Ehrman LLP

20070135511 - Indole derivatives useful as progesterone receptor modulators: The present invention is directed to novel indole derivatives, pharmaceutical compositions containing them and their use in the treatment or prevention of disorders and diseases mediated by agonists and antagonists of the progesterone receptor. The clinical uses of these compounds are related to contraception, the treatment and/or prevention of secondary... Agent: Philip S. Johnson Johnson & Johnson

20070135510 - Indolone compounds useful to treat cognitive impairment: This invention provides a method of treating a subject suffering from a cognitive impairment or a cognitive disorder which comprises administering to the subject an amount of an indolone compound effective to treat the subject's cognitive impairment or disorder.... Agent: Heller Ehrman LLP

20070135513 - Method for producing {n-[1-(s)-carbalkoxy-3-phenylpropyl]-s-alanyl-2s, 3ar, 7as-octahydroindole-2-carboxylic acid} compounds: A method for preparing optionally substituted {N-[1-(S)-carbalkoxy-3-phenylpropyl]-S-alanyl-2S,3aR,7aS-octahydroindole-2-carboxylic acid} and pharmaceutically acceptable salts thereof, wherein a racemic mixture of optionally substituted trans-octahydroindole-2-carboxylic acid is reacted with the N-carboxyanhydride of {N-[1-(S)-alkoxycarbonyl-3-phenylpropyl]-L-alanine}, which is optionally substituted on the phenyl ring, in a suitable inert solvent, and subsequently the resulting optionally substituted {N-[1-S-carbalkoxy-3-phenylpropyl]-S-alanyl-2S,3aR,7aS-octahydroindole-2-carboxylic acid},... Agent: Hammer & Hanf, PC

20070135512 - Novel crystalline forms of perindopril erbumine: Disclosed are two new crystalline forms, δ and ε, of perindopril erbumine. Those forms are suitable as therapeutic active substances for medicaments for the treatment of cardio-vascular diseases, especially high blood pressure and heart failure. The ε crystalline form is obtained in the crystallisation of perindopril erbumine at from 30... Agent: Hammer & Hanf

20070135514 - Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases: The present invention is drawn to methods of characterization of the properties and functions of SV2 proteins. The invention further includes methods of identifying compounds or agents which modulate the activity of SV2 proteins. Included in these methods is the identification of compounds or agents which modulate the binding of... Agent: Morgan Lewis & Bockius LLP

20070135515 - Method for producing sorbicillactone a: e

20070135516 - Irciniastatins a and b: The Indo-Pacific marine sponge Ircinia ramosa has been found to contain two powerful (GI50 0.001 to <0.0001 μg/ml) murine and human cancer cell growth inhibitors, denominated herein as irciniastatin A and irciniastatin B. Both were isolated (10-3 to 10-4% yields) by cancer cell line bioassay-guided techniques and named irciniastatins A... Agent: Susan Stone Rosenfield Fennemore Craig

20070135517 - Antitumor medicine: There is provided an antitumor medicine comprising 1,5-D-anhydrofructose and/or ascopyrone. The antitumor medicine has effects of ascopyrone in inhibiting the growth and metastasis of tumors, is expected to inhibit inflammation and exerts an excellent effect on prognosis.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070135518 - Use of low-dose ladostigil for neuroprotection: The subject invention provides a method of preventing a neurodegenerative disease in a subject or oxidative stress in the brain of a subject, comprising administering to the subject a less than cholinesterase-inhibitory amount or a less than monoamine oxidase-inhibitory amount of R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan or a salt thereof effective to prevent the... Agent: Cooper & Dunham, LLP

20070135519 - Chemoprotective methods and compositions: Compositions and methods for reducing, preventing, mitigating, and/or delaying the onset of, attenuating the severity of, and/or hastening the resolution of, for example, one or more chemotherapy-associated toxicities in a subject receiving one or more chemotherapeutic agents.... Agent: Scott A. Whitaker, Ph.d., J.d., Sr. Intellectual Property Counsel

20070135520 - Cis-trans isomerisation of semicarbazone compounds: The present invention relates to the isomerisation of the Z-isomer I-Z of semicarbazone compounds of the general formula (I) into its E-isomer I-E, where the variables in formula (I) have meanings given in claim 1.... Agent: Hutchison Law Group PLLC

20070135521 - Agent for preventing metabolic syndrome: Novel, safe, and highly effective agents for preventing insulin resistance and for preventing metabolic syndrome that contain astaxanthin and/or an ester thereof as an active component are provided. Even when a high-fat diet intake is continued, insulin resistance and subsequent hyperinsulinemia are suppressed by using the agent for preventing insulin... Agent: Le-nhung Mcleland

20070135522 - Punctual stimulation therapy: The invention relates to the use of a sterile aqueous solution of a substance inhibiting the enzymatic decomposition of endogenous opioide neuropeptides, especially enkephalins, for producing a preparation provided for intravenous infusion, in order to intensify the action of punctual stimulation therapy carried out with an electrical current. One such... Agent: William Collard Collard & Roe, P.C.

20070135523 - Novel benzamidine derivatives having anti-inflammatory and immunosuppressive activity: R5 represents one or two substituents independently selected from hydrogen and the methyl, methoxyl and hydroxyl groups, n is a whole number from 0 to 6, and the amidine group is in the para or meta position relative to the “-A-NH—” group.... Agent: Sughrue Mion, PLLC

20070135524 - Process for the preparation of polymorphs of selective serotonin reuptake inhibitor: The present invention is directed to Form II, III, IV and V of sertraline hydrochloride and methods for its preparation. According to the present invention, the various polymorphs of sertraline hydrochloride may be produced either, directly from sertraline base or sertraline acetate.... Agent: Conley Rose, P.C.

20070135525 - Materials and methods for treating viral infections: The subject invention provides materials and methods for treating various health conditions, including the prevention and/or treatment of a viral infection. In a preferred embodiment, a cysteamine compound is administered to a subject to treat an influenza virus infection. More preferably, a cysteamine compound is administered to a subject to... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070135526 - Synthesis of (1)-beta-elemene, (-)-beta-elemenal, (-)-beta-elemenol, (-)-beta-elemene fluoride and their analogues, intermediates, and composition and uses thereof: The present invention provides convergent processes for preparing (−)-beta-elemene, (−)-beta-elemenal, (−)-beta-elemenol, and (−)-beta-elemene fluoride and analogues thereof. Also provided are intermediates useful for preparing (−)-beta-elemene. The present invention further provides novel compositions based on analogues of (−)-beta-elemene, (−)-beta-elemenal, (−)-beta-elemenol, (−)-beta-elemene fluoride and methods for the treatment of cancer, such as... Agent: Long Range International Usa Limited, Inc.

20070129283 - Compositions and methods for reducing food cravings: Disclosed are compositions for reducing food cravings, comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound is an α-MSH agonist. Also disclosed are methods of reducing food cravings, comprising identifying an individual in need thereof and treating that individual... Agent: Knobbe Martens Olson & Bear LLP

20070129281 - Pharmaceutical compounds: The invention provides novel inhibitors of protein tyrosine phosphatase sulfenyl amide and their use in medicine, for example in the treatment or prevention of disease states such as cancer, diabetes, rheumatoid arthritis and hypertension. Also provided are novel crystal structures and the use of the crystal structures and their X-ray... Agent: Heslin Rothenberg Farley & Mesiti PC

20070129282 - Pharmaceutical treatments and compositions: The invention provides compositions comprising formula 1 steroids, e.g., 16α-bromo-3β-hydroxy-5α-androstan-17-one hemihydrate and one or more excipients, including compositions that comprise a liquid formulation comprising less than about 3% v/v water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds... Agent: Hollis-eden Pharmaceuticals, Inc.

20070129284 - Single-chain insulin: The present invention is related to single-chain insulin having insulin activity comprising a B- and an A-chain or a modified B- and A-chain connected by a connecting peptide of from 6-11 amino acids. The single-chain insulins will have biological insulin activity and an IGF-1 receptor affinity similar to or lower... Agent: Novo Nordisk, Inc. Patent Department

20070129287 - Hemoglobin conjugates: The invention provides a conjugate of hemoglobin and a nucleic acid cross-linking agent.... Agent: Sughrue Mion, PLLC

20070129285 - Protein a compositions and methods of use: Methods and compositions for modulating an immune response in a subject are provided. Methods include administering to the subject a composition comprising an effective amount of a lymphocyte differentiation factor, e.g., protein A (PA), sufficient to modulate the immune response. Compositions include a lymphocyte differentiation factor, e.g., protein A (PA),... Agent: Pillsbury Winthrop Shaw Pittman LLP

20070129286 - Treatment solution and method for preventing posterior capsular opacification by selectively inducing detachment and/or death of lens epithelial cells: A treatment solution used to prevent posterior capsular opacification is applied or introduced into the lens capsular bag before, during, or after cataract surgery. The treatment solution comprises an ion transport mechanism interference agent, which either alone or in combination with other treatment agents such as an osmotic stress agent... Agent: Mcandrews Held & Malloy, Ltd

20070129288 - Antibacterial amide macrocycles: The invention relates to antibacterial amide macrocycles, to methods for the production thereof, and to the use of the same for producing pharmaceuticals for the treatment and/or prophylaxis of illness, especially bacterial infections.... Agent: Jeffrey M. Greenman

20070129289 - Deoxo-proline-containing tamandarin and didemnin analogs, dehydro-proline-containing tamandarin and didemnin analogs, and methods of making and using them: The present invention relates to tamandarin and didemnin analogs which have a deoxo-proline residue or a dehydro-proline residue in their structure. These analogs are useful as anti-cancer agents and for other purposes. Methods of making these analogs and methods of using them as inhibitors of protein synthesis, cell growth, and... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070129290 - Metabolite derivatives of the hdac inhibitor fk228: The present invention relates to HDAC inhibitor derivatives, particularly derivatives of the free thiol of metabolites of the HDAC inhibitor FK228, pharmaceutical compositions thereof, and to methods of using such derivatives and pharmaceutical compositions thereof in the treatment of diseases associated with HDAC, in particular, tumor or cell proliferation diseases.... Agent: Elmore Patent Law Group, PC

20070129296 - Cardiac muscle function and manipulation: A method of causing cardiomyocyte growth and/or differentiation, the method comprising exposing a cardiomyocyte to neuregulin (NRG) thereby activating the MAP kinase pathway in the cardiomyocyte and causing growth and/or differentiation of the cardiomyocyte. Use of neuregulin, neuregulin polypeptide, neuregulin derivatives, or compounds which mimic the activities of neuregulins in... Agent: Jones Day

20070129299 - Compositions and methods for enhanced mucosal delivery of pyy peptide: Pharmaceutical compositions are described comprising PYY(3-36) (SEQ ID NO: 2), a solubilizing agent, a lipid, a polyol.... Agent: Nastech Pharmaceutical Company Inc

20070129294 - Compound and method of treatment: The invention relates to a peptide suitable for treatment of tinea and to processes for producing peptides and compositions, for treatment of tinea.... Agent: Stinson Morrison Hecker LLP Attn: Patent Group

20070129300 - Cytotoxic factors for modulating cell death: Cytotoxic factors having use in modulating cell death, and their use in methods of treating necrosis or apoptosis-related conditions are disclosed. The invention also relates to methods for identifying active agents useful in treating conditions related to cell death. The present inventors have found that different pathogens produce different cytotoxic... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP

20070129291 - Genobix agonists and antagonists for use in the treatment of metabolic disorders: The present invention relates to the field of metabolic research, in particular the discovery of compounds effective for reducing body mass and useful for treating obesity-related diseases and disorders. The obesity-related diseases or disorders envisioned to be treated by the methods of the invention include, but are not limited to,... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070129302 - Il-17c antagonists and methods of using the same: The present invention relates IL-17RE antagonists, such as soluble receptors and anti-IL-17RE antibodies, that are useful in blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17C. IL-17C is a cytokine that is involved in inflammatory processes and human disease. IL-17RE is a receptor for IL-17C. The present invention includes... Agent: Zymogenetics, Inc. Intellectual Property Department

20070129298 - In-solution activation of factor vii: The present invention is directed to a method for activation of Factor VII to FVIIa in solution.... Agent: Maxygen, Inc. Intellectual Property Department

20070129295 - Method for purifying fsh: The invention provides a method for purifying recombinant FSH.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070129301 - Methods and compositions for modulating hgf/met: The invention provides methods and compositions for modulating the HGF/c-met signaling pathway, in particular by regulating binding of HGF β chain to c-met.... Agent: Genentech, Inc.

20070129303 - Methods for production of growth-promoting proteins and peptides for kidney epithelial cells: Novel growth peptides derived from protein factors having molecular weights of about 22 and 45 kDa stimulate mitogenic activity of epithelial, but not fibroblastic cells, in particular, kidney epithelial cells. A source of the factors is scrape-wounded kidney epithelial cells in culture. Synthetic peptides having sixteen amino acids or less,... Agent: Barnes & Thornburg LLP

20070129304 - Methods of enhancing functioning of the large intestine: The invention relates to glucagon-related peptides and their use for the prevention or treatment of disorders involving the large intestine. In particular, it has now been demonstrated that GLP-2 and peptidic agonists of GLP-2 can cause proliferation of the tissue of large intestine. Thus, the invention provides methods of proliferating... Agent: Connolly Bove Lodge & Hutz LLP

20070129293 - Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions: A method of treating, preventing, delaying the onset, and/or reducing the effects of proinflammatory cytokines in conditions including, but not limited to, sepsis, adhesion formation, wounds, organ failure, chronic disease, general inflammatory conditions resulting from infection, scarring resulting from injury and incisions, and combinations thereof.... Agent: Warren Pharmaceuticals, Inc

20070129297 - Treatment and prevention of asthma: The invention provides compositions and methods for treating asthmatic conditions. Such compositions and methods utilize a lung surfactant mixture comprising a lung surfactant polypeptide.... Agent: The Scripps Research Institute

20070129292 - Treatment of aspergillus infections with alpha thymosin peptides: A method for treating a human infected with Aspergillus by using thymosin alpha 1 as an immuno-stimulator in activating dendritic cells. The method is particularly useful in preventing an infection by Aspergillus in an immuno-compromised host being treated with a bone marrow transplantation.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070129305 - Cell penetrating peptides for intracellular delivery of molecules: The present invention concerns cell-penetrating peptides which comprise an amino acid sequence consisting of GLX9WRAX9WRX1LX2RSLX9WX3X4X5X6X7X8 (SEQ ID No: 1), wherein X1 is A, L or G, X2 is W or none, X3 is R or K, X4 is K, L or S, X5 is L or K, X6 is R... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070129306 - Methods for reducing cd36 expression: The invention provides a method of reducing CD36 expression in a cell. The method comprises contacting the cell with an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the... Agent: Hoffmann & Baron, LLP

20070129307 - Insulin epitopes for the treatment of type 1 diabetes: The invention provides compounds and methods useful for the diagnosis, prediction, therapy, or prophylaxis of type 1 diabetes. The compounds of the invention include peptides derived from IAPP (islet amyloid polypeptide) precursor, proinsulin, insulin, IGRP, IA-1 or phogrin peptides.... Agent: Jeffrey J. King Black Lowe & Graham PLLC

20070129308 - Method and peptide for regulating cellular activity: Method and peptide for regulating cellular activity includes a panel of synthesized peptides that have biological effects on inhibiting or enhancing cellular activity. Selected peptides can be used as therapy to reduce and/or inhibit, or initiate and/or enhance, an inflammatory response in a subject.... Agent: Dinesh Agarwal, P.C.

20070129309 - Conjugates useful in the treatment of prostate cancer: Chemical conjugates which comprise oligopeptides, having amino acid sequences that are selectively proteolytically cleaved by free prostate specific antigen (PSA) and known cytotoxic agents are disclosed. The conjugates of the invention are characterized by attachment of the cleavable oligopeptide to the oxygen atom at the 4-position on a vinca drug... Agent: Merck And Co., Inc

20070129310 - Antibacterial agents: Compounds of formula (II) have antibacterial activity: wherein: Q represents a radical of formula —N(OH)CH(═0) or formula —C(═O)NH(OH); R1 represents hydrogen, methyl or trifluoromethyl or, except when Q is a radical of formula —N(OH)CH(═0), a hydroxy, halo or amino group; R2 represents a group R10—(D)n—(ALK)m— wherein R10 represents hydrogen or... Agent: Banner & Witcoff, Ltd.

20070129312 - Convalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites: This invention herein describes a method of facilitating the entry of drugs into cells and tissues at physiologically protected sites at pharmacokinetically useful levels and also a method of targeting drugs to physiologically protected sites in vivo. Also provided are drug conjugates with an amino acid or derivative thereof for... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070129311 - Inactivators and bivalent inhibitors of glyoxalase i and methods inhibiting tumor growth: Compounds comprising two human GlxI inhibitors covalently linked via a chemical linker are provided, wherein each of said two human GlxI inhibitors, which may be the same or different, is an S-substituted glutathione or an S-substituted glutathione prodrug, wherein said GlxI inhibitors each have a γ-glutamyl amino group, wherein said... Agent: Sughrue Mion, PLLC

20070129314 - Method of regulating glucose metabolism, and reagents related thereto: The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070129313 - Sulfonylamino-peptidomimetics active on the somatostatin receptor subtypes 4 (sstr4) and 1 (sstr1): The invention relates to 1-naphthalenesulfonylamino based peptidomimetics of formula (I), wherein B, R1 and R2 are as defined in the claims, and pharmaceutically acceptable salts thereof. Compounds of formula (I) possess high affinity and selectivity for the somatostatin receptor subtype SSTR4 or the somatostatin receptor subfamily SSTR1/SSTR4.... Agent: Oliff & Berridge, PLC

20070129315 - Colchicoside analogues: The present invention relates to colchicine derivatives, in particular to the 3-demethyl and 3-demethylthio-colchicine of the general formula (I) in which X is oxygen or sulfur, a method for the preparation thereof and pharmaceutical compositions containing them. The compounds of formula (I) have muscle relaxing, anti-inflammatory and anti-gout activity.... Agent: Young & Thompson

20070129316 - Muscle-strengthening drugs and anti-inflammatory drugs: A muscle-strengthening, anti-inflammatory, antiasthmatic, antidiarrheal or an antidepressant method, or a method for the treatment of diminution of vision, hepatitis, inflammatory intestinal syndrome, functional enteropathy, functional hepatopathy, functional nephropathy, dementia, climacteric symptoms, senile dementia and/or Alzheimer disease, said method comprising: administering to skin a composition comprising (a) at least one... Agent: Oliff & Berridge, PLC

20070129317 - Use of boswellic acid and its derivatives for inhibiting normal and increased leucocytic elastase or plasmin activity: The invention concerns the use of pure boswellic acid, a physiologically acceptable salt, a derivative, a salt of the derivative or a plant preparation containing boswellic acid for preventing and/or combatting diseases which are caused by increased leucocytic elastase or plasmin activity or can be treated by the inhibition of:... Agent: Buchanan, Ingersoll & Rooney PC

20070129323 - Antisense antiviral compound and method for treating picornavirus infection: The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Picornaviridae family and in the treatment of a viral infection. The compounds are particularly useful in the treatment of Enterovirus and/or Rhinovirus infection in a mammal. The antisense antiviral... Agent: Perkins Coie LLP

20070129318 - Antisense oligonucleotide having anticancerous activity: An antisense oligonucleotide having anti-carcinogenicity, for example, an inhibitory action on growth of cancer cells and a therapeutic or prophylactic action on cancer and the like, as well as an inhibitor of cancer cell growth and a therapeutic or prophylactic agent for cancer, which comprise the antisense oligonucleotide are provided.... Agent: Birch Stewart Kolasch & Birch

20070129319 - Genes encoding human deubiquitinating enzymes: Described is a novel human deubiquitinating enzyme, DUB-3, (SEQ ID NO: 1), and variants and fragments thereof. Also described are nucleic acid molecules encoding the enzyme, and use of the polypeptide and nucleic acid molecules in treatment of cancer, assays.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20070129324 - Mammalian mdm2 binding proteins and uses thereof: Isolated nucleic acid sequences encoding mammalian MDM2 binding protein and polypeptide sequences for the mammalian MDM2 binding protein are provided. Also provided are vectors containing these nucleic acid sequences, host cells which express these proteins and antibodies targeted to these proteins. In addition, methods and compositions for modulating the G1... Agent: Licata & Tyrrell P.C.

20070129320 - Methods and compositions for inducing innate immune responses: The invention relates to TLR ligand formulations that comprise immune stimulating complexes and their use in inducing innate immunity.... Agent: Wolf Greenfield & Sacks, P.C.

20070129321 - Nanoarrays of single virus particles, methods and instrumentation for the fabrication and use thereof: A novel coordination chemistry or metal ion binding approach to controlling the site-isolation and orientation of virus particles, such as TMV, on a nanoarray template generated by lithography including Dip Pen Nanolithography. By using the surface chemistry that is inherent in many viruses, metal-ion based or inorganic coordination chemistry was... Agent: Foley And Lardner LLP Suite 500

20070129322 - Recombinant protective protein from streptococcus pneumoniae: The present invention discloses amino acid sequences and nucleic acid sequences relating to a Streptococcus pneumoniae surface associated Pneumo Protective Protein (PPP) having a molecular weight of about 20 kilo Daltons (kDa). The PPP exhibits the ability to reduce colonization of pneumococcal bacteria. Thus the present invention also pertains to... Agent: Hunton & Williams LLP Intellectual Property Department

20070129325 - Use of corrinoids for application in skin diseases: in which R stands for CN, OH, CH3 or H2O, for building up and improving the resistance of the skin is claimed. The compounds are suitable in particular for preventive treatment in cases of predisposition to chronic skin diseases, for the prevention and treatment of allergic skin reactions, for the... Agent: Friedrich Kueffner

20070129326 - Methods for producing modified microcrystalline chitosan and uses therefor: Disclosed are methods of producing modified microcrystalline chitosan. Chitosan in aqueous solution is degraded enzymatically, hydrolytically or oxidatively. The chitosan solution is then alkalized with agitation using aqueous hydroxides and/or their salts to attain a pH not lower than 7.0. The precipitated modified microcrystalline chitosan is highly pure and may... Agent: Cameron Kerrigan Squire, Sanders & Dempsey LLP

20070129327 - Blood flow promoters for cauda equina tissues: It is intended to provide highly safe and efficacious blood flow promoters for cauda equina tissues. Among prostaglandin-like compounds having a weak hypotensive effect, compounds having an effect of promoting the blood flow in cauda equina tissues (excluding limaprost) are useful as highly safe blood flow promoters for cauda equina... Agent: Sughrue Mion, PLLC

20070129328 - Pharmaceutical compositions of neurokinin receptor antagonists and cyclodextrin and methods for improved injection site toleration: This invention relates to pharmaceutical compositions for improving anesthesia recovery and preventing nausea and emesis and a method for improved injection site tolerance. In particular, the invention is directed to pharmaceutical compositions with an improved injection site toleration comprising an effective amount of a neurokinin receptor antagonist with a pharmaceutically... Agent: Pharmacia & Upjohn

20070129329 - Stabilized pharmaceutical composition of pramipexole and method of preparation thereof: Stabilized pharmaceutical compositions comprising pramipexole or pharmaceutically acceptable salts thereof and one or more dextrins and to methods of preparation of the same. The said stabilized composition is in form of tablets comprising pramipexole dihydrochloride, β-cyclodextrin and one or more pharmaceutically acceptable excipients. A process for preparing the stabilized tablet... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20070129330 - 1,3-diaza-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders: The present invention relates to the use of compounds from the group of 1,3-diaza-dibenzo[e,h]azulenes and of their pharmaceutically acceptable salts and solvates for the for the use in the treatment and prevention of diseases, damages and disorders of the central nervous system (CNS) caused by disorders of the neurochemical equilibrium... Agent: Darby & Darby P.C.

20070129331 - Pharmaceutical compositions and methods of use of lipophilic, silicon-substituted, cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs and derivatives: Novel compositions of silicon-substituted carboxylic acid-containing-nonsteroidal anti-inflammatory drugs, their preparation and use in methods for treating, preventing and/or reducing inflammation, pain, angiogenesis, and cortical dementias including Alzheimer's disease, inflammation-related cardiovascular disorders and cancer are described. The compositions and methods are effective at decreasing or reversing the gastrointestinal, renal and other... Agent: Bell, Boyd & Lloyd, LLP

20070129332 - Processes to prepare eplerenone: v

20070129333 - 1-thia-2,4a-diaza-cyclopenta[b]naphthalene-3,4-diones and related compounds as anti-infective agents: Certain compounds of Formula I and Formula II disclosed herein are potent and selective inhibitors of bacterial DNA synthesis and bacterial replication. The invention also provides antimicrobial compositions, including pharmaceutical compositions, containing one or more compounds of Formula I or Formula II and one or more carriers, excipients, or diluents.... Agent: Cantor Colburn, LLP

20070129334 - Orally active purine-based inhibitors of heat shock protein 90: Novel purine compounds and tautomers and pharmaceutically acceptable salts thereof are described, as are pharmaceutical compositions comprising the same, complexes comprising the same, e.g., HSP90 complexes, and methods of using the same. Methods of using the novel purine compounds of the invention, and tautomers and pharmaceutically acceptable salts thereof, include... Agent: Wilson Sonsini Goodrich & Rosati

20070129335 - T-type calcium channel blocker: v

20070129336 - Camphanylidene and phenylalkyl inositol polyphosphate compounds, compositions, and methods of their use: This invention relates to new camphanylidene and phenyl alkyl inositol polyphosphate derivatives that inhibit the absorption of sodium ions in epithelial cells and regulate inducible nitric oxide synthase (iNOS) in macrophages. The invention provides methods for inhibiting sodium ion absorption by epithelial cells and/or regulating inducible nitric oxide synthase (iNOS)... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20070129337 - Use of ketol-acid reductoisomerase inhibitors to prevent or treat fungal infection of plants: The invention concerns the use of ketol-acid reductoisomerase inhibitors for treating fungal diseases affecting crops. The invention concerns methods for treating crops against fungal diseases comprising applying a ketol-acid reductoisomerase inhibitor. The invention also concerns methods for identifying novel fungicidal compounds comprising a step which consists in identifying ketol-acid reductoisomerase... Agent: Baker & Botts L.L.P.

20070129338 - Thrombopoietin mimetics: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070129339 - Method of improving beta-adrenergic receptor function: The present invention relates to a method of increasing the sensitivity of a hyperinsulinemic patient to the anti-obesity and antidiabetic effects of a β adrenergic receptor (β AR) agonist. The method comprises administering to the patient the β AR agonist and an agent that reduces plasma insulin levels and thereby... Agent: Nixon & Vanderhye, PC

20070129340 - Ed-71 preparation: An object of the present invention is to provide a preparation that can suppress the generation of main degradation products of ED-71, tachysterol and trans forms of ED-71, generated under storage at room temperature. The present invention provides a preparation comprising (5Z,7E)-(1R,2R,3R)-2-(3-hydroxypropoxy)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol, fat and oil, and an antioxidant.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070129342 - Compositions containing ansamycin: Provided are pharmaceutical compositions containing an oil phase and an aqueous phase, the oil phase including an ansamycin and less than 2% w/w oleic acid, wherein the ansamycin is geldanamycin, 17-aminogeldanamycin, 17-allyalamino-17-demethoxy-geldanamycin, compound 563, or compound 237 having the structures below, or a salt of any one of the aforementioned... Agent: Wilson Sonsini Goodrich & Rosati

20070129341 - Imidazole derivatives used as tafia inhibitors: o

20070129343 - New anionic and neutral complexes of ruthenium (ii) with nitrogen oxide: A class of anionic and neutral complexes of ruthenium (II) containing nitrogen oxide (NO) and optionally a nitrogen ligand is described; a process for their preparation is also described. The preparation process includes the use of starting complexes of ruthenium (III) which are reacted with suitable reagents so as to... Agent: Stetina Brunda Garred & Brucker

20070129344 - Bicyclic 6-alkylidene-penem beta-lactamase inhibitors and beta-lactam antibiotic combination: a broad spectrum antibiotic: The present invention provides a β-lactam antibiotic such as cefepime and a compound of formula I, pharmaceutical compositions and the use thereof for the treatment of bacterial infection or disease in a patient in need thereof.... Agent: Wilmerhale/wyeth

20070129345 - Lactam compounds and methods of using the same: The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1 and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1.... Agent: Fish & Richardson PC

20070129347 - Cyclohexylacetic acid compounds: e

20070129346 - Melanocortin receptor agonists: The present invention relates a compound of formula 1, and pharmaceutically acceptable salt, hydrate, solvate, or isomer thereof effective as agonist of melanocortin receptor, and an agonistic composition of melanocortin receptor comprising the same as active ingredient.... Agent: Birch Stewart Kolasch & Birch

20070129348 - Receptor antagonist: [wherein ring A represents an optionally substituted aromatic ring; ring B represents an optionally substituted benzene ring; X represents oxygen, S(O)n (n is an integer of 0 to 2), or NR3 (R3 represents hydrogen, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group); and R1 and R2 each... Agent: Takeda Pharmaceuticals North America, Inc Intellectual Property Department

20070129349 - Sulfonamide compounds for the treatment of neurodegenerative disorders: wherein R1, R2, R3, m, and n are as defined Compounds of the Formula I have activity inhibiting production of Aβ-peptide. The invention also relates to pharmaceutical compositions and methods for treating disorders and diseases, for example, neurodegenerative and/or neurological disorders, e.g., Alzheimer's disease, in a mammal comprising compounds of... Agent: Pfizer Inc

20070129350 - Methods for treatment of diabetes: Phenserine compounds and pharmaceutically acceptable salts thereof are found to be useful in the management or treatment of diabetes and/or complications, such as vascular dementia, and insulin resistance, associated with diabetes. The phenserine compounds of the invention are carbamates that inhibit the activity of acetylcholinesterase.... Agent: Trask Britt

20070129351 - Novel processes for the preparation of cyclopropyl-amide derivatives: The present invention is directed to novel processes for the preparation of cyclopropyl-amide derivatives, useful for the treatment of disorders and conditions mediated by the histamine receptor.... Agent: Philip S. Johnson Johnson & Johnson

20070129352 - Novel crystal forms, methods for their preparation and method for preparation of olanzapine: The invention is directed to a series of novel crystalline olanzapine forms, in particular hydrated and solvated crystalline forms of olanzapine, methods of use in pharmaceutical compositions, and method of treating psychiatric disorders using the crystalline forms. One series of the crystalline forms are hydrates, i.e. water containing crystals, wherein... Agent: Kenyon & Kenyon LLP

20070129353 - Alpha-helix mimetics and method relating to the treatment of cancer stem cells: The invention provides α-mimetic structures and a chemical library relating thereto. Additionally, the invention provides methods wherein a-mimetic compounds are used to treat cancer stem cells.... Agent: Davis Wright Tremaine, LLP

20070129354 - Biphenyl carboxylic amide p38 kinase inhibitors: e

20070129356 - Mitotic kinesin inhibitors: The present invention relates to 2-phenylpyrimidinone compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.... Agent: Merck And Co., Inc

20070129355 - Pyrimidine derivatives useful for the treatment of diseases mediated by crth2: The present invention relates to a pyrimidine derivative of the formula (I) and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The pyrimidine derivative of the present invention has excellent CRTH2 (G-protein-coupled chemoattractant receptor, expressed on Th2 cells) antagonistic activity and can be used for the... Agent: Jones Day

20070129361 - Lactam-containing diaminoalkyl, beta-aminoacids, alpha-aminoacids and derivatives thereof as factor xa inhibitors: e

20070129357 - Novel crystals of fluorobenzamide derivative: There are provided novel crystals of (−)-N-{2-[(R)-3-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidino]ethyl}-4-fluorobenzamide monophosphate.... Agent: Sughrue Mion, PLLC

20070129360 - Pyrimidine-2,4-diamines and their uses: The present invention relates to diaryl pyrimidine-2,4-diamines, pharmaceutical compositions thereof, and the use of the compounds and compositions for the inhibition of kinases. The compounds, analogs, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions can be used in the treatment and prevention of cancer.... Agent: Fenwick & West LLP

20070129358 - Sbstituted chroman derivatives, processes for their preparation and their use as antiinflammatory agents: e

20070129359 - Tetrahydronaphthalene derivatives, processes for their preparation and their use as antiinflammatory agents:

20070129363 - N-type calcium channel antagonists for the treatment of pain:

20070129362 - Pyrimidine-2,4-diamines and their uses: The present invention relates to diaryl pyrimidine-2,4-diamines, pharmaceutical compositions thereof, and the use of the compounds and compositions for the inhibition of kinases. The compounds, analogs, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions can be used in the treatment and prevention of cancer.... Agent: Fenwick & West LLP

20070129364 - Pyrrolopyridine kinase inhibiting compounds: or stereoisomers or pharmaceutically acceptable salts thereof, are inhibitors of least one of the Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mek1, PDK-1, GSK3β, EGFR, p70S6K, BMX, SGK, CaMKII, Tie-2, IGF-1R, Ron, Met, and KDR kinases in animals, including humans, for the treatment and/or prevention of various... Agent: Osi Pharmaceuticals, Inc.

20070129365 - 6-substituted pyridoindolone derivatives, production and therapeutic use thereof:

20070129366 - Methods for the treatment of chronic pain and compositions therefor: The invention discloses cathepsin S as a suitable target for the development of new therapeutics to treat or ameliorate chronic pain. The invention relates to methods to treat and/or ameliorate chronic pain and pharmaceutical compositions therefor comprising modulators with inhibitory effect on cathepsin S enzyme activity and/or cathepsin S gene... Agent: Novartis Corporate Intellectual Property

20070129369 - Heteroaryl substituted cyclohexyl-1,4-diamine compounds: e

20070129367 - Pyridine derivatives as cb2 receptor modulators: The present invention relates to novel pyridine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070129368 - Tricyclic hydroxamate and benzamide derivatives, compositions and methods: The present invention relates to compounds and methods for inhibiting histone deacetylase enzymatic activity. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit histone deacetylases (IIDACs), and in the treatment of conditions... Agent: Nixon & Vanderhye, PC

20070129370 - Novel pharmaceutical compositions with increased activity: The invention relates to novel pharmaceutical combinations with improved sodium channel blocking effect. Further, the invention relates to the use of said pharmaceutical combinations in chronic pain, in disturbances of the motor system, in epilepsy, as well as in other therapeutic fields where the use of sodium channel blockers is... Agent: Rakoczy Molino Mazzochi Siwik LLP

20070129371 - Novel ethylenediamine derivatives: The compound is useful as a preventive and/or therapeutic agent for cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS),... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070129372 - P38 kinase inhibiting agents: are inhibitors of p38 and are useful in the treatment of inflammation such as in the treatment of rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; inflamed joints, eczema, psoriasis or other inflammatory skin conditions such as sunburn; inflammatory eye conditions including conjunctivitis; pyresis, pain and other... Agent: Merck And Co., Inc

20070129373 - Phthalazinone-piperidino-derivatives as pde4 inhibitors: e

20070129375 - 6-substituted 2-quinolinones and 2-quinoxalinones as poly (adp-ribose) polymerase inhibitors:

20070129374 - Indazol-3-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (vr1): Compounds of formula (I), which are useful as therapeutic compounds, particularly in the treatment of pain and other conditions ameliorated by the modulation of the function of the vanilloid-1 receptor (VR1).... Agent: Merck And Co., Inc

20070129376 - Azole derivative useful as antifungal agents with reduced interaction with metabolic cytochromes: The present invention relates to novel compounds, of the general formula (I), the N-oxide forms thereof, the salts thereof with pharmaceutically acceptable acids and the stereochemical isomers thereof, which are useful as antifungal agents; to pharmaceutical compositions containing such compounds as the active ingredient; to methods for the production of... Agent: Nixon & Vanderhye, PC

20070129377 - Process for preparing substituted aryl cycloalkanol derivatives: Processes are disclosed for preparing substituted aryl cycloalkanol derivatives, particularly chiral substituted aryl cycloalkanol derivatives of the general formula:... Agent: Woodcock Washburn LLP

20070129378 - Compounds for the treatment of inflammatory disorders and microbial diseases: o

20070129379 - Hiv integrase inhibitors: The invention encompasses a series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.... Agent: Louis J. Wille Bristol-myers Squibb Company

20070129380 - 2-substituted pyrimidines: e

20070129381 - Pharmaceutically active pyrrolidine ester derivatives:

20070129382 - Crf receptor antagonists, their preparations, their pharmaceutical composition, and their uses: CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in warm-blooded animals. CRF receptor antagonists which are labeled with a positron emitting isotope for use in PET are also disclosed.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070129384 - Fungicidal mixtures: F

20070129383 - Substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative and use thereof:

20070129385 - Amorphous valganciclovir hydrochloride: The present invention relates to an amorphous form of valganciclovir hydrochloride and the pharmaceutical compositions thereof. The amorphous form can be directly prepared by spray-drying or azeotropic distillation of reaction mass. The amorphous form is useful in treating viral infections, for example, herpes simplex and cytomegalovirus.... Agent: Ranbaxy Inc.

20070129386 - Reversible inhibitors of s-adenosyl-l-homocysteine hydrolase and uses thereof: The present invention provides compositions and methods for reversibly inhibiting S-adenosyl-L-homocysteine (SAH) hydrolase. The compounds of the present invention can be used in combination with an anti-hemorrhagic viral infection agent, an immunosuppressant, a homocysteine lowering agent, or an anti-neoplasm agent. The compositions and methods of the present invention can be... Agent: Morrison & Foerster LLP

20070129387 - Maleate salts of a quinazoline derivative useful as an antiangiogenic agent: The present invention relates to AZD2171 maleate salt, to particular crystalline forms of AZD2171 maleate salt, to processes for their preparation, to pharmaceutical compositions containing them as active ingredient, to their use in the manufacture of medicaments for use in the production of antiangiogenic and/or vascular permeability reducing effects in... Agent: Morgan Lewis & Bockius LLP

20070129388 - Spirocyclic derivatives: e

20070129390 - Carbamate compounds which inhibit leukocyte adhesion mediated by vla-4: Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease,... Agent: Foley & Lardner LLP

20070129391 - Composition for preventing or treating damages of the mucosa in the gastrointestinal tracts: Provided is a composition for preventing or treating damages of the mucosa in the gastrointestinal tracts, comprising revaprazan or a salt thereof and a pharmaceutically acceptable carrier. Revaprazan or its salt has an excellent preventive or treatment effect for gastrointestinal mucosal damage by potentiating a defensive factor in the gastrointestinal... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070129389 - Use of pyridinyl-pyrimidinylamino-benzamide derivatives for the treatment of amyloid related disorders: or a N-Oxide or a pharmaceutically acceptable salt thereof having an activity on protein kinases VEGFR-2, Tie-2, c-Src, c-Met, FGFR-1, Flt-1, HER-2, c-Abl, c-Raf, PDGFR-beta, c-Kit, or on a combination of the above enzymes, for the treatment and/or prevention of neurological and vascular disorders related to beta-amyloid generation and/or aggregation... Agent: Novartis Corporate Intellectual Property

20070129392 - Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders: The present invention is directed to compounds having the structure (I) wherein R1, R2, R3, R4, R5 and m are as defined herein. The compounds of this invention are novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders in mammalian subjects. These compounds are also useful... Agent: Dla Piper US LLP

20070129393 - Novel compounds: The invention provides compounds of formula (I) wherein m, R1, n, R2, q, X, Y, Z, t, R3, R4, R5, R6, R7 and R8 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.... Agent: Fish & Richardson P.C.

20070129395 - Process for the preparation of purified crystalline cci-779: The present invention provides purified crystalline CCI-779 and processes for preparing the same.... Agent: Howson And Howson Cathy A. Kodroff

20070129394 - Rapamycin peptides conjugates: synthesis and uses thereof: The present invention relates to new rapamycin derivatives for the inhibition of cell proliferation. The compounds can advantageously target two proteins in dividing cells and interfere with cell cycle. There is thus provided derivatives of rapamycin in which the 42 position of rapamycin is linked to an amino acid or... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20070129397 - Ester derivatives: Ar signifies optionally substituted aryl or heteroaryl; B1 and B2 signify aliphatic hydrocarbon; R1 signifies fluorine-substituted cycloalkyl; R2, R3 and R4 signify lower alkyl, single bond or alkylene bonded to B1, or R2 and R3 are united to signify alkylene; R5 and R7 signify hydrogen, lower alkyl, or a single... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070129396 - Muscarinic acetylcholine receptor antagonists: Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070129398 - Novel quinuclidine derivatives and medicinal compositions containing the same: A compound of formula (I), wherein B is a phenyl ring, a 5 to 10 membered heteroaromatic group containing one or more heteroatoms, or a naphthalenyl, 5,6,7,8-tetrahydronaphthalenyl, benzo[1,3]dioxolyl, or biphenyl group; R1, R2 and R3 each independently represent a hydrogen or halogen atom, or a hydroxy group, a phenyl group,... Agent: Morrison & Foerster LLP

20070129399 - Tetrahydroisoquinoline-and tetrahydrobenzazepine derivatives as igf-1r inhibitors: Compounds of the formula (I): where R2, R5, R6 have the meanings as given in the description, and U, V and W, respectively, may be CR2′, CR4′ and CR6′, respectively (with the definitions of R2′, R4′ and R6′ again as in the description), or may be N, were synthesized. They... Agent: Harness, Dickey & Pierce, P.L.C

20070129400 - Modulators of glucocorticoid receptor, ap-1, and/or nf-kb activity, and use thereof: or an enantiomer, a diastereomer, a pharmaceutically acceptable salt, or hydrate thereof, where J is selected from NR1 or C(R4)(R4a); K is selected from NR2 or C(R5)(R5a); L is selected from NR3 or C(R6)(R6a); and A, X, Y, R1, R2, R3, R4, R4a, R5, R5a, R6, R6a, R8, R10, R11,... Agent: Louis J. Wille Bristol-myers Squibb Company

20070129401 - Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof:

20070129402 - Sustained release formulations: The invention provides sustained release formulations comprising donepezil, stereoisomers of donepezil, pharmaceutically acceptable salts of donepezil, or pharmaceutically acceptable salts of stereoisomers of donepezil. The formulations have desirable pharmacokinetic characteristics. Examples include AUC, Tmax, Cmax, dosage-corrected AUC, and dosage-corrected Cmax.... Agent: Venable LLP

20070129403 - Method of treating schizophrenia and/or glucoregulatory abnormalities: e

20070129404 - Novel indazole derivatives: An object of the present invention is to create a novel indazole derivative useful as a drug and to find a novel pharmacological action of the derivative. The compound of the present invention is represented by the formula [I] and has an excellent Rho kinase inhibiting action. In the formula,... Agent: Frishauf, Holtz, Goodman & Chick, PC

20070129405 - Novel process for preparation of substituted sulfoxides: The present invention relates to a process for preparing substituted sulfoxides either as a single enantiomer or in an enantiomerically enriched form. Thus, racemic omeprazole is reacted with (S)-camphorsulfonyl chloride to form a diastereomeric mixture and the diastereomers are separated by fractional crystallization, followed by deprotection to give esomeprazole.... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20070129406 - Novel substituted sulfoxides: The present invention relates to a process for preparing substituted sulfoxides either as a single enantiomer or in an enantiomerically enriched form. Thus, racemic omeprazole is reacted with (S)-camphorsulfonyl chloride to form a diastereomeric mixture and the diastereomers are separated by fractional crystallization, followed by deprotection to give esomeprazole.... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20070129407 - Anthranilamides, process for the production thereof, and pest controllers containing the same: An anthranilamide compound represented by the formula (I) or its salt. In the formula, R1 is halogen, alkyl, haloalkyl, etc.; each of R2 and R3 which are independent of each other, is halogen, alkyl, haloalkyl, etc.; A is alkyl substituted by Y; Y is C3-4 cycloalkyl which may be substituted... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070129408 - New compounds for the treatment of neurological, psychiatric or pain disorders: The present invention is directed to novel compounds, their use in therapy and pharmaceutical compositions comprising said novel compounds.... Agent: Birch, Stewart, Kolasch & Birch, LLP

20070129409 - Androgen receptor modulators: The present invention is directed to a new class of 5-cyano-2-amino pyridines and to their use as androgen receptor modulators. A further aspect of the invention is directed to a new animal model for finding compounds capable of alleviating androgenic alopecia.... Agent: Warner-lambert Company

20070129410 - Octahydrophenanthrene hydrazinde derivatives useful as glucocorticoid receptor modulators: The present invention relates to compounds of the formula (I) their isomer, prodrugs of these compounds or isomers, or a pharmaceutically acceptable salts of these compounds, isomers or prodrugs; wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and X are defined as in the specification, to pharmaceutical compositions... Agent: Pharmacia & Upjohn

20070129411 - Treatment of proliferative diseases with epothilone derivatives and radiation: This invention relates to organic compounds of formula (I) in particular to pharmaceutical compositions for use in combination with ionizing radiation for the delay of progression or treatment of a proliferative disease, especially a solid tumor disease.... Agent: Novartis Corporate Intellectual Property

20070129412 - Methods for treating parkinson's disease: The efficacy of levodopa therapy in patients being treated for Parkinson's disease is enhanced by administering high doses of a partial glycine agonist. The frequency and severity of levodopa-induced side effects in Parkinson's disease patients are also reduced by administration of a partial glycine agonist.... Agent: Harness, Dickey, & Pierce, P.l.c

20070129413 - Coupling reactions useful in the preparation of (1h-tetrazol-5-yl) biphenyl derivatives: The present invention relates to a process for the manufacture of intermediates that may be used for the manufacture of ARBs (also called angiotension II receptor antagonists or AT1 receptor antagonists) comprising as a common structural feature a (1H-tetrazol-5-yl)-biphenyl ring. Form PCT/ISA/210 (continuation of first sheet (3)) (January 2004)... Agent: Novartis Corporate Intellectual Property

20070129415 - Method of treating isolated systolic hypertension: This invention relates to the use of eprosartan to treat isolated systolic hypertension.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070129414 - Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1h-imidazole-1-yl)methyl]- 4h-carbbazol-4-one or its salt: 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one or its salt is prepared in high yield by reacting a compound of formula 2 with a compound of formula 3 and a compound of formula 4 in the presence of an acid, an alkylsilylhalide compound or an acylhalide compound, in an solvent, and thus, such an inventive process... Agent: Anderson, Kill & Olick, P.C.

20070129416 - 4,4,5,5, tetrasubstituted imidazolines: 2

20070129417 - Hexahydro-cyclooctyl pyrazole cannabinoid modulators:

20070129418 - Ophthalmic compositions for treating ocular hypertension: This invention relates to potent potassium channel blocker compounds of Formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective... Agent: Merck And Co., Inc

20070129420 - New pyrrolidinium derivatives: New pyrrolidinium derivatives having the chemical structure of general formula (I) are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them and their use in therapy as antagonists of M3 muscarinic receptors.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070129419 - Serotonin transporter (sert) inhibitors for the treatment of depression and anxiety: and to pharmaceutically acceptable acid addition salts thereof. The compounds of formula I are good inhibitors of the serotonin transporter (SERT inhibitors). By virtue of their efficacy as SERT inhibitors, the compounds of the present invention are particularly useful for the treatment of CNS disorders and psychotic disorders, in particular... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070129421 - Vinylogous acid derivatives: d

20070129422 - Somatostatin receptor 1 and/or 4 selective agonists and antagonists: The invention relates to (hetero)arylsulfonylamino based peptidomimetics of formula (I), wherein R1, R2, R3, A, B, D, Q, k and n are defined as disclosed, or a pharmaceutically acceptable salt or ester thereof. Compounds of formula (I) possess high affinity and selectivity for the somatostatin receptor subtypes SSTR1 and/or SSTR4... Agent: Oliff & Berridge, PLC

20070129423 - Method for treating pain: e

20070129424 - Method for treating pain:

20070129425 - Dissolution of arterial cholesterol plaques by pharmacological preparation: A biocompatible lipid solubilzer, preferably a biliary acid or salt or a biliary precursor or derivative being made bioavailable in the systemic circulation of a patient via a variety of routes of administration including topical-mucous membrane, topical-dermatological such as via a skin patch, intravenous, subcutaneous, rectal, intramuscular, intradermal, inhalatory, intrarterial,... Agent: Filiberto Zadini

20070129426 - Therapeutic drugs for arthritis: The present invention relates to the coumestans compounds extracted from Compositae plants, drug compositions or health products comprising the compounds and the use in treatment of rheumatic arthritis or rheumatoid arthritis, osteoarthritis. The animal experiments in vivo or in vitro indicate that the coumestans compounds can effectively treat and alleviate... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20070129427 - Novel compound and pharmaceutical composition: e

20070129428 - Composition for improving skin, hair and coat health containing flavanones: The present invention pertains to a composition for preventing, decreasing and/or treating skin and hair/coat disorders, such as is effected by inflammatory reactions, environmental factors, ageing or cancer. In particular, the present invention relates to the use of flavanones compounds or their derivatives in nutritional, cosmetic or pharmaceutical compositions for... Agent: Bell, Boyd & Lloyd LLP

20070129429 - Materials and methods for treating coagulation disorders: This invention is drawn to compounds which are more easily metabolized by the metabolic drug detoxification systems. Particularly, warfarin analogs which have been designed to include esters within the structure of the compounds are taught. The invention teaches methods of reducing the toxicity of drugs comprising the introduction of ester... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070129430 - Agent for enhancing the production of collagen, their preparation and use: The present invention has an object to provide an agent for enhancing collagen production and use thereof, and solves the object by establishing an agent for enhancing collagen production, which comprises as effective ingredients L-ascorbic acid or its derivative and a fatty acid or its derivative, and use thereof.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070129431 - Multinuclear platinum compounds: Multinuclear platinum compounds, compositions that include the platinum compounds, methods for making the platinum compounds, and methods for treating cellular proliferative diseases by administering the platinum compounds.... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20070129432 - Zinc-monocysteine complex and method of using zinc-cysteine complexes: A method of providing zinc to a subject in need of treatment includes administering to the subject an effective amount of a zinc-cysteine complex. The zinc-cysteine complex is preferably a zinc-monocysteine complex. The complexes of zinc-cysteine of the present invention increase the activity of antioxidant enzymes catalase and glutathione peroxidase,... Agent: Garvey Smith Nehrbass & North, LLC

20070129433 - Diphenylamine derivatives: The invention relates to compounds of the formula (I) in which: i and j=1; R1 is in position 3 or 4 on the phenyl ring and represents a cyano group, an alkoxy group substituted by halogen, a thioalkyl group, an alkylcarbonyl group or an alkylsulfonyl group; and R2 represents a... Agent: Millen, White, Zelano & Branigan, P.C.

20070129434 - Analgesics and methods of use: A method for inducing analgesia and/or inhibiting abuse of abusive substances includes administration of d-methadone metabolites or their structural analogs. The d-methadone metabolites, EMDP and EDDP, and their structural analogs may be incorporated into a suitable pharmaceutical composition for administration to patients. The invention includes the method itself, certain structural... Agent: Ip Group Of Dla Piper US LLP

20070129435 - Pharmaceutical composition for treating stress incontinence and/or mixed incontinence: This invention describes the use of beta-3-adrenoceptor agonists for the treatment of functional bladder disorders, particularly stress incontinence and/or mixed incontinence.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070129436 - Agent for suppressing body fat accumulation: Novel and highly effective agents for suppressing fat accumulation and for suppressing body fat gain that contain astaxanthin and/or an ester thereof as an active component are provided. The agent for suppressing fat accumulation according to the present invention effectively suppresses accumulation of fat both in subcutaneous fat and in... Agent: Le-nhung Mcleland

20070129437 - Process for preparing simvastatin and intermediates thereof: Novel processes for the preparation of simvastatin and intermediates of such processes. Preferred embodiments include the preparation of lovastatin amides, protected lovastatin amide derivatives, simvastatin dihydroxy acid amide derivatives, alkali salts, simvastatin dihydroxy acids, simvastatin ammonium salts, and simvastatin.... Agent: Kenyon & Kenyon LLP

20070129438 - Method for suppressing proliferation of abnormal prion protein: A method for suppressing proliferation of abnormal prion proteins is provided. Specifically, the method involves systemically, orally, intracerebrally or intraspinally administering an essential amino acid, in particular, one having a branched side chain, that is, one selected from leucine, isoleucine, and valine. Of these, leucine is most preferred.... Agent: Crowell & Moring LLP Intellectual Property Group

20070129439 - Compositions containing substituted quinolines and substituted diphenyl sulfones and methods of use: Combination therapies of substituted quinolines and substituted diphenyl sulfones are disclosed. More specifically, compositions containing substituted quinolines and substituted diphenyl sulfones are disclosed. In addition, methods of using the compositions in the treatment of neurodegenerative disorders, including, inter alia, Alzheimer's dementia, HIV-1 associated dementia, and Creutzfeld-Jakob disease are also disclosed.... Agent: Woodcock Washburn LLP

20070129440 - Polypharmacophoric agents: One aspect of the present invention relates to polypharmacophoric compounds. In certain embodiments, the polyphamacophore compounds comprise individual pharmacophore units selected from the group consisting of D-1 agonists, D-2 agonists, D-3 agonists, D-4 agonists, irreversible monoamine inhibitors, reversible monoamine inhibitors, monoamine transporter inhibitors, COMT inhibitors, MAO inhibitors, and dopamine transporter... Agent: Foley & Lardner LLP

20070129441 - Protection of cells from adverse external or intrinsic effects, cellular degeneration and death by n-acylethanolamines: The present invention includes compositions and methods for treating diseases of the eye and skin by modulating the amount of intracellular calcium using transdermal or transcorneal delivery of one or more N-acylethanolamines in a carrier.... Agent: Chalker Flores, LLP

20070129442 - N-arylhydrazine derivatives for seed treatment: e

20070129444 - Novel weight reduction composition and uses thereof: The present invention relates to a novel compound, N-benzylpropylhexedrine, and a process for preparing the compound. The invention also provides methods for reducing weight, decreasing appetite, inhibiting weight gain, and treating narcolepsy in patients by administering a pharmaceutical composition comprising N-benzylpropylhexedrine.... Agent: Mallinckrodt Inc.

20070129443 - Production method of aminochlorohydrin sulfate: Highly pure (2R,3S)-3-tert-butoxycarbonylamino-1-chloro-2-hydroxy-4-phenylbutane or (2S,3R)-3-tert-butoxycarbonylamino-1-chloro-2-hydroxy-4-phenylbutane may be conveniently produced in high yield by: (a) reacting compound (1) with lithiumchloromethane to give compound (2) and at least a byproduct; (b) dissolving compound (2) and the byproduct in a polar solvent and adding water to the solution to precipitate compound (2) as... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070129445 - Therapeutic agents: Substituted cycloalkyl compounds with 3 to 6 carbon atoms in the ring, one carbon linked to each of two side groups R and R′, and pharmaceutically acceptable salts thereof in which R is phenyl optionally substituted by one or more halo substituents or R is naphthyl; and R′ is —[X—Y—S(O)m—Z—N—R1—R2],... Agent: Bromberg & Sunstein LLP

20070129447 - Method of drug therapy in treatment of cardiac arrhythmias: A method for treatment of cardiac arrhythmias is disclosed. The method comprises the combining of a sodium channel blocking medication and a potassium channel blocking medication into a therapeutic dosage and the delivery of the therapeutic dosage to a patient in treatment of a heart rhythm problem. The heart rhythm... Agent: Jansson Shupe & Munger Ltd.

20070129446 - Use of fepradinol for the production of a pharmaceutical composition for the treatment of rosacea: The invention relates to the use of fepradinol for the production of novel pharmaceutical compositions, in particular, dermatological compositions, of use for the treatment of rosacea.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070129448 - Compositions and methods of delivery of pharmacological agents: The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serun albumin and/or deferoxamine. The human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of... Agent: Morrison & Foerster LLP